<html xmlns="http://www.w3.org/1999/xhtml"> <head> <style type="text/css">
      	     		 
      	    a                          {background : #ffffff; }
      	    article                    {border-style : dotted; border-width : 2px; }
		 	
		 	div                        {background : #ffffcc;}
		 	div.abstract-title         {font-weight : bold ; font-size : 16pt;}
		 	div.ack                    {border-style : solid ; border-color : red; margin : 2em; }
		 	div.article-meta           {border-style : solid; border-width : 1 pt; margin 1em;}
		 	div.boxed-text             {margin : 5em; border-style : solid;}
		 	div.contrib-group          {margin : 1em; }
		 	div.fig                    {border-style : solid; border-width : 2px; margin : 2em; }
		 	div.funding                {font-weight : bold ; font-size : 16pt;}
		 	div.given-names            {font-style : italic;}
		 	div.intro                  {border-style : inset; margin : 5px;}
		 	div.introduction           {border-style : inset; margin : 5px;}
		 	div.journal-meta           {border-style : solid; border-width : 1 pt; margin 1em;}
		 	div.journal-title-group    {background : #ffeeee;}
		 	div.article-title          {font-weight : bold ; font-size : 18pt;}
		 	div.kwd                    {font-style : italic}
		 	div.meta-name              {font-weight : bold ; font-size : 16pt;}
		 	div.name                   {font-weight : bold;}
		 	div.alt-title              {font-style : italic; font-size : 12px;}
		 	
		 	div.sec                    {border : 2px; margin 5px; padding 2px;}
		 	div.title                  {font-family : courier; font-weight : bold;
		 	                            font-size : 16pt; margin : 5px;}
		 	
		 	div.materials_methods      {border-style : double; margin : 5px; }
		 	div.methods                {border-style : double; margin : 5px; }
		 	
		 	div.results                {border-style : solid; margin : 5px;}
		 	div.background             {border-style : dotted; margin : 5px;}
		 	
		 	div.discussion             {border-style : groove; margin : 5px;}
		 	div.conclusion             {border-style : ridge; margin : 5px;}
		 	div.conclusions             {border-style : ridge; margin : 5px;}
		 	div.supplementary-material {border-style : inset; margin : 5px;}
		 	div.abbreviations          {border-style : double; border-color : red; margin : 5px;}
		 	div.competinginterests     {border-style : double; border-color : blue; margin : 5px;}
		 	div.acknowledgements       {border-style : double; border-color : green; margin : 5px;}
		 	div.authors_contributions   {border-style : double; border-color : purple; margin : 5px;}
		 	
		 	div.publisher              {border-style : outset; margin : 5px;}
		 	div.fn-type-conflict       {background : #f88; }
		 	div.fn-type-con            {background : #ddf; }
		 	div.fn-type-other          {background : #ddd; }
		 	
		 	div.unknown                {background : #ffd;
									 	  border-style : solid;
									 	  border-width : 1px;
									 	  padding : 2 px;}
		 	  
      	    table                      {background : #ffffdd;}
		 	tr                         {background : #ddddff; padding : 1px;}
		 	
		 	span                       {background : #ffcccc;}
		 	
		 	span.citation-author       {font-family : helvetica; background : #ffeeee;}
		 	span.collab                {background : #ddffff; }
		 	span.comment               {font-family : courier; font-size : 6px; background : #ffaaff;}
		 	span.contrib               {background : #ffffff;}
		 	span.corresp               {background : #ddffdd; }
		 	span.doi                   {background : #ffffff;}
		 	span.email                 {font-family : courier; }
		 	span.etal                  {font-style : italic;}
		 	span.fpage                 {font-family : courier;}
		 	span.given-names           {background : #ffffff;}
		 	span.iso-abbrev            {background : #ffffff;}
		 	span.issn-epub             {background : #ffffff;}
		 	span.issn-ppub             {background : #ffffff;}
		 	span.journal-title         {background : #ffffff;}
		 	span.lpage                 {font-family : courier;}
		 	span.mixed-article-title   {font-style : italic ;}
		 	span.nlm-ta                {background : #ffffff;}
		 	span.pmc                   {background : #ffffff;}
		 	span.pmcid                 {background : #ffffff;}
		 	span.pmid                  {background : #ffffff;}
		 	span.publisher             {background : #ffffff;}
		 	span.publisher-id          {background : #ffffff;}
		 	span.publisher-name        {background : #ffffff;}
		 	span.source                {background : #ffffff;}
		 	span.subject               {background : #ffffff;}
		 	span.surname               {background : #ffffff;}
		 	span.volume                {font-family : courier; font-weight : bold;}
		 	span.year                  {font-family : courier ; font-style : italic;}
			</style> </head> <body> <div class="front" title="front"> <div class="journal-meta" tagx="journal-meta" title="journal-meta"><span class="nlm-ta" title="nlm-ta">Drugs R D</span><span class="iso-abbrev" title="iso-abbrev">Drugs R D</span><div class="journal-title-group" tagx="journal-title-group" title="journal-title-group"><span class="journal-title" tagx="journal-title" title="journal-title">Drugs in R&amp;amp;D</span></div><span class="issn-ppub" tagx="issn" title="issn-ppub">1174-5886</span><span class="issn-epub" tagx="issn" title="issn-epub">1179-6901</span><div class="publisher" tagx="publisher" title="publisher"><span class="publisher-name" tagx="publisher-name" title="publisher-name">Springer International Publishing</span><span class="publisher-loc" tagx="publisher-loc" title="publisher-loc">Cham</span></div> </div> <div class="article-meta" tagx="article-meta" title="article-meta"><span class="pmcid" title="pmcid"> pmcid: <a href="http://www.ncbi.nlm.nih.gov/pubmed/5629135">5629135</a></span><span class="publisher-id" title="publisher-id">195</span><span class="doi" title="doi"> doi: <a href="https://dx.doi.org/10.1007/s40268-017-0195-7">10.1007/s40268-017-0195-7</a></span><div class="article-categories" title="article-categories">
: <span class="subject" title="subject">Systematic Review</span></div> <div class="title-group"> <div class="article-title" title="article-title">
Impact of Genetic Polymorphisms on Phenytoin Pharmacokinetics and Clinical Outcomes in the Middle East and North Africa Region</div> </div> <div class="contrib-group" title="contrib-group"><span class="contrib" title="contrib"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Dagenais</span><span class="given-names" tagx="given-names" title="given-names">Renée</span></span><a href="#Aff1">1</a></span><span class="contrib" title="contrib"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Wilby</span><span class="given-names" tagx="given-names" title="given-names">Kyle John</span></span><span class="address" title="address"><span class="phone" tagx="phone" title="phone">+974 4403 5606</span><span class="email" tagx="email" title="email">kjw@qu.edu.qa</span></span><a href="#Aff2">2</a></span><span class="contrib" title="contrib"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Elewa</span><span class="given-names" tagx="given-names" title="given-names">Hazem</span></span><a href="#Aff2">2</a></span><span class="contrib" title="contrib"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Ensom</span><span class="given-names" tagx="given-names" title="given-names">Mary H. H.</span></span><a href="#Aff1">1</a><a href="#Aff3">3</a></span><span class="citation_author_institution" id="Aff1">[1], <div class="institution-wrap" title="institution-wrap"><span class="institution-id" title="institution-id">0000 0001 2288 9830</span><span class="institution-id" title="institution-id">grid.17091.3e</span><span class="institution" title="institution">Faculty of Pharmaceutical Sciences, Pharmaceutical Sciences Building, </span><span class="institution" title="institution">University of British Columbia, </span></div></span><span class="citation_author_institution" id="Aff2">[2], <div class="institution-wrap" title="institution-wrap"><span class="institution-id" title="institution-id">0000 0004 0634 1084</span><span class="institution-id" title="institution-id">grid.412603.2</span><span class="institution" title="institution">College of Pharmacy, </span><span class="institution" title="institution">Qatar University, </span></div></span><span class="citation_author_institution" id="Aff3">[3], <div class="institution-wrap" title="institution-wrap"><span class="institution-id" title="institution-id">grid.413941.a</span><span class="institution" title="institution">Department of Pharmacy, </span><span class="institution" title="institution">Children’s and Women’s Health Centre of British Columbia, </span></div></span></div><span class="pub-date-epub" title="pub-date-epub">epub: <span>2017-7-7</span></span><span class="pub-date-pmc-release" title="pub-date-pmc-release">pmc-release: <span>2017-7-7</span></span><span class="pub-date-ppub" title="pub-date-ppub">ppub: <span>2017-9</span></span><span class="volume" tagx="volume" title="volume">17</span><span class="issue" tagx="issue" title="issue">3</span><span class="fpage" tagx="fpage" title="fpage">341</span><span class="lpage" tagx="lpage" title="lpage">361</span><div class="permissions"><span class="copyright" title="copyright">(C) , </span><span class="license" title="license"><span class="license-p" title="license-p"><b>Open Access</b>This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/), which permits any noncommercial use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.</span></span></div> <div class="abstract" title="abstract"> <div class="abstract-title" title="abstract-title">
Abstract</div> <div class="background" title="sec"> <div class="title" tagx="title" title="title">
Background</div> <p id="Par1">Genetic polymorphisms are known to influence outcomes with phenytoin yet effects in the Middle East and North Africa region are poorly understood.</p> </div> <div class="objectives" title="sec"> <div class="title" tagx="title" title="title">
Objectives</div> <p id="Par2">The objective of this systematic review was to evaluate the impact of genetic polymorphisms on phenytoin pharmacokinetics and clinical outcomes in populations originating from the Middle East and North Africa region, and to characterize genotypic and allelic frequencies within the region for genetic polymorphisms assessed.</p> </div> <div class="methods" title="sec"> <div class="title" tagx="title" title="title">
Methods</div> <p id="Par3">MEDLINE (1946–3 May, 2017), EMBASE (1974–3 May, 2017), Pharmacogenomics Knowledge Base, and Public Health Genomics Knowledge Base online databases were searched. Studies were included if genotyping and analyses of phenytoin pharmacokinetics were performed in patients of the Middle East and North Africa region. Study quality was assessed using a National Institutes of Health assessment tool. A secondary search identified studies reporting genotypic and allelic frequencies of assessed genetic polymorphisms within the Middle East and North Africa region.</p> </div> <div class="results" title="sec"> <div class="title" tagx="title" title="title">
Results</div> <p id="Par4">Five studies met the inclusion criteria. <i>CYP2C9</i>, <i>CYP2C19</i>, and multidrug resistance protein 1 C3435T variants were evaluated. While <i>CYP2C9*2</i> and <i>*3</i> variants significantly reduced phenytoin metabolism, the impacts of <i>CYP2C19*2</i> and <i>*3</i> variants were unclear. The multidrug resistance protein 1 CC genotype was associated with drug-resistant epilepsy, but reported impacts on phenytoin pharmacokinetics were conflicting. Appreciable variability in minor allele frequencies existed both between and within countries of the Middle East and North Africa region.</p> </div> <div class="conclusions" title="sec"> <div class="title" tagx="title" title="title">
Conclusions</div> <p id="Par5"><i>CYP2C9</i> decrease-of-function alleles altered phenytoin pharmacokinetics in patients originating from the Middle East and North Africa region. The impacts of <i>CYP2C19</i> and multidrug resistance protein 1 C3435T variants on phenytoin pharmacokinetic and clinical outcomes are unclear and require further investigation. Future research should focus on the clinical outcomes associated with phenytoin therapy.</p> <p id="Par6">PROSPERO 2017: CRD42017057850</p> </div> </div> <div class="custom-meta-group" title="custom-meta-group"> <meta name="issue-copyright-statement" value="© Springer International Publishing AG 2017" /> </div> </div> </div> <div class="body" title="body"> <div class="keypoints" title="sec"> <div class="title" tagx="title" title="title">
Key Points</div> <p id="Par7"> <div class="table-wrap_UNKNOWN" id="Taba"> </div></p><table frame="hsides" rules="groups"> <tbody> <tr> <td align="left">In patients originating from the Middle East and North Africa region, phenytoin metabolism was significantly decreased by genetic polymorphisms of the cytochrome P450 (CYP) 2C9 enzyme; the impacts of <i>CYP2C19</i> and multidrug resistance protein 1 C3435T polymorphisms were unclear.</td> </tr> <tr> <td align="left">The impacts of genetic polymorphisms on clinical outcomes associated with phenytoin are not well described in the literature and warrant further investigation.</td> </tr> </tbody> </table>  <p /> </div> <div class="introduction" title="introduction"> <div class="title" tagx="title" title="title">
Introduction</div> <p id="Par8">Since the discovery of its anticonvulsant properties in 1938 [<a href="#CR1">1</a>], phenytoin has been widely used for both the acute management and chronic prevention of seizures [<a href="#CR2">2</a>, <a href="#CR3">3</a>]. Its primary mechanism in treating and preventing seizures is through preferential binding to inactivated sodium channels, which inhibits neuronal generation of sustained high-frequency bursts of action potentials [<a href="#CR4">4</a>]. Phenytoin has a narrow therapeutic index, with 40–80 µmol/L (10–20 mg/L) being the recommend therapeutic range; however, this is often difficult to achieve due to wide interpatient variability in dose response and concentrations achieved from a given dose, as well as the capacity-limited metabolism of phenytoin [<a href="#CR5">5</a>, <a href="#CR6">6</a>].</p> <p id="Par9">Factors such as patient body size and composition, serum albumin levels, comorbid disease states, and drug–drug interactions have been shown to contribute to the interpatient variability of the effect of phenytoin. Additionally, genetic polymorphisms of enzymes and transporters targeting phenytoin pharmacokinetics have been recognized as a significant contributor to the exhibited interpatient variability [<a href="#CR5">5</a>–<a href="#CR7">7</a>]. Evidence linking the cytochrome P450 (CYP) 2C9 polymorphism to the concentration of phenytoin has led to the development of guidelines tailoring the initial dose of phenytoin based on the <i>CYP2C9</i> genotype [<a href="#CR7">7</a>–<a href="#CR9">9</a>]. Though not as well studied, there is evidence to suggest that polymorphisms of <i>CYP2C19</i> may also significantly impact the concentration of phenytoin and warrant dosage adjustments [<a href="#CR7">7</a>, <a href="#CR10">10</a>]. Additional enzymes and drug transporters have been investigated, but the implications of these polymorphisms are not well established [<a href="#CR7">7</a>, <a href="#CR11">11</a>].</p> <p id="Par10">Cited studies investigating the impact of genetic polymorphisms on the pharmacokinetics and pharmacodynamics of phenytoin have predominantly been conducted in patients of European, Indian, and East Asian origin; however, few studies have been conducted in patients originating from the Middle East and North Africa (MENA) region [<a href="#CR11">11</a>, <a href="#CR12">12</a>]. As a result of migration and significant admixture of European, Asian, and African populations dating back over thousands of years, the MENA region has a unique genetic diversity, with great variability in minor allelic frequencies (MAF) of genetic polymorphisms [<a href="#CR13">13</a>–<a href="#CR15">15</a>]. Even within the MENA region itself, there is great diversity. For example, while populations of Arabic and Iranian origin have both European and African ancestry, those of Iranian origin also have a significant level of Asian admixture [<a href="#CR15">15</a>]. Furthermore, as a result of consanguinity, some countries within the MENA region may exhibit relatively less genetic diversity [<a href="#CR15">15</a>]. Therefore, results of previous studies conducted in patients of different ethnic origins are not readily generalizable, and a focused review of the literature addressing genetic polymorphisms and the associated implications regarding phenytoin in individuals originating from the MENA region is warranted.</p> <p id="Par11">The primary objective of this systematic review was to evaluate the impact of genetic polymorphisms on phenytoin pharmacokinetics, specifically in populations originating from the MENA region. Secondary objectives were to evaluate the impact of genetic polymorphisms on clinical outcomes associated with phenytoin therapy, as well as to characterize the genotypic and allelic frequencies of each polymorphism identified in the primary search within the MENA region.</p> </div> <div class="materials_methods" title="materials|methods"> <div class="title" tagx="title" title="title">
Methods</div> <div class="searchstrategy" title="sec"> <div class="title" tagx="title" title="title">
Search Strategy</div> <p id="Par12">A comprehensive search of the MEDLINE (1946–May 2017), EMBASE (1974–May 2017), Pharmacogenomics Knowledge Base (PharmGKB), and Public Health Genomics Knowledge Base (PHGKB) online databases was conducted to identify existing literature addressing the primary research question. An example of the search terms and Boolean connectors used in MEDLINE is outlined in the Appendix, and is reflective of the search strategy used in EMBASE. References of pertinent studies were also searched manually to identify additional studies not identified in the electronic search. For each polymorphism assessed in the studies that met the inclusion criteria, a secondary search was conducted to identify the reported variant MAF, specifically within the MENA region.</p> </div> <div class="selectionofstudies" title="sec"> <div class="title" tagx="title" title="title">
Selection of Studies</div> <p id="Par13">Studies were eligible for inclusion if participants originated from the MENA region, received at least one dose of phenytoin with a subsequent pharmacokinetic analysis, and were genotyped for a polymorphism that may impact phenytoin pharmacokinetics. Although understanding the impact of genetic polymorphisms on clinical outcomes associated with phenytoin therapy was a secondary objective of this review, eligible studies were not required to report on clinical outcomes. Two reviewers (RD, KW) screened potentially relevant studies by title and abstract, and then by full text to exclude any studies that did not fulfill the inclusion criteria. For the review regarding variant MAF, studies were included if participants originated from the MENA region and were genotyped for one or more of the polymorphisms assessed in the primary review.</p> </div> <div class="dataextractionandmanagement" title="sec"> <div class="title" tagx="title" title="title">
Data Extraction and Management</div> <p id="Par14">Data from each included study were extracted and tabulated. Extracted data included: author, year of publication, study population (country of origin, practice setting, inclusion and exclusion criteria), sample size, study design, genetic polymorphism(s) assessed, phenytoin dosing, assay methods for phenytoin serum concentrations and genotyping, MAF of the genetic polymorphism(s), as well as final study results. For studies also including participants from outside of the MENA region, only data regarding participants who originated from the MENA region were extracted.</p> <p id="Par15">Similarly, for studies included in the review of variant MAF, the following data were extracted: author, country of origin, sample size, genetic polymorphism(s) assessed, as well as the computed genotypic and allelic frequencies. If studies eligible for inclusion also reported data from participants originating outside of the MENA region, only data on participants who originated from the MENA region were extracted.</p> </div> <div class="qualityassessment" title="sec"> <div class="title" tagx="title" title="title">
Quality Assessment</div> <p id="Par16">The quality of each study included in the primary review was assessed by two reviewers (RD, KW) using the Quality Assessment Tool for Observational Cohort and Cross-Sectional Studies, from the National Institutes of Health, National Heart, Lung, and Blood Institute [<a href="#CR16">16</a>].</p> </div> <div class="datasynthesis" title="sec"> <div class="title" tagx="title" title="title">
Data Synthesis</div> <p id="Par17">Data extracted from the included studies were assessed descriptively. If two or more studies reported the genotypic or allelic frequency of a given polymorphism, data from all studies were reported. The highest and lowest frequencies extracted for each polymorphism were assessed to estimate variants’ MAF range within the MENA region.</p> </div> </div> <div class="results" title="results"> <div class="title" tagx="title" title="title">
Results</div> <div class="studyselection" title="sec"> <div class="title" tagx="title" title="title">
Study Selection</div> <p id="Par18">A total of five studies fulfilled the inclusion criteria for this review, as depicted in Fig. <a href="#Fig1">1</a>. Of the 30 articles screened for eligibility, ten were excluded for subjects not originating from the MENA region [<a href="#CR17">17</a>–<a href="#CR26">26</a>], seven were excluded for phenytoin concentrations not being assessed [<a href="#CR27">27</a>–<a href="#CR33">33</a>], five were excluded for both subjects not originating from the MENA region and phenytoin concentrations not being assessed [<a href="#CR34">34</a>–<a href="#CR38">38</a>], one was excluded for genetic polymorphisms not being assessed [<a href="#CR39">39</a>], and two were excluded for being poster abstracts [<a href="#CR40">40</a>, <a href="#CR41">41</a>]. Between the five included studies<i>, CYP2C9*1, *2,</i> and <i>*3; CYP2C19*1, *2,</i> and <i>*3;</i> and multidrug resistance protein 1 [<i>MDR1</i>, also known as ATP-binding cassette sub-family B member 1 (ABCB1)] C3435T polymorphisms were evaluated. The study population, phenytoin regimen, and genetic polymorphism(s) assessed varied between studies; summaries of each study are provided in Table <a href="#Tab1">1</a>. </p><div class="fig" title="fig"> <div class="figure" title="figure"><a href="http://doi.org/"><span class="label" tagx="label" title="label">Fig. 1</span></a></div>   <p>Preferred reporting items for systematic reviews and meta-analyses (PRISMA) flow chart of included studies [<a href="#CR146">146</a>]. <i>MENA</i> Middle East and North Africa, <i>PHT</i> phenytoin</p>   </div> <div class="table-wrap_UNKNOWN" id="Tab1"><span class="label" tagx="label" title="label">Table 1</span> <p>Summary of studies assessing the impact of genetic polymorphisms on phenytoin pharmacokinetics and/or clinical outcomes</p>  <table frame="hsides" rules="groups"> <thead> <tr> <th align="left">Study, year</th> <th align="left">Country/study population</th> <th align="left">PHT dosing regimen</th> <th align="left">Genotype(s)/reported allelic frequencies percentage</th> <th align="left" colspan="5">Pharmacokinetic outcomes</th> </tr> </thead> <tbody> <tr> <td align="left" rowspan="4">Aynacioglu et al. [<a href="#CR42">42</a>]</td> <td align="left" rowspan="4">Turkey<br /><br /> Outpatients (<i>n</i> = 280); healthy volunteers (<i>n</i> = 218)<br /><br /> PHT PK analysis in healthy volunteer subgroup (<i>n</i> = 101)</td> <td align="left" rowspan="4">300 mg PO × 1<br /><br /> Sample collected 12-h post-dose</td> <td align="left" rowspan="4"><i>CYP2C9</i><br /><br /> Study population<br /><br /> *1 = 79.4<br /><br /> *2 = 10.6<br /><br /> *3 = 10<br /><br /> Population included in PHT PK analysis:<br /><br /> *1 = 81.7<br /><br /> *2 = 9.4<br /><br /> *3 = 8.9</td> <td align="left" colspan="2">Genotype</td> <td align="left" colspan="3">Serum PHT, mean mg/L (95% CI)</td> </tr> <tr> <td align="left" colspan="2">CYP2C9*1/*1<br /><br />CYP2C9*1/*2<br /><br />CYP2C9*1/*3<br /><br />CYP2C9*2/*2<br /><br />CYP2C9*2/*3<br /><br />CYP2C9*3/*3</td> <td align="left" colspan="3">4.16 (3.86–4.46)<br /><br />5.52 (4.66–6.39)<br /><br />5.65 (4.86–6.43)<br /><br />6.58 (1.64–11.51)<br /><br />Not observed<br /><br />5.92<sup>a</sup></td> </tr> <tr> <td align="left" colspan="2">Genotype</td> <td align="left" colspan="3">p-HPPH/PHT ratio (95% CI)</td> </tr> <tr> <td align="left" colspan="2">CYP2C9*1/*1<br /><br />CYP2C9*1/*2<br /><br />CYP2C9*1/*3<br /><br />CYP2C9*2/*2<br /><br />CYP2C9*2/*3<br /><br />CYP2C9*3/*3</td> <td align="left" colspan="3">0.43 (0.39–0.47)<br /><br />0.26 (0.21–0.31)<br /><br />0.21 (0.18–0.24)<br /><br />0.14 (0.13–0.14)<br /><br />Not observed<br /><br />0.02<sup>a</sup></td> </tr> <tr> <td align="left" rowspan="3">Kerb et al. [<a href="#CR43">43</a>]</td> <td align="left" rowspan="3">Turkey<br /><br /> Healthy volunteers (<i>n</i> = 96)</td> <td align="left" rowspan="3">300 mg PO × 1<br /><br /> Sample collected 12-h post-dose</td> <td align="left" rowspan="3"><i>CYP2C9</i><br /><br /> *1 = 81.3<br /><br /> *2 = 10.1<br /><br /> *3 = 8.8<br /><br /><i>CYP2C19</i><br /><br /> *1 = 88.3<br /><br /> *2 = 11.7<br /><br /><i>MDR1 (ABCB1) C3435T</i><br /><br /> C = 52.6<br /><br /> T = 47.4</td> <td align="left" colspan="2">Genotype</td> <td align="left" colspan="3">Serum PHT, mean mg/L ± SD</td> </tr> <tr> <td align="left" colspan="2">CYP2C9*1/*1<br /><br />CYP2C9*1/*2<br /><br />CYP2C9*1/*3<br /><br />CYP2C9*2/*2<br /><br />CYP2C9*2/*3<br /><br />CYP2C9*3/*3<br /><br />CYP2C19*1/*1<br /><br />CYP2C19*1/*2<br /><br />CYP2C91*2/*2<br /><br />MDR1 CC<br /><br />MDR1 CT<br /><br />MDR1 TT</td> <td align="left" colspan="3">4.20 ± 1.25<br /><br />5.52 ± 1.43<br /><br />5.54 ± 1.47<br /><br />6.58 ± 1.99<br /><br />Not observed<br /><br />5.92<sup>a</sup><br /><br />4.73 ± 1.47<br /><br />4.49 ± 1.68<br /><br />4.40 ± 1.41<br /><br />4.27 ± 1.74<br /><br />4.85 ± 1.33<br /><br />4.87 ± 1.36</td> </tr> <tr> <td align="left" colspan="5">Multiple linear regression indicates the number of polymorphic <i>CYP2C9</i> alleles and <i>MDR1*T</i> alleles account for 14.1 and 1.3% of the variability in phenytoin serum concentrations, respectively (<i>r</i><sup>2</sup> = 0.154, <i>p</i> = 0.0002)</td> </tr> <tr> <td align="left" rowspan="3">Ozkaynakci et al. [<a href="#CR44">44</a>]</td> <td align="left" rowspan="3">Turkey<br /><br /> Epilepsy clinic outpatients taking PHT mono- or polytherapy (<i>n</i> = 101)<br /><br /> Seizure etiology: epilepsy, brain tumor, glioma, head trauma, or AVM<br /><br /> Polytherapy, mostly CBZ, LTG, or VPA</td> <td align="left" rowspan="3">Mean dose 4.1 mg/kg/day PO<br /><br />Mean duration<br /><br /> 96.6 weeks (≥7 days)<br /><br /><i>C</i><sub>tr</sub> collected pre-dose</td> <td align="left" rowspan="3"><i>CYP2C9</i><br /><br /> *1 = 89.2<br /><br /> *2 = 7.4<br /><br /> *3 = 3.4<br /><br /><i>CYP2C19</i><br /><br /> *1 = 70.1<br /><br /> *2 = 19.6<br /><br /> *3 = 10.3</td> <td align="left" colspan="2">Genotype group (CYP2C9, 2C19)</td> <td align="left" colspan="3">Serum PHT <i>C</i><sub>tr</sub>, mean mg/L (SEM)</td> </tr> <tr> <td align="left" colspan="2">*1/*1, *1/*1<br /><br />*1/*1, *1/*2<br /><br />*1/*1, *1/*3<br /><br />*1/*1, *2/*2<br /><br />*1/*1, *2/*3<br /><br />*1/*2, *1/*1<br /><br />*1/*2, *1/*2<br /><br />*1/*2, *1/*3<br /><br />*1/*3, *1/*1<br /><br />*1/*3, *1/*3<br /><br />*1/*3, *2/*3<sup>*</sup></td> <td align="left" colspan="3">7.43 (0.73)<sup>†</sup><br /><br />9.16 (1.46)<sup>***</sup><br /><br />7.51 (2.56)<sup>***</sup><br /><br />9.80 (4.52)<sup>**</sup><br /><br />10.35 (2.29)<sup>***</sup><br /><br />8.90 (1.30)<sup>†</sup><br /><br />14.80 (2.90)<br /><br />16.20<sup>*</sup><br /><br />10.47 (4.68)<br /><br />10 (1.20)<br /><br />27.90 (1.85)</td> </tr> <tr> <td align="left" colspan="5"><sup>*</sup>Reference genotype group for all comparisons: <sup>**</sup><i>p</i> &amp;lt; 0.05, <sup>***</sup><i>p</i> &amp;lt; 0.005, <sup>†</sup><i>p</i> &amp;lt; 0.001</td> </tr> <tr> <td align="left" rowspan="3">Alhazzani et al. [<a href="#CR45">45</a>]</td> <td align="left" rowspan="3">Saudi Arabia<br /><br /> Epileptic patients taking PHT monotherapy: drug responsive (<i>n</i> = 25), drug resistant (<i>n</i> = 25)</td> <td align="left" rowspan="3">300 mg PO daily ≥1 month<br /><br /> Multiple samples collected over 12 h following dose</td> <td align="left" rowspan="3"><i>MDR1 (ABCB1) C3435T</i><br /><br /> Drug responsive<br /><br /> C = 88<br /><br /> T = 12<br /><br />Drug resistant<br /><br /> C = 70<br /><br /> T = 30</td> <td align="left" rowspan="2" colspan="2">PK parameters<sup>b</sup></td> <td align="left" colspan="3">Genotype</td> </tr> <tr> <td align="left">CC</td> <td align="left">CT</td> <td align="left">TT</td> </tr> <tr> <td align="left" colspan="2"><i>C</i><sub>max</sub> (mg/mL)<br /><br /><i>T</i><sub>max</sub> (h)<br /><br />AUC<sub>0–12h</sub> (mg h/mL)<br /><br /><i>t</i>½ (h)<br /><br />Cl (L/h)</td> <td align="left">20.4 (0.29)<br /><br />6 (0.12)<br /><br />302 (0.45)<br /><br />19.2 (0.36)<br /><br />0.8 (0.11)</td> <td align="left">28 (0.10)<br /><br />6 (0.08)<br /><br />545 (0.71)<br /><br />30.2 (0.12)<br /><br />0.5 (0.04)</td> <td align="left">32 (0.16)<br /><br />6 (0.08)<br /><br />631 (0.48)<br /><br />33.3 (0.4)<br /><br />0.42 (0.21)</td> </tr> <tr> <td align="left" rowspan="8">Ebid et al. [<a href="#CR46">46</a>]</td> <td align="left" rowspan="8">Egypt<br /><br /> Epilepsy clinic outpatients taking PHT for partial (<i>n</i> = 43) or generalized tonic-clonic (<i>n</i> = 57) seizures; healthy volunteers from blood bank unit (<i>n</i> = 50)<br /><br /> PHT phenotyping in epilepsy patients (<i>n</i> = 100)</td> <td align="left" rowspan="8">Baseline dose<br /><br /> 100 mg PO BID ≥1 year<br /><br />Dose adjustment at 3 months: if drug resistant and <i>C</i><sub>tr</sub> &amp;lt;10 mg/L: 150 mg PO TID<br /><br /> If drug resistant and <i>C</i><sub>tr</sub> 10–14 mg/L: 100 mg PO TID<br /><br /> If drug responsive and/or <i>C</i><sub>tr</sub> ≥15 mg/L: stop PHT and end follow-up<br /><br /> <i>C</i><sub>tr</sub> collected pre-dose</td> <td align="left" rowspan="8"><i>MDR1 (ABCB1) C3435T</i><br /><br /> Drug responsive<br /><br /> C = 36.5<br /><br /> T = 63.5<br /><br /> Drug resistant<br /><br /> C = 74.6<br /><br /> T = 25.4<br /><br /> Healthy volunteers<br /><br /> C = 48<br /><br /> T = 52</td> <td align="left" colspan="5">3-month evaluation (<i>n</i> = 100)</td> </tr> <tr> <td align="left" colspan="2" /> <td align="left" colspan="2">Responsive, <i>n</i> = 18 (%)</td> <td align="left">Resistant, <i>n</i> = 82 (%)</td> </tr> <tr> <td align="left" colspan="2">Serum PHT <i>C</i><sub>tr</sub>, mg/L<br /><br /> &amp;lt;10<br /><br /> 10 to &amp;lt;15<br /><br /> ≥15</td> <td align="left" colspan="2">50<br /><br />44.4<br /><br />6.7</td> <td align="left">79.3<br /><br />17.1<br /><br />3.7</td> </tr> <tr> <td align="left" colspan="2">Genotype<br /><br /> CC<br /><br /> CT<br /><br /> TT</td> <td align="left" colspan="2">0<br /><br />44.4<br /><br />55.6</td> <td align="left">48.8<br /><br />40.2<br /><br />11</td> </tr> <tr> <td align="left" colspan="5">6-month evaluation (<i>n</i> = 79)</td> </tr> <tr> <td align="left" /> <td align="left" colspan="3">Responsive, <i>n</i> = 19 (%)</td> <td align="left">Resistant, <i>n</i> = 60 (%)</td> </tr> <tr> <td align="left">Serum PHT <i>C</i><sub>tr</sub>, mg/L<br /><br /> &amp;lt;10<br /><br /> 10 to &amp;lt;15<br /><br /> ≥15</td> <td align="left" colspan="3">10.5<br /><br />31.6<br /><br />57.9</td> <td align="left">15<br /><br />68.3<br /><br />16.7</td> </tr> <tr> <td align="left">Genotype<br /><br /> CC<br /><br /> CT<br /><br /> TT</td> <td align="left" colspan="3">26.3<br /><br />47.4<br /><br />26.3</td> <td align="left">58.3<br /><br />36.7<br /><br />5</td> </tr> </tbody> </table> <div class="table-wrap-foot_UNKNOWN"> <p><i>AUC</i><sub><i>0–12h</i></sub> area under the concentration–time curve from 0 to 12 h post-dose, <i>AVM</i> arteriovenous malformation, <i>BID</i> twice daily, <i>CBZ</i> carbamazepine, <i>CI</i> confidence interval, <i>Cl</i> clearance, <i>C</i><sub><i>max</i></sub> maximum plasma concentration, <i>C</i><sub><i>tr</i></sub> trough concentration, <i>CYP</i> cytochrome P450, <i>LTG</i> lamotrigine, <i>PHT</i> phenytoin, <i>p-HPPH</i> 5-(<i>p</i>-hydroxyphenyl)-5-phenylhydantoin metabolite, <i>PK</i> pharmacokinetic, <i>PO</i> orally by mouth, <i>SD</i> standard deviation, <i>SEM</i> standard error of the mean, <i>t½</i> half-life, <i>TID</i> three times daily, <i>T</i><sub><i>max</i></sub> time to <i>C</i><sub>max</sub>, <i>VPA</i> valproic acid</p> <p><sup>a</sup>From one individual, cannot calculate 95% CI, SD, or SEM</p> <p><sup>b</sup>Mean (SEM) reported</p> </div> </div> <p /> <p id="Par19">Upon assessment, each of the five studies was rated to be of poor quality. The ratings of each study against the 14 quality assessment tool criteria are summarized in Table <a href="#Tab2">2</a>. Factors contributing to poor quality ratings included: unclear descriptions of study subject selection, introducing potential for selection bias; insufficient reporting of study subjects’ baseline characteristics; relatively small sample sizes, limiting the power to assess the impact of polymorphic genotypes with low frequencies; and absence of adjustments for potential confounders that could affect phenytoin pharmacokinetics (e.g., antiepileptic polytherapy, concomitant medications, comorbid medical conditions, or serum albumin levels) or clinical outcomes (e.g., seizure control at baseline, seizure etiology, or type of seizure). <div class="table-wrap_UNKNOWN" id="Tab2"><span class="label" tagx="label" title="label">Table 2</span> </div></p><p>Summary of methodological quality ratings of included studies<sup>a</sup></p>  <table frame="hsides" rules="groups"> <thead> <tr> <th align="left">Criteria</th> <th align="left">Aynacioglu et al. [<a href="#CR42">42</a>]</th> <th align="left">Kerb et al. [<a href="#CR43">43</a>]</th> <th align="left">Ozkaynakci et al. [<a href="#CR44">44</a>]</th> <th align="left">Alhazzani et al. [<a href="#CR45">45</a>]</th> <th align="left">Ebid et al. [<a href="#CR46">46</a>]</th> </tr> </thead> <tbody> <tr> <td align="left">1. Research question or objective clearly stated</td> <td align="left">Yes</td> <td align="left">No</td> <td align="left">Yes</td> <td align="left">Yes</td> <td align="left">Yes</td> </tr> <tr> <td align="left">2. Study population clearly specified and defined</td> <td align="left">No</td> <td align="left">No</td> <td align="left">No</td> <td align="left">No</td> <td align="left">No</td> </tr> <tr> <td align="left">3. At least 50% of eligible persons participate</td> <td align="left">NR</td> <td align="left">NR</td> <td align="left">NR</td> <td align="left">NR</td> <td align="left">NR</td> </tr> <tr> <td align="left">4a. All subjects selected from same or similar population and same time period</td> <td align="left">CD</td> <td align="left">CD</td> <td align="left">CD</td> <td align="left">CD</td> <td align="left">CD</td> </tr> <tr> <td align="left">4b. Inclusion and exclusion criteria pre-specified and uniformly applied</td> <td align="left">NR</td> <td align="left">NR</td> <td align="left">Yes</td> <td align="left">Yes</td> <td align="left">Yes</td> </tr> <tr> <td align="left">5. Sample size justification, power description, or variance and effect estimate provided</td> <td align="left">No</td> <td align="left">No</td> <td align="left">No</td> <td align="left">No</td> <td align="left">No</td> </tr> <tr> <td align="left">6. Exposure<sup>b</sup> of interest measured prior to outcome(s) being measured</td> <td align="left">NA</td> <td align="left">NA</td> <td align="left">NA</td> <td align="left">NA</td> <td align="left">NA</td> </tr> <tr> <td align="left">7. Timeframe sufficient to see association between exposure<sup>b</sup> and outcome if it existed</td> <td align="left">Yes</td> <td align="left">Yes</td> <td align="left">Yes</td> <td align="left">Yes</td> <td align="left">Yes</td> </tr> <tr> <td align="left">8. Study examined different levels of exposure<sup>b</sup> as related to outcome</td> <td align="left">NA</td> <td align="left">NA</td> <td align="left">NA</td> <td align="left">NA</td> <td align="left">NA</td> </tr> <tr> <td align="left">9. Exposure<sup>b</sup> measures clearly defined, valid, reliable, and implemented consistently</td> <td align="left">Yes</td> <td align="left">CD</td> <td align="left">Yes</td> <td align="left">CD</td> <td align="left">Yes</td> </tr> <tr> <td align="left">10. Exposure<sup>b</sup> assessed more than once over time</td> <td align="left">NA</td> <td align="left">NA</td> <td align="left">NA</td> <td align="left">NA</td> <td align="left">NA</td> </tr> <tr> <td align="left">11. Outcome measures clearly defined, valid, reliable, and implemented consistently</td> <td align="left">Yes</td> <td align="left">CD</td> <td align="left">CD</td> <td align="left">CD</td> <td align="left">Yes</td> </tr> <tr> <td align="left">12. Outcome assessors blinded to participant exposure status</td> <td align="left">NA</td> <td align="left">NA</td> <td align="left">NA</td> <td align="left">NA</td> <td align="left">NA</td> </tr> <tr> <td align="left">13. Loss to follow-up after baseline was 20% or less</td> <td align="left">NA</td> <td align="left">NA</td> <td align="left">NA</td> <td align="left">NA</td> <td align="left">Yes</td> </tr> <tr> <td align="left">14. Key potential confounding variables measured and adjusted for statistically</td> <td align="left">No</td> <td align="left">No</td> <td align="left">No</td> <td align="left">No</td> <td align="left">No</td> </tr> </tbody> </table> <div class="table-wrap-foot_UNKNOWN"> <p><i>CD</i> cannot determine, <i>NA</i> not applicable, <i>NR</i> not reported</p> <p><sup>a</sup>Studies were rated against the 14 criteria of the Quality Assessment Tool for Observational Cohort and Cross-Sectional Studies, from the National Institutes of Health, National Heart, Lung, and Blood Institute [<a href="#CR16">16</a>]</p> <p><sup>b</sup>Exposure was defined as study participants’ allelic make-up for the polymorphism of interest</p> </div>  <p /> <p id="Par20">A total of 82 studies were conducted within the MENA region and investigated the prevalence of <i>CYP2C9</i>, <i>CYP2C19</i>, and/or <i>MDR1</i> variant alleles [<a href="#CR27">27</a>, <a href="#CR29">29</a>, <a href="#CR42">42</a>–<a href="#CR121">121</a>]. These studies were included in the secondary part of the review. Specific single nucleotide polymorphisms reviewed were<i>: CYP2C9*1</i>, <i>*2</i>, and <i>*3</i>; <i>CYP2C19*1</i>, <i>*2</i>, and <i>*3</i>; and <i>MDR1 (ABCB1)</i> C3435T. The study populations and computed genotypic and allelic frequencies for <i>CYP2C9</i>, <i>CYP2C19</i>, and <i>MDR1</i> are summarized in Tables <a href="#Tab3">3</a>, <a href="#Tab4">4</a>, and <a href="#Tab5">5</a>, respectively. <div class="table-wrap_UNKNOWN" id="Tab3"><span class="label" tagx="label" title="label">Table 3</span> </div></p><p>Genotypic and allelic frequencies of <i>CYP2C9</i> in the Middle East and North Africa region</p>  <table frame="hsides" rules="groups"> <thead> <tr> <th align="left" rowspan="2">References</th> <th align="left" rowspan="2">Country</th> <th align="left" rowspan="2">Study population</th> <th align="left" rowspan="2">Sample size</th> <th align="left" colspan="6">Genotypic frequencies (%)</th> <th align="left" colspan="3">Allelic frequencies (%)</th> </tr> <tr> <th align="left">*1/*1</th> <th align="left">*1/*2</th> <th align="left">*1/*3</th> <th align="left">*2/*2</th> <th align="left">*2/*3</th> <th align="left">*3/*3</th> <th align="left">*1</th> <th align="left">*2</th> <th align="left">*3</th> </tr> </thead> <tbody> <tr> <td align="left">[<a href="#CR47">47</a>]</td> <td align="left">Egypt</td> <td align="left">Healthy volunteers</td> <td char="." align="char">247</td> <td char="." align="char">66.4</td> <td align="left">19.0</td> <td char="." align="char">11.7</td> <td align="left">2.4</td> <td align="left">0</td> <td char="." align="char">0.4</td> <td char="." align="char">81.8</td> <td align="left">11.9</td> <td align="left">6.3</td> </tr> <tr> <td align="left">[<a href="#CR48">48</a>]</td> <td align="left">Egypt</td> <td align="left">Healthy volunteers (<i>n</i> = 154), patients taking maintenance warfarin (<i>n</i> = 46)</td> <td char="." align="char">200</td> <td char="." align="char">81.5</td> <td align="left">4.5</td> <td char="." align="char">8.5</td> <td align="left">4.5</td> <td align="left">0.5</td> <td char="." align="char">0.5</td> <td char="." align="char">88.0</td> <td align="left">7.0</td> <td align="left">5.0</td> </tr> <tr> <td align="left" rowspan="2">[<a href="#CR49">49</a>]</td> <td align="left" rowspan="2">Egypt</td> <td align="left">Warfarin-resistant patients</td> <td char="." align="char">41</td> <td char="." align="char">60.9</td> <td align="left">19.5</td> <td char="." align="char">19.5</td> <td align="left">0</td> <td align="left">0</td> <td char="." align="char">0</td> <td char="." align="char">80.4</td> <td align="left">9.8</td> <td align="left">9.8</td> </tr> <tr> <td align="left">Warfarin-responsive patients</td> <td char="." align="char">30</td> <td char="." align="char">73.3</td> <td align="left">20.0</td> <td char="." align="char">6.7</td> <td align="left">0</td> <td align="left">0</td> <td char="." align="char">0</td> <td char="." align="char">86.7</td> <td align="left">10.0</td> <td align="left">3.3</td> </tr> <tr> <td align="left">[<a href="#CR50">50</a>]</td> <td align="left">Egypt</td> <td align="left">Patients taking maintenance warfarin</td> <td char="." align="char">63</td> <td char="." align="char">76.2</td> <td align="left">7.9</td> <td char="." align="char">6.3</td> <td align="left">3.2</td> <td align="left">0</td> <td char="." align="char">6.3</td> <td char="." align="char">83.4</td> <td align="left">7.1</td> <td align="left">9.5</td> </tr> <tr> <td align="left">[<a href="#CR51">51</a>]</td> <td align="left">Egypt</td> <td align="left">Patients taking maintenance warfarin</td> <td char="." align="char">84</td> <td char="." align="char">83.3</td> <td align="left">NA</td> <td char="." align="char">11.9</td> <td align="left">NA</td> <td align="left">NA</td> <td char="." align="char">4.8</td> <td char="." align="char">89.3</td> <td align="left">NA</td> <td align="left">10.7</td> </tr> <tr> <td align="left">[<a href="#CR52">52</a>]</td> <td align="left">Egypt<sup>a</sup></td> <td align="left">Patients taking maintenance warfarin</td> <td char="." align="char">207</td> <td char="." align="char">62.6</td> <td align="left">17.4</td> <td char="." align="char">11.8</td> <td align="left">1.0</td> <td align="left">4.1</td> <td char="." align="char">1.0</td> <td char="." align="char">74.2</td> <td align="left">11.1</td> <td align="left">8.5</td> </tr> <tr> <td align="left">[<a href="#CR53">53</a>]</td> <td align="left">Iran</td> <td align="left">Healthy volunteers</td> <td char="." align="char">200</td> <td char="." align="char">82.0</td> <td align="left">10.5</td> <td char="." align="char">0</td> <td align="left">7.5</td> <td align="left">0</td> <td char="." align="char">0</td> <td char="." align="char">87.2</td> <td align="left">12.8</td> <td align="left">0</td> </tr> <tr> <td align="left" rowspan="2">[<a href="#CR54">54</a>]</td> <td align="left" rowspan="2">Iran</td> <td align="left">Healthy volunteers</td> <td char="." align="char">50</td> <td char="." align="char">82.0</td> <td align="left">12.0</td> <td char="." align="char">6.0</td> <td align="left">0</td> <td align="left">0</td> <td char="." align="char">0</td> <td char="." align="char">91.0</td> <td align="left">6.0</td> <td align="left">3.0</td> </tr> <tr> <td align="left">Patients taking maintenance valproic acid</td> <td char="." align="char">68</td> <td char="." align="char">80.9</td> <td align="left">11.8</td> <td char="." align="char">4.4</td> <td align="left">1.5</td> <td align="left">1.5</td> <td char="." align="char">0</td> <td char="." align="char">89.0</td> <td align="left">8.1</td> <td align="left">2.9</td> </tr> <tr> <td align="left" rowspan="2">[<a href="#CR55">55</a>]</td> <td align="left" rowspan="2">Iran</td> <td align="left">Warfarin-sensitive patients</td> <td char="." align="char">21</td> <td char="." align="char">19.0</td> <td align="left">66.7</td> <td char="." align="char">14.3</td> <td align="left">0</td> <td align="left">0</td> <td char="." align="char">0</td> <td char="." align="char">52.4</td> <td align="left">47.6</td> <td align="left">NA</td> </tr> <tr> <td align="left">Patients with normal warfarin response</td> <td char="." align="char">37</td> <td char="." align="char">75.7</td> <td align="left">21.6</td> <td char="." align="char">2.7</td> <td align="left">0</td> <td align="left">0</td> <td char="." align="char">0</td> <td char="." align="char">86.5</td> <td align="left">13.5</td> <td align="left">NA</td> </tr> <tr> <td align="left">[<a href="#CR56">56</a>]</td> <td align="left">Iran</td> <td align="left">Patients taking maintenance warfarin</td> <td char="." align="char">100</td> <td char="." align="char">39.0</td> <td align="left">41.0</td> <td char="." align="char">9.0</td> <td align="left">2.0</td> <td align="left">9.0</td> <td char="." align="char">0</td> <td char="." align="char">64.0</td> <td align="left">27.0</td> <td align="left">9.0</td> </tr> <tr> <td align="left">[<a href="#CR57">57</a>]</td> <td align="left">Jordan</td> <td align="left">Healthy volunteers</td> <td char="." align="char">263</td> <td char="." align="char">62.7</td> <td align="left">21.7</td> <td char="." align="char">12.2</td> <td align="left">1.9</td> <td align="left">1.5</td> <td char="." align="char">0</td> <td char="." align="char">79.7</td> <td align="left">13.5</td> <td align="left">6.8</td> </tr> <tr> <td align="left">[<a href="#CR58">58</a>]</td> <td align="left">Kuwait</td> <td align="left">Patients taking maintenance warfarin</td> <td char="." align="char">108</td> <td char="." align="char">69.4</td> <td align="left">21.3</td> <td char="." align="char">6.5</td> <td align="left">0</td> <td align="left">2.8</td> <td char="." align="char">0</td> <td char="." align="char">83.4</td> <td align="left">12.0</td> <td align="left">4.6</td> </tr> <tr> <td align="left">[<a href="#CR59">59</a>]</td> <td align="left">Libya</td> <td align="left">Healthy volunteers</td> <td char="." align="char">161</td> <td char="." align="char">65.8</td> <td align="left">14.9</td> <td char="." align="char">13.7</td> <td align="left">1.9</td> <td align="left">2.5</td> <td char="." align="char">1.2</td> <td char="." align="char">80.1</td> <td align="left">10.6</td> <td align="left">9.3</td> </tr> <tr> <td align="left">[<a href="#CR60">60</a>]</td> <td align="left">Libya</td> <td align="left">Patients taking maintenance VKA</td> <td char="." align="char">231</td> <td char="." align="char">60.6</td> <td align="left">22.5</td> <td char="." align="char">10.0</td> <td align="left">2.2</td> <td align="left">3.9</td> <td char="." align="char">0.9</td> <td char="." align="char">76.8</td> <td align="left">15.4</td> <td align="left">7.8</td> </tr> <tr> <td align="left" rowspan="3">[<a href="#CR61">61</a>]</td> <td align="left" rowspan="3">Morocco</td> <td align="left">Low-dose acenocoumarol</td> <td char="." align="char">20</td> <td char="." align="char">55.0</td> <td align="left">25.0</td> <td char="." align="char">5.0</td> <td align="left">10.0</td> <td align="left">0</td> <td char="." align="char">5.0</td> <td char="." align="char">70.0</td> <td align="left">22.5</td> <td align="left">7.5</td> </tr> <tr> <td align="left">Medium-dose acenocoumarol</td> <td char="." align="char">58</td> <td char="." align="char">72.4</td> <td align="left">19.0</td> <td char="." align="char">6.9</td> <td align="left">1.7</td> <td align="left">0</td> <td char="." align="char">0</td> <td char="." align="char">85.4</td> <td align="left">11.2</td> <td align="left">3.4</td> </tr> <tr> <td align="left">High-dose acenocoumarol</td> <td char="." align="char">36</td> <td char="." align="char">94.4</td> <td align="left">2.8</td> <td char="." align="char">0</td> <td align="left">2.8</td> <td align="left">0</td> <td char="." align="char">0</td> <td char="." align="char">95.8</td> <td align="left">4.2</td> <td align="left">0</td> </tr> <tr> <td align="left">[<a href="#CR62">62</a>]</td> <td align="left">Oman<sup>a</sup></td> <td align="left">Patients taking maintenance warfarin</td> <td char="." align="char">212</td> <td char="." align="char">73.6</td> <td align="left">11.3</td> <td char="." align="char">8.5</td> <td align="left">NA</td> <td align="left">2.4</td> <td char="." align="char">0.9</td> <td char="." align="char">84.2</td> <td align="left">6.8</td> <td align="left">6.4</td> </tr> <tr> <td align="left">[<a href="#CR63">63</a>]</td> <td align="left">Oman</td> <td align="left">Patients taking maintenance warfarin</td> <td char="." align="char">189</td> <td char="." align="char">80.4</td> <td align="left">12.7</td> <td char="." align="char">5.8</td> <td align="left">1.1</td> <td align="left">0</td> <td char="." align="char">0</td> <td char="." align="char">89.6</td> <td align="left">7.5</td> <td align="left">2.9</td> </tr> <tr> <td align="left">[<a href="#CR64">64</a>]</td> <td align="left">Saudi Arabia</td> <td align="left">Healthy volunteers</td> <td char="." align="char">131</td> <td char="." align="char">68.7</td> <td align="left">26.7</td> <td char="." align="char">4.6</td> <td align="left">0</td> <td align="left">0</td> <td char="." align="char">0</td> <td char="." align="char">84.3</td> <td align="left">13.4</td> <td align="left">2.3</td> </tr> <tr> <td align="left">[<a href="#CR65">65</a>]</td> <td align="left">Saudi Arabia</td> <td align="left">Healthy volunteers</td> <td char="." align="char">192</td> <td char="." align="char">64.1</td> <td align="left">17.2</td> <td char="." align="char">13.0</td> <td align="left">2.1</td> <td align="left">2.1</td> <td char="." align="char">1.6</td> <td char="." align="char">79.2</td> <td align="left">11.7</td> <td align="left">9.1</td> </tr> <tr> <td align="left">[<a href="#CR66">66</a>]</td> <td align="left">Sudan<sup>a</sup></td> <td align="left">Patients taking maintenance warfarin</td> <td char="." align="char">203</td> <td char="." align="char">71.9</td> <td align="left">8.9</td> <td char="." align="char">0</td> <td align="left">0</td> <td align="left">0</td> <td char="." align="char">0</td> <td char="." align="char">84.0</td> <td align="left">4.9</td> <td align="left">0</td> </tr> <tr> <td align="left">[<a href="#CR67">67</a>]</td> <td align="left">Tunisia<sup>a</sup></td> <td align="left">Healthy volunteers</td> <td char="." align="char">258</td> <td char="." align="char">61.6</td> <td align="left">19.4</td> <td char="." align="char">13.2</td> <td align="left">2.7</td> <td align="left">3.1</td> <td char="." align="char">0</td> <td char="." align="char">77.9</td> <td align="left">14.0</td> <td align="left">8.1</td> </tr> <tr> <td align="left">[<a href="#CR43">43</a>]</td> <td align="left">Turkey</td> <td align="left">Healthy volunteers</td> <td char="." align="char">96</td> <td char="." align="char">66.7</td> <td align="left">13.5</td> <td char="." align="char">15.6</td> <td align="left">3.1</td> <td align="left">0</td> <td char="." align="char">1.0</td> <td char="." align="char">81.2</td> <td align="left">9.9</td> <td align="left">8.9</td> </tr> <tr> <td align="left">[<a href="#CR68">68</a>]</td> <td align="left">Turkey</td> <td align="left">Healthy volunteers</td> <td char="." align="char">64</td> <td char="." align="char">64.0</td> <td align="left">14.1</td> <td char="." align="char">15.6</td> <td align="left">3.1</td> <td align="left">0</td> <td char="." align="char">3.1</td> <td char="." align="char">78.9</td> <td align="left">10.2</td> <td align="left">10.9</td> </tr> <tr> <td align="left">[<a href="#CR69">69</a>]</td> <td align="left">Turkey</td> <td align="left">Healthy volunteers</td> <td char="." align="char">85</td> <td char="." align="char">68.2</td> <td align="left">11.8</td> <td char="." align="char">14.1</td> <td align="left">3.5</td> <td align="left">1.2</td> <td char="." align="char">1.2</td> <td char="." align="char">81.2</td> <td align="left">10.0</td> <td align="left">8.8</td> </tr> <tr> <td align="left">[<a href="#CR42">42</a>]</td> <td align="left">Turkey</td> <td align="left">Healthy volunteers (<i>n</i> = 218), outpatients with variable diagnoses (<i>n</i> = 280)</td> <td char="." align="char">499</td> <td char="." align="char">61.7</td> <td align="left">18.0</td> <td char="." align="char">17.2</td> <td align="left">1.0</td> <td align="left">1.1</td> <td char="." align="char">0.8</td> <td char="." align="char">79.4</td> <td align="left">10.6</td> <td align="left">10.0</td> </tr> <tr> <td align="left">[<a href="#CR44">44</a>]</td> <td align="left">Turkey</td> <td align="left">Outpatients of epilepsy clinic</td> <td char="." align="char">102</td> <td char="." align="char">78.4</td> <td align="left">14.7</td> <td char="." align="char">6.9</td> <td align="left">0</td> <td align="left">0</td> <td char="." align="char">0</td> <td char="." align="char">89.2</td> <td align="left">7.4</td> <td align="left">3.4</td> </tr> <tr> <td align="left">[<a href="#CR70">70</a>]</td> <td align="left">Turkey<sup>a</sup></td> <td align="left">Patients taking maintenance warfarin</td> <td char="." align="char">205</td> <td char="." align="char">60.0</td> <td align="left">18.0</td> <td char="." align="char">13.7</td> <td align="left">1.5</td> <td align="left">3.9</td> <td char="." align="char">1.0</td> <td char="." align="char">76.8</td> <td align="left">12.7</td> <td align="left">9.8</td> </tr> <tr> <td align="left">[<a href="#CR71">71</a>]</td> <td align="left">Turkey</td> <td align="left">Patients taking maintenance warfarin</td> <td char="." align="char">100</td> <td char="." align="char">50.0</td> <td align="left">21.0</td> <td char="." align="char">24.0</td> <td align="left">0</td> <td align="left">5.0</td> <td char="." align="char">0</td> <td char="." align="char">72.5</td> <td align="left">13.0</td> <td align="left">14.5</td> </tr> <tr> <td align="left">[<a href="#CR72">72</a>]</td> <td align="left">Turkey</td> <td align="left">Patients taking maintenance anticoagulant</td> <td char="." align="char">292</td> <td char="." align="char">56.5</td> <td align="left">23.0</td> <td char="." align="char">8.6</td> <td align="left">3.0</td> <td align="left">7.2</td> <td char="." align="char">1.7</td> <td char="." align="char">72.2</td> <td align="left">18.2</td> <td align="left">9.6</td> </tr> </tbody> </table> <div class="table-wrap-foot_UNKNOWN"> <p><i>CYP</i> cytochrome P450, <i>NA</i> not assessed, <i>VKA</i> vitamin-K antagonist, <i>VPA</i> valproic acid</p> <p><sup>a</sup>Additional CYP2C9 alleles assessed; therefore, percentages do not add to 100%</p> </div>  <div class="table-wrap_UNKNOWN" id="Tab4"><span class="label" tagx="label" title="label">Table 4</span> <p>Genotypic and allelic frequencies of <i>CYP2C19</i> in the Middle East and North Africa region</p>  <table frame="hsides" rules="groups"> <thead> <tr> <th align="left" rowspan="2">References</th> <th align="left" rowspan="2">Country</th> <th align="left" rowspan="2">Study population</th> <th align="left" rowspan="2">Sample size</th> <th align="left" colspan="6">Genotypic frequencies (%)</th> <th align="left" colspan="3">Allelic frequencies (%)</th> </tr> <tr> <th align="left">*1/*1</th> <th align="left">*1/*2</th> <th align="left">*1/*3</th> <th align="left">*2/*2</th> <th align="left">*2/*3</th> <th align="left">*3/*3</th> <th align="left">*1</th> <th align="left">*2</th> <th align="left">*3</th> </tr> </thead> <tbody> <tr> <td align="left">[<a href="#CR67">67</a>]</td> <td align="left">Bahrain<sup>a</sup></td> <td align="left">Healthy volunteers</td> <td char="." align="char">75</td> <td align="left">33.3</td> <td char="." align="char">33.3</td> <td align="left">NA</td> <td char="." align="char">8.0</td> <td align="left">NA</td> <td align="left">NA</td> <td char="." align="char">53.3</td> <td char="." align="char">26.0</td> <td align="left">NA</td> </tr> <tr> <td align="left">[<a href="#CR47">47</a>]</td> <td align="left">Egypt</td> <td align="left">Healthy volunteers</td> <td char="." align="char">247</td> <td align="left">78.5</td> <td char="." align="char">20.2</td> <td align="left">0.4</td> <td char="." align="char">0.8</td> <td align="left">0</td> <td align="left">0</td> <td char="." align="char">88.9</td> <td char="." align="char">10.9</td> <td align="left">0.2</td> </tr> <tr> <td align="left">[<a href="#CR73">73</a>]</td> <td align="left">Egypt</td> <td align="left">Male agricultural workers</td> <td char="." align="char">120</td> <td align="left">93.3</td> <td char="." align="char">5.8</td> <td align="left">NA</td> <td char="." align="char">0.8</td> <td align="left">NA</td> <td align="left">NA</td> <td char="." align="char">96.2</td> <td char="." align="char">3.8</td> <td align="left">NA</td> </tr> <tr> <td align="left" rowspan="2">[<a href="#CR74">74</a>]</td> <td align="left" rowspan="2">Gaza Strip</td> <td align="left">Children with hematological malignancy</td> <td char="." align="char">52</td> <td align="left">80.8</td> <td char="." align="char">15.4</td> <td align="left">1.9</td> <td char="." align="char">1.9</td> <td align="left">0</td> <td align="left">0</td> <td char="." align="char">89.4</td> <td char="." align="char">9.6</td> <td align="left">1.0</td> </tr> <tr> <td align="left">Healthy volunteers</td> <td char="." align="char">200</td> <td align="left">86.5</td> <td char="." align="char">6.5</td> <td align="left">1.5</td> <td char="." align="char">3</td> <td align="left">0.5</td> <td align="left">2.0</td> <td char="." align="char">90.5</td> <td char="." align="char">6.5</td> <td align="left">3.0</td> </tr> <tr> <td align="left">[<a href="#CR53">53</a>]</td> <td align="left">Iran</td> <td align="left">Healthy volunteers</td> <td char="." align="char">200</td> <td align="left">75.0</td> <td char="." align="char">22.0</td> <td align="left">0</td> <td char="." align="char">3.0</td> <td align="left">0</td> <td align="left">0</td> <td char="." align="char">86.0</td> <td char="." align="char">14.0</td> <td align="left">0</td> </tr> <tr> <td align="left">[<a href="#CR75">75</a>]</td> <td align="left">Iran<sup>a</sup></td> <td align="left">Healthy volunteers</td> <td char="." align="char">180</td> <td align="left">41.7</td> <td char="." align="char">18.3</td> <td align="left">NA</td> <td char="." align="char">2.2</td> <td align="left">NA</td> <td align="left">NA</td> <td char="." align="char">65.3</td> <td char="." align="char">13.1</td> <td align="left">0</td> </tr> <tr> <td align="left">[<a href="#CR27">27</a>]</td> <td align="left">Iran</td> <td align="left">Healthy volunteers of Baluch descent</td> <td char="." align="char">140</td> <td align="left">78.6</td> <td char="." align="char">20.0</td> <td align="left">0.7</td> <td char="." align="char">0</td> <td align="left">0</td> <td align="left">0.7</td> <td char="." align="char">88.9</td> <td char="." align="char">10.0</td> <td align="left">1.1</td> </tr> <tr> <td align="left">[<a href="#CR76">76</a>]</td> <td align="left">Iran</td> <td align="left">Patients with erosive reflux esophagitis</td> <td char="." align="char">82</td> <td align="left">70.7</td> <td char="." align="char">24.3</td> <td align="left">3.7</td> <td char="." align="char">1.3</td> <td align="left">0</td> <td align="left">0</td> <td char="." align="char">84.8</td> <td char="." align="char">13.4</td> <td align="left">1.8</td> </tr> <tr> <td align="left">[<a href="#CR56">56</a>]</td> <td align="left">Iran</td> <td align="left">Patients taking maintenance warfarin</td> <td char="." align="char">99</td> <td align="left">76.8</td> <td char="." align="char">21.2</td> <td align="left">0.1</td> <td char="." align="char">0</td> <td align="left">0.1</td> <td align="left">0</td> <td char="." align="char">87.9</td> <td char="." align="char">11.1</td> <td align="left">1.0</td> </tr> <tr> <td align="left">[<a href="#CR77">77</a>]</td> <td align="left">Iran</td> <td align="left">Patients taking clopidogrel for elective PCI</td> <td char="." align="char">112</td> <td align="left" colspan="6">NR</td> <td char="." align="char">89.0</td> <td align="left">10.1</td> <td char="." align="char">0.9</td> </tr> <tr> <td align="left">[<a href="#CR78">78</a>]</td> <td align="left">Iran</td> <td align="left">Patients with PCI for CAD</td> <td char="." align="char">43</td> <td align="left">72.1</td> <td char="." align="char">23.3</td> <td align="left">NA</td> <td char="." align="char">4.7</td> <td align="left">NA</td> <td align="left">NA</td> <td char="." align="char">83.7</td> <td char="." align="char">16.3</td> <td align="left">NA</td> </tr> <tr> <td align="left" rowspan="2">[<a href="#CR79">79</a>]</td> <td align="left" rowspan="2">Iran</td> <td align="left">Patients with in-stent restenosis while taking appropriate DAPT for PCI</td> <td char="." align="char">50</td> <td align="left">86.0</td> <td char="." align="char">14.0</td> <td align="left">NA</td> <td char="." align="char">0</td> <td align="left">NA</td> <td align="left">NA</td> <td char="." align="char">93.0</td> <td char="." align="char">7.0</td> <td align="left">NA</td> </tr> <tr> <td align="left">Patients without in-stent restenosis while taking DAPT for PCI</td> <td char="." align="char">50</td> <td align="left">92.0</td> <td char="." align="char">8.0</td> <td align="left">NA</td> <td char="." align="char">0</td> <td align="left">NA</td> <td align="left">NA</td> <td char="." align="char">96.0</td> <td char="." align="char">4.0</td> <td align="left">NA</td> </tr> <tr> <td align="left">[<a href="#CR80">80</a>]</td> <td align="left">Israel</td> <td align="left">Healthy volunteers</td> <td char="." align="char">140</td> <td align="left">70.7</td> <td char="." align="char">25.0</td> <td align="left">1.4</td> <td char="." align="char">2.9</td> <td align="left">0</td> <td align="left">0</td> <td char="." align="char">83.9</td> <td char="." align="char">15.4</td> <td align="left">0.7</td> </tr> <tr> <td align="left" rowspan="2">[<a href="#CR81">81</a>]</td> <td align="left" rowspan="2">Israel</td> <td align="left">Volunteers of Yemenite descent</td> <td char="." align="char">36</td> <td align="left">77.8</td> <td char="." align="char">19.4</td> <td align="left">0</td> <td char="." align="char">2.8</td> <td align="left">0</td> <td align="left">0</td> <td char="." align="char">87.5</td> <td char="." align="char">12.5</td> <td align="left">0</td> </tr> <tr> <td align="left">Volunteers of Bedouin descent</td> <td char="." align="char">50</td> <td align="left">76.0</td> <td char="." align="char">20.0</td> <td align="left">2.0</td> <td char="." align="char">2.0</td> <td align="left">0</td> <td align="left">0</td> <td char="." align="char">87.0</td> <td char="." align="char">12.0</td> <td align="left">1.0</td> </tr> <tr> <td align="left">[<a href="#CR57">57</a>]</td> <td align="left">Jordan</td> <td align="left">Healthy volunteers</td> <td char="." align="char">158</td> <td align="left">78.5</td> <td char="." align="char">18.4</td> <td align="left">0</td> <td char="." align="char">3.2</td> <td align="left">0</td> <td align="left">0</td> <td char="." align="char">87.7</td> <td char="." align="char">12.3</td> <td align="left">0</td> </tr> <tr> <td align="left">[<a href="#CR82">82</a>]</td> <td align="left">Jordan</td> <td align="left">Healthy male volunteers</td> <td char="." align="char">78</td> <td align="left">74.4</td> <td char="." align="char">19.2</td> <td align="left">0</td> <td char="." align="char">6.4</td> <td align="left">0</td> <td align="left">0</td> <td char="." align="char">84.0</td> <td char="." align="char">16.0</td> <td align="left">0</td> </tr> <tr> <td align="left">[<a href="#CR67">67</a>]</td> <td align="left">Kuwait<sup>a</sup></td> <td align="left">Healthy volunteers</td> <td char="." align="char">100</td> <td align="left">41.0</td> <td char="." align="char">35.0</td> <td align="left">NA</td> <td char="." align="char">3.0</td> <td align="left">NA</td> <td align="left">NA</td> <td char="." align="char">61.5</td> <td char="." align="char">22.0</td> <td align="left">NA</td> </tr> <tr> <td align="left">[<a href="#CR83">83</a>]</td> <td align="left">Lebanon</td> <td align="left">Healthy volunteers</td> <td char="." align="char">161</td> <td align="left">75.8</td> <td char="." align="char">20.5</td> <td align="left">0.6</td> <td char="." align="char">3.1</td> <td align="left">0</td> <td align="left">0</td> <td char="." align="char">86.3</td> <td char="." align="char">13.4</td> <td align="left">0.3</td> </tr> <tr> <td align="left">[<a href="#CR84">84</a>]</td> <td align="left">Saudi Arabia<sup>a</sup></td> <td align="left">Healthy volunteers</td> <td char="." align="char">201</td> <td align="left">40.3</td> <td char="." align="char">14.4</td> <td align="left">NA</td> <td char="." align="char">0.005</td> <td align="left">NA</td> <td align="left">NA</td> <td char="." align="char">62.9</td> <td char="." align="char">11.2</td> <td align="left">NA</td> </tr> <tr> <td align="left">[<a href="#CR85">85</a>]</td> <td align="left">Saudi Arabia</td> <td align="left">Healthy military recruits</td> <td char="." align="char">97</td> <td align="left" colspan="6">NR</td> <td char="." align="char">87.0</td> <td align="left">13.0</td> <td char="." align="char">0</td> </tr> <tr> <td align="left">[<a href="#CR86">86</a>]</td> <td align="left">Saudi Arabia</td> <td align="left">Patients taking clopidogrel for ACS</td> <td char="." align="char">90</td> <td align="left">67.0</td> <td char="." align="char">3.0</td> <td align="left">0</td> <td char="." align="char">32.0</td> <td align="left">0</td> <td align="left">0</td> <td char="." align="char">67.8</td> <td char="." align="char">32.2</td> <td align="left">0</td> </tr> <tr> <td align="left">[<a href="#CR67">67</a>]</td> <td align="left">Tunisia<sup>a</sup></td> <td align="left">Healthy volunteers</td> <td char="." align="char">258</td> <td align="left">47.3</td> <td char="." align="char">12.8</td> <td align="left">NA</td> <td char="." align="char">0.3</td> <td align="left">NA</td> <td align="left">NA</td> <td char="." align="char">69.8</td> <td char="." align="char">8.9</td> <td align="left">0</td> </tr> <tr> <td align="left">[<a href="#CR43">43</a>]</td> <td align="left">Turkey</td> <td align="left">Healthy volunteers</td> <td char="." align="char">94</td> <td align="left">78.1</td> <td char="." align="char">16.7</td> <td align="left">NA</td> <td char="." align="char">3.1</td> <td align="left">NA</td> <td align="left">NA</td> <td char="." align="char">88.3</td> <td char="." align="char">11.7</td> <td align="left">0</td> </tr> <tr> <td align="left">[<a href="#CR87">87</a>]</td> <td align="left">Turkey</td> <td align="left">Healthy volunteers</td> <td char="." align="char">404</td> <td align="left">76.0</td> <td char="." align="char">22.3</td> <td align="left">0.7</td> <td char="." align="char">1.0</td> <td align="left">0</td> <td align="left">0</td> <td char="." align="char">87.5</td> <td char="." align="char">12.1</td> <td align="left">0.4</td> </tr> <tr> <td align="left">[<a href="#CR44">44</a>]</td> <td align="left">Turkey</td> <td align="left">Outpatients of epilepsy clinic</td> <td char="." align="char">102</td> <td align="left">55.9</td> <td char="." align="char">17.6</td> <td align="left">10.8</td> <td char="." align="char">5.9</td> <td align="left">9.8</td> <td align="left">0</td> <td char="." align="char">70.1</td> <td char="." align="char">19.6</td> <td align="left">10.3</td> </tr> <tr> <td align="left">[<a href="#CR88">88</a>]</td> <td align="left">Turkey<sup>a</sup></td> <td align="left">Children, 2–18 years old</td> <td char="." align="char">244</td> <td align="left">44.3</td> <td char="." align="char">12.3</td> <td align="left">0</td> <td char="." align="char">1.2</td> <td align="left">0</td> <td align="left">0</td> <td char="." align="char">65.6</td> <td char="." align="char">10.0</td> <td align="left">0</td> </tr> <tr> <td align="left">[<a href="#CR89">89</a>]</td> <td align="left">Turkey</td> <td align="left">Patients taking clopidogrel for ICVD</td> <td char="." align="char">51</td> <td align="left">70.6</td> <td char="." align="char">25.5</td> <td align="left">0</td> <td char="." align="char">3.9</td> <td align="left">0</td> <td align="left">0</td> <td char="." align="char">83.3</td> <td char="." align="char">16.7</td> <td align="left">0</td> </tr> </tbody> </table> <div class="table-wrap-foot_UNKNOWN"> <p><i>ACS</i> acute coronary syndrome, <i>CAD</i> coronary artery disease, <i>CYP</i> cytochrome P450, <i>DAPT</i> dual anti-platelet therapy, <i>ICVD</i> ischemic cerebrovascular disease, <i>MACE</i> major adverse cardiac event, <i>NA</i> not assessed, <i>NR</i> not reported, <i>PCI</i> percutaneous coronary intervention</p> <p><sup>a</sup>Additional CYP2C19 alleles assessed; therefore, percentages do not add to 100%</p> </div> </div> <div class="table-wrap_UNKNOWN" id="Tab5"><span class="label" tagx="label" title="label">Table 5</span> <p>Genotypic and allelic frequencies of <i>MDR1</i> (<i>ABCB1</i>) C3435T in the Middle East and North Africa region</p>  <table frame="hsides" rules="groups"> <thead> <tr> <th align="left" rowspan="2">References</th> <th align="left" rowspan="2">Country</th> <th align="left" rowspan="2">Study population</th> <th align="left" rowspan="2">Sample size</th> <th align="left" colspan="3">Genotypic frequencies (%)</th> <th align="left" colspan="2">Allelic frequencies (%)</th> </tr> <tr> <th align="left">CC</th> <th align="left">CT</th> <th align="left">TT</th> <th align="left">C</th> <th align="left">T</th> </tr> </thead> <tbody> <tr> <td align="left" rowspan="3">[<a href="#CR46">46</a>]</td> <td align="left" rowspan="3">Egypt</td> <td align="left">Healthy volunteers</td> <td char="." align="char">50</td> <td align="left">24.0</td> <td char="." align="char">48.0</td> <td char="." align="char">28.0</td> <td char="." align="char">48.0</td> <td char="." align="char">52.0</td> </tr> <tr> <td align="left">Patients with drug-responsive epilepsy</td> <td char="." align="char">37</td> <td align="left">13.5</td> <td char="." align="char">46.0</td> <td char="." align="char">40.5</td> <td char="." align="char">36.5</td> <td char="." align="char">63.5</td> </tr> <tr> <td align="left">Patients with drug-resistant epilepsy</td> <td char="." align="char">63</td> <td align="left">55.6</td> <td char="." align="char">38.1</td> <td char="." align="char">6.3</td> <td char="." align="char">74.6</td> <td char="." align="char">25.4</td> </tr> <tr> <td align="left" rowspan="2">[<a href="#CR90">90</a>]</td> <td align="left" rowspan="2">Egypt</td> <td align="left">Patients taking clopidogrel for ACS or PCI who experienced MACE</td> <td char="." align="char">84</td> <td align="left">39.3</td> <td char="." align="char">47.6</td> <td char="." align="char">13.1</td> <td char="." align="char">63.1</td> <td char="." align="char">36.9</td> </tr> <tr> <td align="left">Patients taking clopidogrel for ACS or PCI who did not experience MACE</td> <td char="." align="char">106</td> <td align="left">37.7</td> <td char="." align="char">44.3</td> <td char="." align="char">17.9</td> <td char="." align="char">59.9</td> <td char="." align="char">40.1</td> </tr> <tr> <td align="left">[<a href="#CR91">91</a>]</td> <td align="left">Egypt</td> <td align="left">Patients taking maintenance warfarin</td> <td char="." align="char">84</td> <td align="left">29.8</td> <td char="." align="char">54.8</td> <td char="." align="char">15.4</td> <td char="." align="char">57.1</td> <td char="." align="char">42.9</td> </tr> <tr> <td align="left">[<a href="#CR92">92</a>]</td> <td align="left">Egypt</td> <td align="left">Patients with hypercholesterolemia</td> <td char="." align="char">50</td> <td align="left">38.0</td> <td char="." align="char">40.0</td> <td char="." align="char">22.0</td> <td char="." align="char">58.0</td> <td char="." align="char">42.0</td> </tr> <tr> <td align="left">[<a href="#CR93">93</a>]</td> <td align="left">Egypt</td> <td align="left">Patients taking imatinib for newly diagnosed Philadelphia chromosome-positive CML</td> <td char="." align="char">100</td> <td align="left">44.0</td> <td char="." align="char">47.0</td> <td char="." align="char">9.0</td> <td char="." align="char">67.5</td> <td char="." align="char">32.5</td> </tr> <tr> <td align="left" rowspan="2">[<a href="#CR94">94</a>]</td> <td align="left" rowspan="2">Egypt</td> <td align="left">Healthy child volunteers</td> <td char="." align="char">35</td> <td align="left">28.6</td> <td char="." align="char">48.6</td> <td char="." align="char">22.9</td> <td char="." align="char">47.1</td> <td char="." align="char">52.9</td> </tr> <tr> <td align="left">Children with immune thrombocytopenia</td> <td char="." align="char">48</td> <td align="left">8.3</td> <td char="." align="char">62.5</td> <td char="." align="char">27.1</td> <td char="." align="char">67.6</td> <td char="." align="char">32.4</td> </tr> <tr> <td align="left">[<a href="#CR95">95</a>]</td> <td align="left">Iran</td> <td align="left">Patients admitted for primary care</td> <td char="." align="char">933</td> <td align="left">31.6</td> <td char="." align="char">64.5</td> <td char="." align="char">3.9</td> <td char="." align="char">49.1</td> <td char="." align="char">50.9</td> </tr> <tr> <td align="left" rowspan="3">[<a href="#CR96">96</a>]</td> <td align="left" rowspan="3">Iran</td> <td align="left">Healthy volunteers</td> <td char="." align="char">200</td> <td align="left">23.5</td> <td char="." align="char">45.0</td> <td char="." align="char">31.5</td> <td char="." align="char">46.0</td> <td char="." align="char">54.0</td> </tr> <tr> <td align="left">Patients with drug-responsive epilepsy</td> <td char="." align="char">200</td> <td align="left">16.0</td> <td char="." align="char">40.0</td> <td char="." align="char">44.0</td> <td char="." align="char">36.0</td> <td char="." align="char">64.0</td> </tr> <tr> <td align="left">Patients with drug-resistant epilepsy</td> <td char="." align="char">132</td> <td align="left">25.7</td> <td char="." align="char">41.7</td> <td char="." align="char">32.6</td> <td char="." align="char">46.6</td> <td char="." align="char">53.4</td> </tr> <tr> <td align="left" rowspan="2">[<a href="#CR97">97</a>]</td> <td align="left" rowspan="2">Iran</td> <td align="left">Iranian Azeri Turkish volunteers</td> <td char="." align="char">92</td> <td align="left">19.6</td> <td char="." align="char">53.3</td> <td char="." align="char">27.2</td> <td char="." align="char">46.2</td> <td char="." align="char">53.8</td> </tr> <tr> <td align="left">Iranian Azeri Turkish patients with Behçet’s disease</td> <td char="." align="char">69</td> <td align="left">18.8</td> <td char="." align="char">46.4</td> <td char="." align="char">34.8</td> <td char="." align="char">42.0</td> <td char="." align="char">58.0</td> </tr> <tr> <td align="left" rowspan="2">[<a href="#CR98">98</a>]</td> <td align="left" rowspan="2">Iran</td> <td align="left">Healthy female volunteers</td> <td char="." align="char">200</td> <td align="left">70.5</td> <td char="." align="char">25.0</td> <td char="." align="char">4.5</td> <td char="." align="char">83.0</td> <td char="." align="char">17.0</td> </tr> <tr> <td align="left">Female patients with breast cancer</td> <td char="." align="char">100</td> <td align="left">75.0</td> <td char="." align="char">16.0</td> <td char="." align="char">9.0</td> <td char="." align="char">83.0</td> <td char="." align="char">17.0</td> </tr> <tr> <td align="left" rowspan="2">[<a href="#CR99">99</a>]</td> <td align="left" rowspan="2">Iran</td> <td align="left">Healthy female volunteers</td> <td char="." align="char">54</td> <td align="left">18.5</td> <td char="." align="char">55.6</td> <td char="." align="char">25.9</td> <td char="." align="char">47.0</td> <td char="." align="char">53.0</td> </tr> <tr> <td align="left">Female patients with breast cancer</td> <td char="." align="char">50</td> <td align="left">20.0</td> <td char="." align="char">54.0</td> <td char="." align="char">26.0</td> <td char="." align="char">46.3</td> <td char="." align="char">53.7</td> </tr> <tr> <td align="left" rowspan="2">[<a href="#CR100">100</a>]</td> <td align="left" rowspan="2">Iran</td> <td align="left">Healthy female volunteers</td> <td char="." align="char">77</td> <td align="left">15.6</td> <td char="." align="char">58.4</td> <td char="." align="char">26.0</td> <td char="." align="char">44.8</td> <td char="." align="char">55.2</td> </tr> <tr> <td align="left">Female patients with breast cancer</td> <td char="." align="char">106</td> <td align="left">15.1</td> <td char="." align="char">53.7</td> <td char="." align="char">31.1</td> <td char="." align="char">42.0</td> <td char="." align="char">58.0</td> </tr> <tr> <td align="left">[<a href="#CR101">101</a>]</td> <td align="left">Jordan</td> <td align="left">Healthy volunteers</td> <td char="." align="char">100</td> <td align="left">17.0</td> <td char="." align="char">50.0</td> <td char="." align="char">33.0</td> <td char="." align="char">42.0</td> <td char="." align="char">58.0</td> </tr> <tr> <td align="left">[<a href="#CR102">102</a>]</td> <td align="left">Jordan</td> <td align="left">Patients of ear, nose, and throat clinic</td> <td char="." align="char">251</td> <td align="left">16.3</td> <td char="." align="char">48.2</td> <td char="." align="char">35.4</td> <td char="." align="char">40.4</td> <td char="." align="char">59.6</td> </tr> <tr> <td align="left">[<a href="#CR103">103</a>]</td> <td align="left">Jordan</td> <td align="left">Patients receiving methotrexate for RA</td> <td char="." align="char">159</td> <td align="left">37.7</td> <td char="." align="char">45.3</td> <td char="." align="char">17.0</td> <td char="." align="char">60.4</td> <td char="." align="char">39.6</td> </tr> <tr> <td align="left" rowspan="2">[<a href="#CR104">104</a>]</td> <td align="left" rowspan="2">Jordan</td> <td align="left">Healthy female volunteers</td> <td char="." align="char">150</td> <td align="left">26.7</td> <td char="." align="char">43.3</td> <td char="." align="char">30.0</td> <td char="." align="char">48.3</td> <td char="." align="char">51.7</td> </tr> <tr> <td align="left">Female patients with breast cancer</td> <td char="." align="char">150</td> <td align="left">45.3</td> <td char="." align="char">41.3</td> <td char="." align="char">13.3</td> <td char="." align="char">66.0</td> <td char="." align="char">34.0</td> </tr> <tr> <td align="left">[<a href="#CR105">105</a>]</td> <td align="left">Lebanon</td> <td align="left">Children with ALL</td> <td char="." align="char">127</td> <td align="left">27.6</td> <td char="." align="char">44.1</td> <td char="." align="char">28.3</td> <td char="." align="char">49.6</td> <td char="." align="char">50.4</td> </tr> <tr> <td align="left">[<a href="#CR106">106</a>]</td> <td align="left">Morocco</td> <td align="left">Healthy volunteers</td> <td char="." align="char">100</td> <td align="left">39.0</td> <td char="." align="char">51.0</td> <td char="." align="char">10.0</td> <td char="." align="char">64.5</td> <td char="." align="char">35.5</td> </tr> <tr> <td align="left">[<a href="#CR107">107</a>]</td> <td align="left">Saudi Arabia</td> <td align="left">Healthy volunteers</td> <td char="." align="char">179</td> <td align="left">35.2</td> <td char="." align="char">45.2</td> <td char="." align="char">19.6</td> <td char="." align="char">57.8</td> <td char="." align="char">42.2</td> </tr> <tr> <td align="left" rowspan="2">[<a href="#CR108">108</a>]</td> <td align="left" rowspan="2">Saudi Arabia</td> <td align="left">Healthy female volunteers</td> <td char="." align="char">100</td> <td align="left">93.0</td> <td char="." align="char">5.0</td> <td char="." align="char">2.0</td> <td char="." align="char">95.5</td> <td char="." align="char">4.5</td> </tr> <tr> <td align="left">Female patients with breast cancer</td> <td char="." align="char">100</td> <td align="left">73.0</td> <td char="." align="char">11.0</td> <td char="." align="char">16.0</td> <td char="." align="char">78.5</td> <td char="." align="char">21.5</td> </tr> <tr> <td align="left" rowspan="2">[<a href="#CR45">45</a>]</td> <td align="left" rowspan="2">Saudi Arabia</td> <td align="left">Patients with PHT-responsive epilepsy</td> <td char="." align="char">25</td> <td align="left">80.0</td> <td char="." align="char" colspan="2">20.0</td> <td char="." align="char">88.0</td> <td char="." align="char">12.0</td> </tr> <tr> <td align="left">Patients with PHT-resistant epilepsy</td> <td char="." align="char">25</td> <td align="left">52.0</td> <td char="." align="char" colspan="2">48.0</td> <td char="." align="char">70.0</td> <td char="." align="char">30.0</td> </tr> <tr> <td align="left">[<a href="#CR43">43</a>]</td> <td align="left">Turkey</td> <td align="left">Healthy volunteers</td> <td char="." align="char">96</td> <td align="left">29.2</td> <td char="." align="char">46.9</td> <td char="." align="char">24.0</td> <td char="." align="char">52.6</td> <td char="." align="char">47.4</td> </tr> <tr> <td align="left">[<a href="#CR109">109</a>]</td> <td align="left">Turkey</td> <td align="left">Healthy volunteers</td> <td char="." align="char">107</td> <td align="left">27.1</td> <td char="." align="char">41.1</td> <td char="." align="char">31.8</td> <td char="." align="char">47.7</td> <td char="." align="char">52.3</td> </tr> <tr> <td align="left" rowspan="3">[<a href="#CR110">110</a>]</td> <td align="left" rowspan="3">Turkey</td> <td align="left">Healthy volunteers</td> <td char="." align="char">174</td> <td align="left">28.2</td> <td char="." align="char">46.0</td> <td char="." align="char">25.9</td> <td char="." align="char">51.1</td> <td char="." align="char">48.9</td> </tr> <tr> <td align="left">Patients with CBZ-responsive epilepsy</td> <td char="." align="char">53</td> <td align="left">30.2</td> <td char="." align="char">54.7</td> <td char="." align="char">15.1</td> <td char="." align="char">57.5</td> <td char="." align="char">42.5</td> </tr> <tr> <td align="left">Patients with CBZ-resistant epilepsy</td> <td char="." align="char">44</td> <td align="left">29.5</td> <td char="." align="char">59.1</td> <td char="." align="char">11.4</td> <td char="." align="char">59.1</td> <td char="." align="char">40.9</td> </tr> <tr> <td align="left" rowspan="2">[<a href="#CR29">29</a>]</td> <td align="left" rowspan="2">Turkey</td> <td align="left">Children with drug-responsive epilepsy</td> <td char="." align="char">83</td> <td align="left">26.5</td> <td char="." align="char">45.8</td> <td char="." align="char">27.7</td> <td char="." align="char">49.4</td> <td char="." align="char">50.6</td> </tr> <tr> <td align="left">Children with drug-resistant epilepsy</td> <td char="." align="char">69</td> <td align="left">24.6</td> <td char="." align="char">43.5</td> <td char="." align="char">31.9</td> <td char="." align="char">46.4</td> <td char="." align="char">53.6</td> </tr> <tr> <td align="left">[<a href="#CR111">111</a>]</td> <td align="left">Turkey</td> <td align="left">Patients receiving fentanyl for spinal anesthesia</td> <td char="." align="char">83</td> <td align="left">28.9</td> <td char="." align="char">54.2</td> <td char="." align="char">16.9</td> <td char="." align="char">56.0</td> <td char="." align="char">44.0</td> </tr> <tr> <td align="left" rowspan="2">[<a href="#CR112">112</a>]</td> <td align="left" rowspan="2">Turkey</td> <td align="left">Patients with normal CAG</td> <td char="." align="char">85</td> <td align="left">27.1</td> <td char="." align="char">41.2</td> <td char="." align="char">31.8</td> <td char="." align="char">47.6</td> <td char="." align="char">52.4</td> </tr> <tr> <td align="left">Patients with CAD found on CAG</td> <td char="." align="char">113</td> <td align="left">27.4</td> <td char="." align="char">48.7</td> <td char="." align="char">23.9</td> <td char="." align="char">51.8</td> <td char="." align="char">48.2</td> </tr> <tr> <td align="left" rowspan="2">[<a href="#CR113">113</a>]</td> <td align="left" rowspan="2">Turkey</td> <td align="left">Healthy male volunteers</td> <td char="." align="char">102</td> <td align="left">26.5</td> <td char="." align="char">49.0</td> <td char="." align="char">24.5</td> <td char="." align="char">51.0</td> <td char="." align="char">49.0</td> </tr> <tr> <td align="left">Male individuals with primary infertility</td> <td char="." align="char">192</td> <td align="left">27.6</td> <td char="." align="char">57.3</td> <td char="." align="char">15.1</td> <td char="." align="char">56.3</td> <td char="." align="char">43.7</td> </tr> <tr> <td align="left" rowspan="2">[<a href="#CR114">114</a>]</td> <td align="left" rowspan="2">Turkey</td> <td align="left">Healthy volunteers</td> <td char="." align="char">130</td> <td align="left">25.4</td> <td char="." align="char">44.6</td> <td char="." align="char">30.0</td> <td char="." align="char">47.7</td> <td char="." align="char">52.3</td> </tr> <tr> <td align="left">Patients with familial Mediterranean fever</td> <td char="." align="char">142</td> <td align="left">16.9</td> <td char="." align="char">59.9</td> <td char="." align="char">23.2</td> <td char="." align="char">46.8</td> <td char="." align="char">53.2</td> </tr> <tr> <td align="left" rowspan="2">[<a href="#CR115">115</a>]</td> <td align="left" rowspan="2">Turkey</td> <td align="left">Healthy volunteers</td> <td char="." align="char">250</td> <td align="left">27.2</td> <td char="." align="char">42.4</td> <td char="." align="char">30.4</td> <td char="." align="char">48.4</td> <td char="." align="char">51.6</td> </tr> <tr> <td align="left">Patients with familial Mediterranean fever</td> <td char="." align="char">309</td> <td align="left">20.4</td> <td char="." align="char">55.3</td> <td char="." align="char">24.3</td> <td char="." align="char">48.1</td> <td char="." align="char">51.9</td> </tr> <tr> <td align="left">[<a href="#CR116">116</a>]</td> <td align="left">Turkey</td> <td align="left">Patients with familial Mediterranean fever</td> <td char="." align="char">41</td> <td align="left">3.7</td> <td char="." align="char">54.2</td> <td char="." align="char">43.4</td> <td char="." align="char">29.2</td> <td char="." align="char">70.8</td> </tr> <tr> <td align="left">[<a href="#CR117">117</a>]</td> <td align="left">Turkey</td> <td align="left">Renal transplant recipients taking tacrolimus</td> <td char="." align="char">92</td> <td align="left">30.4</td> <td char="." align="char">47.8</td> <td char="." align="char">21.7</td> <td char="." align="char">54.3</td> <td char="." align="char">45.7</td> </tr> <tr> <td align="left" rowspan="2">[<a href="#CR118">118</a>]</td> <td align="left" rowspan="2">Turkey</td> <td align="left">Renal transplant recipients taking cyclosporine who did not develop gingival hyperplasia</td> <td char="." align="char">114</td> <td align="left">27.2</td> <td char="." align="char">44.7</td> <td char="." align="char">28.1</td> <td char="." align="char">49.6</td> <td char="." align="char">50.4</td> </tr> <tr> <td align="left">Renal transplant recipients taking cyclosporine who developed gingival hyperplasia</td> <td char="." align="char">40</td> <td align="left">32.5</td> <td char="." align="char">37.5</td> <td char="." align="char">30.0</td> <td char="." align="char">51.3</td> <td char="." align="char">48.7</td> </tr> <tr> <td align="left" rowspan="2">[<a href="#CR119">119</a>]</td> <td align="left" rowspan="2">Turkey</td> <td align="left">Patients taking clozapine who did not develop agranulocytosis</td> <td char="." align="char">91</td> <td align="left">29.7</td> <td char="." align="char">53.8</td> <td char="." align="char">16.5</td> <td char="." align="char">56.6</td> <td char="." align="char">43.4</td> </tr> <tr> <td align="left">Patients taking clozapine who developed agranulocytosis</td> <td char="." align="char">10</td> <td align="left">20.0</td> <td char="." align="char">60.0</td> <td char="." align="char">20.0</td> <td char="." align="char">50.0</td> <td char="." align="char">50.0</td> </tr> <tr> <td align="left">[<a href="#CR120">120</a>]</td> <td align="left">Turkey</td> <td align="left">Patients with non-small-cell lung cancer</td> <td char="." align="char">79</td> <td align="left">24.1</td> <td char="." align="char">62.0</td> <td char="." align="char">13.9</td> <td char="." align="char">55.1</td> <td char="." align="char">44.9</td> </tr> <tr> <td align="left" rowspan="2">[<a href="#CR121">121</a>]</td> <td align="left" rowspan="2">Turkey</td> <td align="left">Healthy volunteers</td> <td char="." align="char">150</td> <td align="left" colspan="3">NR</td> <td char="." align="char">52.3</td> <td char="." align="char">47.7</td> </tr> <tr> <td align="left">Patients with colorectal cancer</td> <td char="." align="char">103</td> <td align="left" colspan="3">NR</td> <td char="." align="char">61.2</td> <td char="." align="char">38.8</td> </tr> </tbody> </table> <div class="table-wrap-foot_UNKNOWN"> <p><i>ACS</i> acute coronary syndrome, <i>ALL</i> acute lymphoblastic leukemia, <i>AML</i> acute myeloid leukemia, <i>CAD</i> coronary artery disease, <i>CAG</i> coronary angiography, <i>CBZ</i> carbamazepine, <i>CML</i> chronic myeloid leukemia, <i>MACE</i> major adverse cardiac event, <i>NA</i> not assessed, <i>NR</i> not reported, <i>PCI</i> percutaneous coronary intervention, <i>PHT</i> phenytoin, <i>RA</i> rheumatoid arthritis</p> </div> </div> <p /> </div> <div class="cyp2c9" title="sec"> <div class="title" tagx="title" title="title">
CYP2C9</div> <p id="Par21">CYP2C9 accounts for 70–90% of phenytoin metabolism [<a href="#CR122">122</a>], with (<i>S</i>)-5-(<i>p</i>-hydroxyphenyl)-5-phenylhydantoin (p-HPPH) being the major resultant metabolite [<a href="#CR5">5</a>, <a href="#CR7">7</a>]. Although up to 60 different CYP2C9 haplotypes have been identified, <i>CYP2C9*2</i> and <i>*3</i> are the two most common allelic variants [<a href="#CR123">123</a>, <a href="#CR124">124</a>]. Both variants exhibit reduced functional activity, with losses of 29 and 94% enzymatic activity reported for <i>CYP2C9*2</i> and <i>*3</i>, respectively, when compared with the wild-type genotype [<a href="#CR125">125</a>, <a href="#CR126">126</a>]. Three of the included studies investigated <i>CYP2C9</i> genotypes [<a href="#CR42">42</a>–<a href="#CR44">44</a>].</p> <p id="Par22">Aynacioglu et al. [<a href="#CR42">42</a>] genotyped all outpatients and healthy volunteers for CYP2C9, and phenotyped phenytoin through assessment of serum phenytoin and p-HPPH concentrations in a subset of 101 of the Turkish healthy volunteers. Twelve hours following a single dose of phenytoin, serum phenytoin concentrations differed significantly across groups with 0, 1, and 2 loss of function mutations (<i>p</i> &amp;lt; 0.001). Study results indicated serum phenytoin concentration in the <i>CYP2C9*1/*1</i> wild-type genotype group was significantly lower when compared with <i>CYP2C9*1/*2</i>, <i>CYP2C9*1/*3</i>, and <i>CYP2C9*2/*2</i> genotype groups, with the difference in means being −1.36 mg/L (<i>p</i> = 0.009), −1.49 mg/L (<i>p</i> = 0.001), and −2.42 mg/L (<i>p</i> = 0.02), respectively. Accordingly, results also indicated the ratio of serum p-HPPH-to-phenytoin concentration of the <i>CYP2C9*1/*1</i> wild-type genotype group was significantly higher than that of <i>CYP2C9*1/*2</i>, <i>CYP2C9*1/*3</i>, and <i>CYP2C9*2/*2</i> genotype groups, with the difference in means being 0.17 (<i>p</i> = 0.002), 0.22 (<i>p</i> &amp;lt; 0.0001), and 0.29 (<i>p</i> = 0.006), respectively. Differences between wild-type and <i>CYP2C9*3/*3</i> genotypes were not compared statistically, as the latter was present in only one individual.</p> <p id="Par23">It was identified that data from the 96 healthy Turkish volunteers in the study conducted by Kerb et al. [<a href="#CR43">43</a>] were derived from the 101 volunteers of the Aynacioglu et al. study [<a href="#CR42">42</a>]. Thus, the results regarding influence of <i>CYP2C9</i> genotype on measured phenytoin concentrations and the p-HPPH-to-phenytoin ratio are reflected in the aforementioned results [<a href="#CR42">42</a>, <a href="#CR43">43</a>]. Using these data in a multiple linear regression analysis, Kerb et al. determined that the number of polymorphic <i>CYP2C9</i> alleles accounted for 14.1% of variability in phenytoin serum concentrations [<a href="#CR43">43</a>]. The final regression equation, which also included the number of <i>MDR1</i> C3435T alleles, had an <i>r</i><sup>2</sup> = 0.154 (<i>p</i> = 0.0002).</p> <p id="Par24">Ozkaynakci et al. [<a href="#CR44">44</a>] reported data for 11 different combinations of <i>CYP2C9</i> and <i>CYP2C19</i> genotypes; therefore, the independent impact of the CYP2C9 genotype on serum phenytoin concentrations was difficult to discern. When compared with the <i>CYP2C9</i> and <i>CYP2C19</i> wild-type genotype group, <i>CYP2C9*1/*3</i>, <i>CYP2C19*2/*3</i> was the only genotype group with a serum phenytoin trough that was significantly different, with a mean concentration that was 20.47 mg/L higher than the wild-type genotype group (<i>p</i> &amp;lt; 0.001). The mean serum phenytoin trough of the <i>CYP2C9*1/*3, CYP2C19*2/*3</i> genotype group was also significantly higher than several other genotype groups (Table <a href="#Tab1">1</a>). Clinical outcomes associated with <i>CYP2C9</i> polymorphisms were not reported and therefore could not be assessed.</p> </div> <div class="cyp2c19" title="sec"> <div class="title" tagx="title" title="title">
CYP2C19</div> <p id="Par25">CYP2C19 accounts for 10–30% of phenytoin metabolism, with greater metabolic contributions as CYP2C9 becomes saturated [<a href="#CR122">122</a>, <a href="#CR127">127</a>]. CYP2C19 primarily forms the (<i>R</i>)-p-HPPH metabolite [<a href="#CR5">5</a>, <a href="#CR7">7</a>]. Up to 35 different CYP2C19 haplotypes have been identified, of which <i>CYP2C19*2</i> and <i>*3</i> are the two most common null alleles; presence of two null alleles results in a non-functional CYP2C19 enzyme [<a href="#CR124">124</a>, <a href="#CR125">125</a>]. A third haplotype, <i>CYP2C19*17</i>, results in increased expression and activity of the enzyme [<a href="#CR125">125</a>]; however, this haplotype was not assessed in the included studies. Two of the included studies investigated <i>CYP2C19</i> genotypes [<a href="#CR43">43</a>, <a href="#CR44">44</a>].</p> <p id="Par26">In the study conducted by Kerb et al. [<a href="#CR43">43</a>], the <i>CYP2C19</i> genotype did not significantly affect serum phenytoin concentration (<i>p</i> = 0.52) or p-HPPH-to-phenytoin ratio (<i>p</i> value not reported). As with CYP2C9, as a result of Ozkaynakci et al. [<a href="#CR44">44</a>] reporting the data for 11 different <i>CYP2C9</i> and <i>CYP2C19</i> genotype groups, it is difficult to distinguish the independent impact of <i>CYP2C19</i> genotype on serum phenytoin concentrations; therefore, no inferences can be made. As with CYP2C9, clinical outcomes were not reported and therefore could not be assessed.</p> </div> <div class="mdr1(abcb1)c3435t" title="sec"> <div class="title" tagx="title" title="title">
MDR1 (ABCB1) C3435T</div> <p id="Par27">The <i>MDR1</i> (<i>ABCB1</i>) gene encodes for human P-glycoprotein, an efflux transporter of which phenytoin is a substrate [<a href="#CR128">128</a>, <a href="#CR129">129</a>]. The <i>MDR1</i> C3435T polymorphism is a silent mutation that decreases transporter expression and alters substrate specificity [<a href="#CR130">130</a>, <a href="#CR131">131</a>]; therefore, it has the potential to affect substrate absorption and tissue distribution. The resultant impact of this polymorphism on pharmacokinetic and pharmacodynamic outcomes of phenytoin therapy is unclear [<a href="#CR7">7</a>, <a href="#CR130">130</a>, <a href="#CR132">132</a>]. Three of the included studies investigated the <i>MDR1</i> C3435T polymorphism [<a href="#CR43">43</a>, <a href="#CR45">45</a>, <a href="#CR46">46</a>].</p> <p id="Par28">Kerb et al. [<a href="#CR43">43</a>] identified that the <i>MDR1</i> C3435T genotype did not significantly impact serum phenytoin concentration overall (<i>p</i> = 0.064), and the number of <i>MDR1 T</i> alleles accounted for only 1.3% of the variability in serum phenytoin concentrations in their multiple regression analysis. As discussed previously, the final regression equation had an <i>r</i><sup>2</sup> = 0.154 (<i>p</i> = 0.0002). When serum phenytoin concentrations were divided into quartiles (25th percentile: &amp;lt;3.79 mg/L, interquartile range: 3.79–5.79 mg/L, 75th percentile: &amp;gt;5.79 mg/L), the frequency distribution of MDR1 genotype indicated that the <i>MDR1 CC</i> genotype was more frequent in the 25th percentile group (<i>p</i> ≤ 0.001, <i>χ</i><sup>2</sup> test). Moreover, while the presence of the <i>MDR1 TT</i> genotype reportedly had significant influence on p-HPPH-to-phenytoin ratio (<i>p</i> &amp;lt; 0.026), absolute values were not provided and there was considerable overlap in the depicted frequency distribution; therefore, clinical significance of this association cannot be inferred.</p> <p id="Par29">Alhazzani et al. [<a href="#CR45">45</a>] identified significant differences between the <i>CC</i>, <i>CT</i>, and <i>TT</i> genotypes (classified as extensive, intermediate, or poor metabolizers, respectively) for the pharmacokinetic parameters of maximum plasma concentration (<i>p</i> &amp;lt; 0.01), area under the plasma concentration–time curve from 0 to 12 h post-dose (<i>p</i> &amp;lt; 0.01), half-life (<i>p</i> &amp;lt; 0.01), and clearance (<i>p</i> &amp;lt; 0.01) using one-way analysis of variance. However, post-hoc analyses were not performed to identify which genotypes differed significantly for these parameters. There was no difference between genotype groups for the parameter of time to maximum plasma concentration (<i>p</i> &amp;gt; 0.05). The reported values for each genotype are presented in Table <a href="#Tab1">1</a>. Moreover, a significant association between the <i>MDR1</i> C3435T genotype and phenytoin response was reported. Non-responders (i.e., phenytoin-resistant patients) had a higher frequency of the <i>T</i> allele (<i>χ</i><sup>2</sup> = 9.76, <i>p</i> = 0.0017) and, accordingly, the <i>CT</i> or <i>TT</i> genotypes (<i>χ</i><sup>2</sup> = 4.37, <i>p</i> = 0.036). The odds ratio (OR) calculated from the identified frequencies was significant for the allelic frequency [OR 3.14; 95% confidence interval (CI) 1.42–7.05], but not for the genotypic (OR 3.69; 95% CI 0.90–5.81).</p> <p id="Par30">Ebid et al. [<a href="#CR46">46</a>] did not identify a significant association between drug resistance or responsiveness and phenytoin concentrations overall, but reported associations between the <i>MDR1 CC</i> genotype and the likelihood of drug-resistant patients having serum phenytoin trough concentrations below or in the lower half of therapeutic range at the 3- and 6-month evaluations. Whether the <i>MDR1</i> C3435T genotype influences the efficacy and toxicity of phenytoin in epilepsy management was also explored. Overall, patients who were drug resistant (i.e., had seizure recurrence in the preceding 3 months) were more likely to have the <i>MDR1 CC</i> genotype than the <i>MDR1 TT</i> genotype when compared with patients responsive to therapy (55.5 vs. 13.5%, <i>χ</i><sup>2</sup> = 24.99; <i>p</i> &amp;lt; 0.0001). Moreover, as would be expected, within the drug-resistant group, seizures occurred at higher frequency in patients with serum phenytoin trough &amp;lt;10 mg/L, with average seizure frequencies of 4.4 and 3.7 at 3 and 6 months, respectively (<i>p</i> &amp;lt; 0.0001).</p> </div> <div class="genotypicandallelicfrequencieswithinthemenaregion" title="sec"> <div class="title" tagx="title" title="title">
Genotypic and Allelic Frequencies Within the MENA Region</div> <p id="Par31">Variant MAF of <i>CYP2C9</i>, <i>CYP2C19</i>, and <i>MDR1 (ABCB1)</i> C3435T have been investigated in a variety of settings and study populations across the MENA region. Studies from 11 different countries were identified for both <i>CYP2C9</i> and <i>CYP2C19</i>, and seven countries for <i>MDR1 (ABCB1)</i> C3435T; study populations and computed genotypic and allelic frequencies for each polymorphism are summarized in Tables <a href="#Tab3">3</a>, <a href="#Tab4">4</a>, and <a href="#Tab5">5</a>, respectively. Overall, there was appreciable variability in MAF both between and within countries of the MENA region for each of <i>CYP2C9</i>, <i>CYP2C19</i>, and <i>MDR1 (ABCB1)</i> C3435T. For example, in studies assessing subjects of Turkish origin, the reported <i>CYP2C19*3</i> MAF ranged from 0 to 10.3% [<a href="#CR43">43</a>, <a href="#CR44">44</a>, <a href="#CR87">87</a>–<a href="#CR89">89</a>].</p> </div> </div> <div class="discussion" title="discussion"> <div class="title" tagx="title" title="title">
Discussion</div> <p id="Par32">The purpose of this systematic review was to evaluate the role of genetic polymorphisms on phenytoin pharmacokinetics and clinical outcomes specifically in populations originating from the MENA region, and to characterize assessed polymorphism variant MAF within the region. Recognizing and understanding factors that contribute to interpatient variability in pharmacokinetics, pharmacodynamics, and associated clinical outcomes is essential to providing patient-individualized pharmacotherapy and disease management. In the management of epilepsy and seizure disorders, the significant role of genetic polymorphisms as one such factor has received increasing recognition, with phenytoin being an antiepileptic drug of particular interest, owing to its unique pharmacokinetic and pharmacodynamic profile [<a href="#CR5">5</a>, <a href="#CR6">6</a>, <a href="#CR17">17</a>–<a href="#CR26">26</a>, <a href="#CR35">35</a>, <a href="#CR38">38</a>–<a href="#CR46">46</a>, <a href="#CR127">127</a>, <a href="#CR133">133</a>, <a href="#CR134">134</a>]</p> <div class="cyp2c9" title="sec"> <div class="title" tagx="title" title="title">
CYP2C9</div> <p id="Par33">Findings of the studies included in this review indicate that the reduced functional capacity of CYP2C9 enzymes with <i>CYP2C9*2</i> and <i>CYP2C9*3</i> variant alleles results in significantly higher serum phenytoin concentrations [<a href="#CR42">42</a>–<a href="#CR44">44</a>]. This difference was significant after only a single dose of phenytoin in healthy volunteers included in the studies by Aynacioglu et al. [<a href="#CR42">42</a>] and Kerb et al. [<a href="#CR43">43</a>]. Although the absolute difference between the wild-type genotype and those with one or two reduced function alleles was only in the range of 1.32–2.42 mg/L, owing to the reduced functional capacity of enzymes with variant alleles, it is reasonable to surmise that the absolute difference in phenytoin concentrations would likely be of clinical significance with repeat dosing [<a href="#CR5">5</a>]. This notion is supported by an in-vitro study of <i>CYP2C9</i> polymorphisms, wherein <i>*2</i> and <i>*3</i> allelic variants decreased maximal velocity by 29 and 79%, respectively, and while the <i>*2</i> variant did not affect the Michaelis constant, the <i>*3</i> variant increased it fourfold [<a href="#CR126">126</a>].</p> <p id="Par34">Ozkaynakci et al. [<a href="#CR44">44</a>] reported a statistically significant difference between the wild-type and <i>CYP2C9*1/*3, CYP2C19*2/*3</i> genotype groups. However, five of the 11 reported genotype groups had frequencies of only 0.98–2.94%, which likely limited the power of the study to detect differences between the wild-type and other genotype groups. Moreover, patients were required to have been taking phenytoin for only 7 days. Therefore, it is possible that some patients were not yet at steady state when phenytoin trough concentrations were drawn, and that absolute differences in concentrations would be statistically and/or clinically significant over time [<a href="#CR5">5</a>]. This is especially noteworthy in those with <i>CYP2C9*2</i> or <i>*3</i> alleles, in whom reduced functional capacity may significantly prolong the time necessary to achieve steady-state concentrations [<a href="#CR5">5</a>, <a href="#CR46">46</a>]. As well, patients were not on a fixed dose of phenytoin; therefore, knowing the mean dose within each genotype group or having a serum concentration adjusted for mean dose in each genotype group would allow for assessment of this as a potential confounder. Although the impact of polytherapy was explored, the study was underpowered to appropriately assess this outcome. Thus, these results do not provide a clear demonstration of the impact of <i>CYP2C9*2</i> and *<i>3</i> allelic variants on phenytoin pharmacokinetics.</p> <p id="Par35">The impact of <i>CYP2C9</i> variants have been more clearly demonstrated in studies conducted in non-MENA populations. In a cohort of Japanese pediatric patients, when controlling for <i>CYP2C19</i> polymorphisms, patients with the <i>CYP2C9*1/*3</i> genotype required phenytoin maintenance doses that were 37.3% lower than those with the wild-type genotype to achieve target concentrations of 15–20 mg/L [<a href="#CR10">10</a>]. Similarly, in a sample of Dutch patients, those with at least one <i>CYP2C9*2</i> or <i>*3</i> allele required phenytoin maintenance doses that were 37% lower to achieve target concentrations of 10–20 mg/L [<a href="#CR24">24</a>]. A study of patients originating from India indicated that those with the <i>CYP2C9*1/*3</i> genotype were more likely than the wild-type genotype to have serum phenytoin concentrations &amp;gt;20 mg/L (OR 4.8; 95% CI 1.89–12.17; <i>p</i> 0.001), despite receiving comparable maintenance doses of phenytoin (5.4 vs. 5.1 mg/kg/day; <i>p</i> = 0.16) [<a href="#CR133">133</a>]. In addition to the impact of <i>CYP2C9</i> polymorphisms on phenytoin pharmacokinetics in non-MENA populations, it also had an effect on phenytoin safety outcomes. A case-control study of Thai patients demonstrated that, when on comparable maintenance phenytoin doses, patients with the <i>CYP2C9*1/*3</i> genotype were more likely to develop phenytoin-induced severe cutaneous adverse reactions (i.e., Stevens–Johnson syndrome, toxic epidermal necrolysis, or drug reaction with eosinophilia and systemic symptoms) within 12 weeks of initiating therapy than those with the wild-type genotype (OR 14.52; 95% CI 1.18–∞; <i>p</i> 0.044) [<a href="#CR134">134</a>]. This association is supported by findings of a meta-analysis conducted in Asian populations, wherein the <i>CYP2C9*3</i> allele was associated with an increased risk of phenytoin-induced severe cutaneous reactions (OR 11.0; 95% CI 6.2–18.0; <i>p</i> &amp;lt; 0.00001) [<a href="#CR17">17</a>]. Furthermore, in a case-control study of Tamilian patients, when adjusting for phenytoin maintenance dose, patients with the <i>CYP2C9*1/*3</i> genotype were significantly more likely to experience phenytoin-induced neurological toxicity (e.g., ataxia, slurred speech, lethargy, nystagmus) when compared with wild-type genotype (adjusted OR 15.3; 95% CI 5.8–40.3; <i>p</i> 0.0001) [<a href="#CR22">22</a>].</p> <p id="Par36">Ultimately, the significant impact of <i>CYP2C9*2</i> and <i>*3</i> allelic variants on phenytoin pharmacokinetics and risk of adverse effects when standard doses are administered has led to development of genotype-specific recommendations. It is suggested that initial doses of phenytoin be reduced by 25% in patients with one variant allele (i.e., <i>CYP2C9*1/*2</i> or <i>*1/*3</i>) and by 50% in patients with two variant alleles (i.e., <i>CYP2C9*2/*2, *2/*3</i> or <i>*3/*3</i>) [<a href="#CR8">8</a>].</p> </div> <div class="cyp2c19" title="sec"> <div class="title" tagx="title" title="title">
CYP2C19</div> <p id="Par37">Results of this review suggest that <i>CYP1C19*2</i> and <i>*3</i> allelic variants, on their own, did not significantly impact the pharmacokinetics of phenytoin. In the single-dose study by Kerb et al. [<a href="#CR43">43</a>], using the same rationale as discussed with CYP2C9, although <i>CYP2C19*1/*2</i> and <i>*2/*2</i> genotypes were not associated with significantly different phenytoin serum concentrations, owing to the non-functional nature of <i>*2</i> alleles, it is possible that statistically and clinically differences would arise after repeat dosing [<a href="#CR5">5</a>].</p> <p id="Par38">For results regarding CYP2C19 reported by Ozkaynakci et al. [<a href="#CR44">44</a>], previously discussed limitations affecting interpretation of results regarding CYP2C9 also apply. Both studies included in this review were likely underpowered to assess the impact of <i>CYP2C19</i> polymorphisms specifically. Moreover, because CYP2C19 accounts for only 10–30% of phenytoin metabolism [<a href="#CR122">122</a>, <a href="#CR127">127</a>], decreased or loss of functional capacity may be less likely to significantly affect phenytoin serum concentrations when compared with <i>CYP2C9</i> allelic variants with reduced function.</p> <p id="Par39">Evidence from studies conducted in non-MENA populations suggest that CYP2C19 allelic variants may significantly impact pharmacokinetics of phenytoin. In the previously described Japanese cohort, those with <i>CYP2C9</i> wild-type genotype and one variant <i>CYP2C19</i> allele (i.e., <i>CYP2C19*1/*2</i> or <i>*1/*3</i>) required phenytoin doses 13.1% lower than patients with wild-type genotypes of both <i>CYP2C9</i> and <i>CYP2C19</i> to achieve target concentrations (<i>p</i> &amp;lt; 0.01), while those with two variant <i>CYP2C19</i> alleles (i.e., <i>CYP2C19*2/*2</i>, <i>*2/*3, or *3/*3)</i> required doses 28.1% lower (<i>p</i> &amp;lt; 0.001) [<a href="#CR10">10</a>]. Regarding clinical outcomes, in the study conducted in Tamilian patients, when adjusting for maintenance dose, patients with <i>CYP2C19*2/*2</i> genotype were significantly more likely to experience phenytoin-induced neurological toxicity when compared with wild-type genotype (adjusted OR 3.0; 95% CI 1.3–7.0; <i>p</i> 0.01) [<a href="#CR22">22</a>]. Evidence from studies assessing both <i>CYP2C9</i> and <i>CYP2C19</i> genotypes suggest additive impact on phenytoin concentrations when variant genotypes of both enzymes are present [<a href="#CR20">20</a>, <a href="#CR22">22</a>]. Although official guidelines have not been developed for dosage adjustments in patients with <i>CYP2C19</i> allelic variants, recommendations for both pediatric and adult patients have been suggested based on the combination of both <i>CYP2C9</i> and <i>CYP2C19</i> genotypes [<a href="#CR10">10</a>, <a href="#CR20">20</a>].</p> </div> <div class="mdr1(abcb1)c3435t" title="sec"> <div class="title" tagx="title" title="title">
MDR1 (ABCB1) C3435T</div> <p id="Par40">The reported impact of the <i>MDR1</i> C3435T genotype on phenytoin pharmacokinetics in this review was inconsistent, and results in all three studies [<a href="#CR43">43</a>, <a href="#CR45">45</a>, <a href="#CR46">46</a>] may have been confounded because of aforementioned factors such as concomitant medications, comorbid conditions, and serum albumin levels, among other patient-specific factors.</p> <p id="Par41">Kerb et al. [<a href="#CR43">43</a>] reported no significant association between <i>MDR1</i> genotype and serum phenytoin concentrations overall. Although post-hoc analysis identified a significant association between the <i>MDR1 CC</i> genotype and serum phenytoin concentrations in the 25th percentile, the association is likely of limited clinical significance because of the narrow concentration range defined by the three classes of low, medium, and high. Unlike CYP2C9 and CYP2C19, transporters encoded by <i>MDR1</i> are not involved in phenytoin metabolism; therefore, it is unclear whether repeat dosing over time would significantly impact the observed degree of difference in phenytoin serum concentrations between genotype groups. Moreover, although presence of <i>MDR1 T</i> alleles accounted for 1.3% of variability in phenytoin serum concentrations, the clinical relevance of this is questionable, especially considering the final regression equation could account for only 15.4% of observed variability [<a href="#CR43">43</a>].</p> <p id="Par42">In contrast, results reported by Alhazzani et al. [<a href="#CR45">45</a>] indicate all pharmacokinetic parameters, with the exception of time to maximum plasma concentration, were significantly affected by the <i>MDR1</i> C3435T genotype. In the absence of post-hoc analyses of the one-way analysis of variance, which genotypes significantly differed for these parameters cannot be confirmed; however, the results trend toward the <i>MDR1 CC</i> genotype group being different. Of note, the classification of extensive, intermediate, and poor metabolizer to describe the <i>MDR1</i> C3435T genotype is misleading, as proteins encoded by <i>MDR1</i> are involved in substrate absorption and distribution, not metabolism [<a href="#CR129">129</a>–<a href="#CR131">131</a>]. The trend of increased maximum plasma concentration, area under the plasma concentration–time curve from 0 to 12 h post-dose, half-life, and clearance in subjects with one or more <i>T</i> alleles holds face validity, as this variant is associated with lower levels of transporter expression [<a href="#CR130">130</a>], which, at the level of the intestine, would result in less phenytoin being effluxed from systemic circulation back into the intestinal lumen. The distributions of responders and non-responders across the extensive, intermediate, and poor metabolizer categories were not reported; therefore, associations between the <i>MDR1</i> C3435T genotype, phenytoin pharmacokinetics, and resultant clinical outcomes could not be assessed.</p> <p id="Par43">The clinical significance of the association between serum phenytoin level and <i>MDR1</i> C3435T genotype reported by Ebid et al. [<a href="#CR46">46</a>] is unclear. Specifically, at the 3-month evaluation, there was no significant association between phenytoin responsiveness and serum concentration overall, while at the 6-month evaluation, a ‘higher’ concentration in the drug-responsive group was not defined and whether or not weight adjusting the doses mitigated reported differences was not explored.</p> <p id="Par44">Reported associations between the <i>MDR1</i> C3435T genotype and drug resistance reported in this review are conflicting [<a href="#CR45">45</a>, <a href="#CR46">46</a>]. Historically, associations between drug-resistant epilepsy and overexpression of transporters encoded by <i>MDR1</i> have been reported [<a href="#CR135">135</a>–<a href="#CR137">137</a>]. Despite this, several limitations must be considered when interpreting the clinical outcomes reported by Ebid et al. [<a href="#CR46">46</a>]. Foremost, distribution of seizure type within the drug-responsive and drug-resistant groups was not reported, nor adjusted for in the results. This is notable, as there is evidence to suggest phenytoin may aggravate generalized seizures [<a href="#CR3">3</a>]. Additional potential confounders, such as baseline seizure control and concomitant antiepileptic drugs, were also not adjusted for. It is unclear if appropriate corrections were made for multiple statistical analyses; thus, it is possible that identified associations were the result of chance.</p> <p id="Par45">The association of <i>MDR1</i> C3435T genetic polymorphisms and drug-resistant epilepsy in general (as opposed to phenytoin specifically) was assessed within Iranian patients [<a href="#CR33">33</a>]. The <i>MDR1 CC</i> wild-type genotype was significantly more frequent in drug-resistant patients, and associations were also made with adult age and female sex; however, the latter two associations may have resulted from performing multiple statistical analyses. The investigators attempted to address confounders such as baseline etiology and seizure type through univariate analyses; however, because baseline characteristics were so different between study groups, residual confounding likely remained [<a href="#CR33">33</a>]. Two studies conducted in Turkish patients with seizure disorders did not find a significant association between the <i>MDR1</i> C3435T genotype and drug resistance [<a href="#CR29">29</a>, <a href="#CR110">110</a>]. More recently, a meta-analysis of studies conducted in Asian, Caucasian (under which populations originating from the MENA region were classified), and Indian populations investigated the role of <i>MDR1</i> gene haplotypes in antiepileptic drug response [<a href="#CR132">132</a>]. Initial results indicated that the presence of the T variant of <i>MDR1</i> C3435T may be associated with lower rates of drug resistance. Once corrected for multiple statistical analyses, there was no significant association overall, but a significant association remained in Caucasian patients (<i>T</i> vs. <i>C</i> allele, OR 0.83; 95% CI 0.71–0.96; <i>p</i> = 0.01) [<a href="#CR132">132</a>]. One hypothesis regarding inconsistency in positive associations found between <i>MDR1</i> genotypes and responsiveness to antiepileptic drugs is that the gene falls within a significant block of high linkage disequilibrium [<a href="#CR138">138</a>]. Therefore, it is possible that the associations identified are not the result of the <i>MDR1</i> polymorphism itself, but to an alternative gene within the linkage disequilibrium block [<a href="#CR138">138</a>].</p> </div> <div class="genotypicandallelicfrequencieswithinthemenaregion" title="sec"> <div class="title" tagx="title" title="title">
Genotypic and Allelic Frequencies Within the MENA Region</div> <p id="Par46">Variability in genotypic and allelic frequencies of <i>CYP2C9</i>, <i>CYP2C19</i>, and <i>MDR1</i> C3435T both between and within the MENA countries for which data were identified was not unexpected. Key factors contributing to this variability were likely small sample sizes and selective patient populations in whom many of the studies were conducted. The allelic frequencies of <i>CYP2C9*2</i> and <i>*3</i>, as well as <i>CYP2C19*2</i> and <i>*3</i> were comparable to those reported for Middle Eastern populations [<a href="#CR139">139</a>, <a href="#CR140">140</a>]. Similar population data for the <i>MDR1</i> C3435T polymorphism were not available for comparison, nor were comparative data specific to North Africa populations.</p> <p id="Par47">Ethnicity significantly affects distributions of variants [<a href="#CR124">124</a>] and contributes to differences in MAF reported for populations outside of the MENA region for each of <i>CYP2C9</i> [<a href="#CR48">48</a>, <a href="#CR50">50</a>, <a href="#CR53">53</a>, <a href="#CR57">57</a>, <a href="#CR65">65</a>, <a href="#CR67">67</a>, <a href="#CR70">70</a>, <a href="#CR139">139</a>], <i>CYP2C19</i> [<a href="#CR27">27</a>, <a href="#CR53">53</a>, <a href="#CR57">57</a>, <a href="#CR67">67</a>, <a href="#CR140">140</a>], and <i>MDR1</i> C3435T [<a href="#CR132">132</a>, <a href="#CR141">141</a>, <a href="#CR142">142</a>]. This emphasizes the importance of population-specific studies assessing genetic polymorphisms.</p> </div> <div class="limitations" title="sec"> <div class="title" tagx="title" title="title">
Limitations</div> <p id="Par48">This review has several limitations that must be considered when interpreting the results. Foremost, in the primary analysis, only three different countries within the MENA region were represented by study populations, with three of five studies being in subjects of Turkish origin. The genotypic diversity across MENA countries as well as the small sample size of the included studies, therefore limit the generalizability of this review. Moreover, only three of the five studies were conducted in patients with seizure disorder, of which only one assessed clinical outcomes, thereby limiting ability to make clinical inferences. The two healthy volunteer studies (which used data from the same subjects) were based on a single dose of phenytoin; therefore, they did not reflect the potential impact of genetic polymorphisms on the steady-state pharmacokinetics of phenytoin or the influence of the non-linear capacity-limited metabolism of phenytoin. Furthermore, all five studies had poor methodological quality and were likely not powered to compare differences between genotypes and alleles of relatively low frequencies. Regarding the review of genotypic and allelic frequencies, the small select study populations and resultant variability in frequency estimates limit generalizability.</p> </div> <div class="futuredirections" title="sec"> <div class="title" tagx="title" title="title">
Future Directions</div> <p id="Par49">Identified limitations of this review highlight the need for future studies to investigate the impact of genetic polymorphisms on the pharmacokinetics of phenytoin and associated clinical outcomes, specifically in patients with epilepsy and seizure disorders. Although the impacts of <i>CYP2C9*2</i> and <i>*3</i> allelic variants on phenytoin metabolism and the risk of adverse effects have been recognized and dosage modification guidelines developed [<a href="#CR8">8</a>, <a href="#CR9">9</a>], the potential impacts of <i>CYP2C19*2</i> and <i>*3</i> allelic variants have not been established and warrant further investigation. Moreover, owing to the limitations of individual studies, the association between the <i>MDR1</i> C3435T genotype and drug-resistant epilepsy as well as phenytoin pharmacokinetics remains to be elucidated. To address these questions, future studies must be appropriately powered to assess differences between genotypes of low frequencies, and account for known confounding factors. Furthermore, studies should be designed to look at both pharmacokinetic and clinical outcomes once phenytoin concentrations have achieved a steady state. If possible, studies should be conducted in patient populations originating from countries of the MENA region that have not yet been assessed.</p> <p id="Par50">Future research may also focus on investigating the prevalence of the <i>HLA-B*15:02</i> allele and its impact on the risk of phenytoin-induced severe cutaneous adverse reactions (i.e., Stevens–Johnson syndrome, toxic epidermal necrolysis, or drug reaction with eosinophilia and systemic symptoms) in populations originating within the MENA region. The presence of this allele has been associated with an increased risk of phenytoin-induced severe cutaneous adverse reactions [<a href="#CR38">38</a>, <a href="#CR143">143</a>–<a href="#CR145">145</a>], resulting in pharmacogenetic guidelines recommending against the use of phenytoin in patients who are <i>HLA-B*15:02</i> carriers [<a href="#CR8">8</a>].</p> </div> </div> <div class="conclusion" title="conclusion"> <div class="title" tagx="title" title="title">
Conclusion</div> <p id="Par51">Results of this review indicate the reduced functional capacities of <i>CYP2C9*2</i> and <i>*3</i> allelic variants significantly decrease phenytoin metabolism in patients originating from the MENA region. The impacts of <i>CYP2C19</i> and <i>MDR1</i> C3435T polymorphisms on phenytoin pharmacokinetics and clinical outcomes in this population are unclear and require further investigation. Future research should focus on better understanding the impact of genetic polymorphisms on clinical outcomes associated with phenytoin therapy.</p> </div> </div> <div class="back" title="back"> <div class="app-group" title="app-group"> <div class="app" title="app"> <div class="appendix:medlinesearchstrategy" title="sec"> <div class="title" tagx="title" title="title">
Appendix: MEDLINE search strategy</div> <p> </p><ol> <li> <p id="Par54">MENA.mp.</p> </li> <li> <p id="Par55">exp Africa, Northern/ or "Middle East and North Africa".mp. or exp Middle East/</p> </li> <li> <p id="Par56">Afghanistan.mp. or exp Afghanistan/</p> </li> <li> <p id="Par57">Bahrain.mp. or exp Bahrain/</p> </li> <li> <p id="Par58">Djibouti.mp. or exp Djibouti/</p> </li> <li> <p id="Par59">Egypt.mp. or exp Egypt/</p> </li> <li> <p id="Par60">Algeria.mp. or exp Algeria/</p> </li> <li> <p id="Par61">Iran.mp. or exp Iran/</p> </li> <li> <p id="Par62">exp Iraq/ or Iraq.mp.</p> </li> <li> <p id="Par63">Israel.mp. or exp Israel/</p> </li> <li> <p id="Par64">Jordan.mp. or exp Jordan/</p> </li> <li> <p id="Par65">Kuwait.mp. or exp Kuwait/</p> </li> <li> <p id="Par66">Lebanon.mp. or exp Lebanon/</p> </li> <li> <p id="Par67">Libya.mp. or exp Libya/</p> </li> <li> <p id="Par68">Morocco.mp. or exp Morocco/</p> </li> <li> <p id="Par69">Oman.mp. or exp Oman/</p> </li> <li> <p id="Par70">Palestine.mp.</p> </li> <li> <p id="Par71">West Bank.mp.</p> </li> <li> <p id="Par72">Gaza.mp.</p> </li> <li> <p id="Par73">Qatar.mp. or exp Qatar/</p> </li> <li> <p id="Par74">Saudi Arabia.mp. or exp Saudi Arabia/</p> </li> <li> <p id="Par75">Somalia.mp. or exp Somalia/</p> </li> <li> <p id="Par76">exp South Sudan/ or exp Sudan/ or Sudan.mp.</p> </li> <li> <p id="Par77">Syria.mp. or exp Syria/</p> </li> <li> <p id="Par78">Tunisia.mp. or exp Tunisia/</p> </li> <li> <p id="Par79">exp Turkey/ or Turkey.mp.</p> </li> <li> <p id="Par80">United Arab Emirates.mp. or exp United Arab Emirates/</p> </li> <li> <p id="Par81">Yemen.mp. or exp Yemen/</p> </li> <li> <p id="Par82">1 or 2 or 3 or 4 or 5 or 6 or 7 or 8 or 9 or 10 or 11 or 12 or 13 or 14 or 15 or 16 or 17 or 18 or 19 or 20 or 21 or 22 or 23 or 24 or 25 or 26 or 27 or 28</p> </li> <li> <p id="Par83">Polymorphism.mp. or exp Polymorphism, Genetic/ or exp Polymorphism, Single Nucleotide/</p> </li> <li> <p id="Par84">Pharmacogenetics.mp. or exp Pharmacogenetics/</p> </li> <li> <p id="Par85">Pharmacogenomics.mp.</p> </li> <li> <p id="Par86">cytochrome p450.mp. or exp Cytochrome P-450 Enzyme System/</p> </li> <li> <p id="Par87">CYP2C9.mp. or exp Cytochrome P-450 CYP2C9/</p> </li> <li> <p id="Par88">CYP2C19.mp. or exp Cytochrome P-450 CYP2C19/</p> </li> <li> <p id="Par89">CYP3A4.mp. or exp Cytochrome P-450 CYP3A/</p> </li> <li> <p id="Par90">CYP2B6.mp. or exp Cytochrome P-450 CYP2B6/</p> </li> <li> <p id="Par91">CYP1A2.mp. or exp Cytochrome P-450 CYP1A2/</p> </li> <li> <p id="Par92">CYP2E1.mp. or exp Cytochrome P-450 CYP2E1/</p> </li> <li> <p id="Par93">CYP2C8.mp. or exp Cytochrome P-450 CYP2C8/</p> </li> <li> <p id="Par94">exp Cytochrome P-450 CYP2A6/ or CYP2A6.mp.</p> </li> <li> <p id="Par95">exp Glucuronosyltransferase/ or UGT.mp.</p> </li> <li> <p id="Par96">UGT1A1.mp.</p> </li> <li> <p id="Par97">UGT1A4.mp.</p> </li> <li> <p id="Par98">UGT1A6.mp.</p> </li> <li> <p id="Par99">UGT1A9.mp.</p> </li> <li> <p id="Par100">P-glycoprotein.mp. or exp P-Glycoprotein/</p> </li> <li> <p id="Par101">multi drug resistance protein.mp. or exp Multidrug Resistance-Associated Proteins/ or exp ATP-Binding Cassette Transporters/</p> </li> <li> <p id="Par102">exp P-Glycoproteins/ or exp P-Glycoprotein/ or MDR1.mp.</p> </li> <li> <p id="Par103">ABCB1.mp.</p> </li> <li> <p id="Par104">30 or 31 or 32 or 33 or 34 or 35 or 36 or 37 or 38 or 39 or 40 or 41 or 42 or 43 or 44 or 45 or 46 or 47 or 48 or 49 or 50</p> </li> <li> <p id="Par105">phenytoin.mp. or exp Phenytoin/</p> </li> <li> <p id="Par106">antiepileptic.mp. or exp Anticonvulsants/</p> </li> <li> <p id="Par107">exp Epilepsy/ or epilepsy.mp.</p> </li> <li> <p id="Par108">52 or 53 or 54</p> </li> <li> <p id="Par109">29 and 51 and 55</p> </li> </ol> <p /> </div> </div> </div> <div class="title" tagx="title" title="title">
Compliance with Ethical Standards</div> <div class="funding" title="sec"> <div class="title" tagx="title" title="title">
Funding</div> <p id="Par52">No funding was received for the preparation of this article.</p> </div> <div class="conflictofinterest" title="sec"> <div class="title" tagx="title" title="title">
Conflict of interest</div> <p id="Par53">Renée Dagenais, Kyle John Wilby, Hazem Elewa, and Mary H.H. Ensom have no conflicts of interest directly relevant to the content of this article.</p> </div> <div class="references">
References</div> <div tag="ref-list"> <ul> <div class="title" tagx="title" title="title">
References</div> <li tag="ref"><a name="CR1" /><span class="label" tagx="label" title="label">1.</span><span class="element-citation'"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Merritt</span><span class="given-names" tagx="given-names" title="given-names">HH</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Putnam</span><span class="given-names" tagx="given-names" title="given-names">TJ</span></span></span><span class="mixed-article-title" title="mixed-article-title">Sodium diphenyl hydantoinate in the treatment of convulsive disorders</span><span class="source" tagx="source" title="source">JAMA.</span><span class="year" tagx="year" title="year">1939</span><span class="volume" tagx="volume" title="volume">11</span><span class="fpage" tagx="fpage" title="fpage">1068</span><span class="lpage" tagx="lpage" title="lpage">1073</span></span></li> <li tag="ref"><a name="CR2" /><span class="label" tagx="label" title="label">2.</span><span class="element-citation'"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Glauser</span><span class="given-names" tagx="given-names" title="given-names">T</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Shinnar</span><span class="given-names" tagx="given-names" title="given-names">S</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Gloss</span><span class="given-names" tagx="given-names" title="given-names">D</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Alldredge</span><span class="given-names" tagx="given-names" title="given-names">B</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Arya</span><span class="given-names" tagx="given-names" title="given-names">R</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Bainbridge</span><span class="given-names" tagx="given-names" title="given-names">J</span></span><span class="etal" title="etal"><i>et al.</i></span></span><span class="mixed-article-title" title="mixed-article-title">Evidence-based guideline: treatment of convulsive status epilepticus in children and adults: report of the guideline committee of the American Epilepsy Society</span><span class="source" tagx="source" title="source">Epilepsy Curr.</span><span class="year" tagx="year" title="year">2016</span><span class="volume" tagx="volume" title="volume">16</span><span class="fpage" tagx="fpage" title="fpage">48</span><span class="lpage" tagx="lpage" title="lpage">61</span><span class="pub-id"><a href="https://dx.doi.org/10.5698/1535-7597-16.1.48">10.5698/1535-7597-16.1.48</a></span><span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/26900382">26900382</a></span></span></li> <li tag="ref"><a name="CR3" /><span class="label" tagx="label" title="label">3.</span><span class="element-citation'"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Glauser</span><span class="given-names" tagx="given-names" title="given-names">T</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Ben-Menachem</span><span class="given-names" tagx="given-names" title="given-names">E</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Bourgeois</span><span class="given-names" tagx="given-names" title="given-names">B</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Cnaan</span><span class="given-names" tagx="given-names" title="given-names">A</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Guerreiro</span><span class="given-names" tagx="given-names" title="given-names">C</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Kälviäinen</span><span class="given-names" tagx="given-names" title="given-names">R</span></span><span class="etal" title="etal"><i>et al.</i></span></span><span class="mixed-article-title" title="mixed-article-title">Updated ILAE evidence review of antiepileptic drug efficacy and effectiveness as initial monotherapy for epileptic seizures and syndromes</span><span class="source" tagx="source" title="source">Epilepsia.</span><span class="year" tagx="year" title="year">2013</span><span class="volume" tagx="volume" title="volume">54</span><span class="fpage" tagx="fpage" title="fpage">551</span><span class="lpage" tagx="lpage" title="lpage">563</span><span class="pub-id"><a href="https://dx.doi.org/10.1111/epi.12074">10.1111/epi.12074</a></span><span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/23350722">23350722</a></span></span></li> <li tag="ref"><a name="CR4" /><span class="label" tagx="label" title="label">4.</span><span class="element-citation'"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Porter</span><span class="given-names" tagx="given-names" title="given-names">RJ</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Meldrum</span><span class="given-names" tagx="given-names" title="given-names">BS</span></span></span><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Katzung</span><span class="given-names" tagx="given-names" title="given-names">BG</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Masters</span><span class="given-names" tagx="given-names" title="given-names">SB</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Trevor</span><span class="given-names" tagx="given-names" title="given-names">AJ</span></span></span><span class="mixed-article-title" title="mixed-article-title">Antiseizure drugs</span><span class="source" tagx="source" title="source">Basic and clinical pharmacology</span><span class="year" tagx="year" title="year">2012</span><span class="edition" tagx="edition" title="edition">12</span><span class="publisher-loc" tagx="publisher-loc" title="publisher-loc">London</span><span class="publisher-name" tagx="publisher-name" title="publisher-name">The McGraw-Hill Companies, Inc.</span></span></li> <li tag="ref"><a name="CR5" /><span class="label" tagx="label" title="label">5.</span><span class="element-citation'"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Winter</span><span class="given-names" tagx="given-names" title="given-names">ME</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Tozer</span><span class="given-names" tagx="given-names" title="given-names">TN</span></span></span><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Burton</span><span class="given-names" tagx="given-names" title="given-names">ME</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Shaw</span><span class="given-names" tagx="given-names" title="given-names">LM</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Schentag</span><span class="given-names" tagx="given-names" title="given-names">JJ</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Evans</span><span class="given-names" tagx="given-names" title="given-names">WE</span></span></span><span class="mixed-article-title" title="mixed-article-title">Phenytoin</span><span class="source" tagx="source" title="source">Applied pharmacokinetics and pharmacodynamics: principles of therapeutic drug monitoring</span><span class="year" tagx="year" title="year">2006</span><span class="edition" tagx="edition" title="edition">4</span><span class="publisher-loc" tagx="publisher-loc" title="publisher-loc">Philadelphia</span><span class="publisher-name" tagx="publisher-name" title="publisher-name">Lippincott Williams &amp;amp; Wilkins</span></span></li> <li tag="ref"><a name="CR6" /><span class="label" tagx="label" title="label">6.</span><span class="element-citation'"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Koch-Weser</span><span class="given-names" tagx="given-names" title="given-names">J</span></span></span><span class="mixed-article-title" title="mixed-article-title">The serum level approach to individualization of drug dosage</span><span class="source" tagx="source" title="source">Eur J Clin Pharmacol.</span><span class="year" tagx="year" title="year">1975</span><span class="volume" tagx="volume" title="volume">9</span><span class="fpage" tagx="fpage" title="fpage">1</span><span class="lpage" tagx="lpage" title="lpage">8</span><span class="pub-id"><a href="https://dx.doi.org/10.1007/BF00613423">10.1007/BF00613423</a></span><span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/786685">786685</a></span></span></li> <li tag="ref"><a name="CR7" /><span class="label" tagx="label" title="label">7.</span><span class="mixed-citation" tagx="mixed-citation" title="mixed-citation">Thorn CF, Whirl-Carrillo M, Leeder JS, Klein TE, Altman RB. PharmGKB summary: phenytoin pathway. Pharmacogenetics Genom. 2012. <a href="https://www.pharmgkb.org/">https://www.pharmgkb.org/</a>. Accessed 22 Feb 2017.</span></li> <li tag="ref"><a name="CR8" /><span class="label" tagx="label" title="label">8.</span><span class="element-citation'"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Caudle</span><span class="given-names" tagx="given-names" title="given-names">KE</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Rettie</span><span class="given-names" tagx="given-names" title="given-names">AE</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Whirl-carrillo</span><span class="given-names" tagx="given-names" title="given-names">M</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Smith</span><span class="given-names" tagx="given-names" title="given-names">LH</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Mintzer</span><span class="given-names" tagx="given-names" title="given-names">SE</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Ta</span><span class="given-names" tagx="given-names" title="given-names">M</span></span><span class="etal" title="etal"><i>et al.</i></span></span><span class="mixed-article-title" title="mixed-article-title">Clinical pharmacogenetics implementation consortium guidelines for <i>CYP2C9</i> and <i>HLA-B</i> genotype and phenytoin dosing</span><span class="source" tagx="source" title="source">Clin Pharmacol Ther.</span><span class="year" tagx="year" title="year">2014</span><span class="volume" tagx="volume" title="volume">96</span><span class="fpage" tagx="fpage" title="fpage">542</span><span class="lpage" tagx="lpage" title="lpage">548</span><span class="pub-id"><a href="https://dx.doi.org/10.1038/clpt.2014.159">10.1038/clpt.2014.159</a></span><span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/25099164">25099164</a></span></span></li> <li tag="ref"><a name="CR9" /><span class="label" tagx="label" title="label">9.</span><span class="element-citation'"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Swen</span><span class="given-names" tagx="given-names" title="given-names">JJ</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Nijenhuis</span><span class="given-names" tagx="given-names" title="given-names">M</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">de Boer</span><span class="given-names" tagx="given-names" title="given-names">A</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Grandia</span><span class="given-names" tagx="given-names" title="given-names">L</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Maitland-van der Zee</span><span class="given-names" tagx="given-names" title="given-names">AH</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Mulder</span><span class="given-names" tagx="given-names" title="given-names">H</span></span><span class="etal" title="etal"><i>et al.</i></span></span><span class="mixed-article-title" title="mixed-article-title">Pharmacogenetics: from bench to byte: an update of guidelines</span><span class="source" tagx="source" title="source">Clin Pharmacol Ther.</span><span class="year" tagx="year" title="year">2011</span><span class="volume" tagx="volume" title="volume">89</span><span class="fpage" tagx="fpage" title="fpage">662</span><span class="lpage" tagx="lpage" title="lpage">673</span><span class="pub-id"><a href="https://dx.doi.org/10.1038/clpt.2011.34">10.1038/clpt.2011.34</a></span><span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/21412232">21412232</a></span></span></li> <li tag="ref"><a name="CR10" /><span class="label" tagx="label" title="label">10.</span><span class="element-citation'"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Yamamoto</span><span class="given-names" tagx="given-names" title="given-names">Y</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Takahashi</span><span class="given-names" tagx="given-names" title="given-names">Y</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Imai</span><span class="given-names" tagx="given-names" title="given-names">K</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Miyakawa</span><span class="given-names" tagx="given-names" title="given-names">K</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Ikeda</span><span class="given-names" tagx="given-names" title="given-names">H</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Ueda</span><span class="given-names" tagx="given-names" title="given-names">Y</span></span><span class="etal" title="etal"><i>et al.</i></span></span><span class="mixed-article-title" title="mixed-article-title">Individualized phenytoin therapy for Japanese pediatric patients with epilepsy based on CYP2C9 and CYP2C19 genotypes</span><span class="source" tagx="source" title="source">Ther Drug Monit.</span><span class="year" tagx="year" title="year">2015</span><span class="volume" tagx="volume" title="volume">37</span><span class="fpage" tagx="fpage" title="fpage">229</span><span class="lpage" tagx="lpage" title="lpage">235</span><span class="pub-id"><a href="https://dx.doi.org/10.1097/FTD.0000000000000128">10.1097/FTD.0000000000000128</a></span><span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/25162219">25162219</a></span></span></li> <li tag="ref"><a name="CR11" /><span class="label" tagx="label" title="label">11.</span><span class="mixed-citation" tagx="mixed-citation" title="mixed-citation">Public Health Genomics Knowledge Base. Phenytoin. 2016. <a href="https://phgkb.cdc.gov/">https://phgkb.cdc.gov/</a>. Accessed 25 Feb 2017.</span></li> <li tag="ref"><a name="CR12" /><span class="label" tagx="label" title="label">12.</span><span class="mixed-citation" tagx="mixed-citation" title="mixed-citation">PharmGKB. Phenytoin. 2017. <a href="https://www.pharmgkb.org/">https://www.pharmgkb.org/</a>. Accessed 25 Feb 2017.</span></li> <li tag="ref"><a name="CR13" /><span class="label" tagx="label" title="label">13.</span><span class="element-citation'"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Henn</span><span class="given-names" tagx="given-names" title="given-names">BM</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Botigué</span><span class="given-names" tagx="given-names" title="given-names">LR</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Gravel</span><span class="given-names" tagx="given-names" title="given-names">S</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Wang</span><span class="given-names" tagx="given-names" title="given-names">W</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Brisbin</span><span class="given-names" tagx="given-names" title="given-names">A</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Byrnes</span><span class="given-names" tagx="given-names" title="given-names">JK</span></span><span class="etal" title="etal"><i>et al.</i></span></span><span class="mixed-article-title" title="mixed-article-title">Genomic ancestry of North Africans supports back-to-Africa migrations</span><span class="source" tagx="source" title="source">PLoS Genet.</span><span class="year" tagx="year" title="year">2012</span><span class="volume" tagx="volume" title="volume">8</span><span class="fpage" tagx="fpage" title="fpage">e1002397</span><span class="pub-id"><a href="https://dx.doi.org/10.1371/journal.pgen.1002397">10.1371/journal.pgen.1002397</a></span><span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/22253600">22253600</a></span></span></li> <li tag="ref"><a name="CR14" /><span class="label" tagx="label" title="label">14.</span><span class="element-citation'"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Yang</span><span class="given-names" tagx="given-names" title="given-names">Y</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Peter</span><span class="given-names" tagx="given-names" title="given-names">I</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Scott</span><span class="given-names" tagx="given-names" title="given-names">SA</span></span></span><span class="mixed-article-title" title="mixed-article-title">Pharmacogenetics in Jewish populations</span><span class="source" tagx="source" title="source">Drug Metabol Drug Interact.</span><span class="year" tagx="year" title="year">2014</span><span class="volume" tagx="volume" title="volume">29</span><span class="fpage" tagx="fpage" title="fpage">221</span><span class="lpage" tagx="lpage" title="lpage">233</span><span class="pub-id"><a href="https://dx.doi.org/10.1515/dmdi-2013-0069">10.1515/dmdi-2013-0069</a></span><span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/24867283">24867283</a></span></span></li> <li tag="ref"><a name="CR15" /><span class="label" tagx="label" title="label">15.</span><span class="element-citation'"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Yang</span><span class="given-names" tagx="given-names" title="given-names">X</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Al-Bustan</span><span class="given-names" tagx="given-names" title="given-names">S</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Feng</span><span class="given-names" tagx="given-names" title="given-names">Q</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Guo</span><span class="given-names" tagx="given-names" title="given-names">W</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Ma</span><span class="given-names" tagx="given-names" title="given-names">Z</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Marafie</span><span class="given-names" tagx="given-names" title="given-names">M</span></span><span class="etal" title="etal"><i>et al.</i></span></span><span class="mixed-article-title" title="mixed-article-title">The influence of admixture and consanguinity on population genetic diversity in Middle East</span><span class="source" tagx="source" title="source">J Hum Genet.</span><span class="year" tagx="year" title="year">2014</span><span class="volume" tagx="volume" title="volume">59</span><span class="fpage" tagx="fpage" title="fpage">615</span><span class="lpage" tagx="lpage" title="lpage">622</span><span class="pub-id"><a href="https://dx.doi.org/10.1038/jhg.2014.81">10.1038/jhg.2014.81</a></span><span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/25253659">25253659</a></span></span></li> <li tag="ref"><a name="CR16" /><span class="label" tagx="label" title="label">16.</span><span class="mixed-citation" tagx="mixed-citation" title="mixed-citation">NIH National Heart, Lung, and Blood Institute. Quality assessment tool for observational cohort and cross-sectional studies. 2014. <a href="https://www.nhlbi.nih.gov/">https://www.nhlbi.nih.gov/</a>. Accessed 1 Feb 2017.</span></li> <li tag="ref"><a name="CR17" /><span class="label" tagx="label" title="label">17.</span><span class="element-citation'"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Chung</span><span class="given-names" tagx="given-names" title="given-names">WH</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Chang</span><span class="given-names" tagx="given-names" title="given-names">WC</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Lee</span><span class="given-names" tagx="given-names" title="given-names">YS</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Wu</span><span class="given-names" tagx="given-names" title="given-names">YY</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Yang</span><span class="given-names" tagx="given-names" title="given-names">CH</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Ho</span><span class="given-names" tagx="given-names" title="given-names">HC</span></span><span class="etal" title="etal"><i>et al.</i></span></span><span class="mixed-article-title" title="mixed-article-title">Genetic variants associated with phenytoin-related severe cutaneous adverse reactions</span><span class="source" tagx="source" title="source">JAMA.</span><span class="year" tagx="year" title="year">2014</span><span class="volume" tagx="volume" title="volume">312</span><span class="fpage" tagx="fpage" title="fpage">525</span><span class="lpage" tagx="lpage" title="lpage">534</span><span class="pub-id"><a href="https://dx.doi.org/10.1001/jama.2014.7859">10.1001/jama.2014.7859</a></span><span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/25096692">25096692</a></span></span></li> <li tag="ref"><a name="CR18" /><span class="label" tagx="label" title="label">18.</span><span class="element-citation'"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Depondt</span><span class="given-names" tagx="given-names" title="given-names">C</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Godard</span><span class="given-names" tagx="given-names" title="given-names">P</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Espel</span><span class="given-names" tagx="given-names" title="given-names">RS</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">da Cruz</span><span class="given-names" tagx="given-names" title="given-names">AL</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Lienard</span><span class="given-names" tagx="given-names" title="given-names">P</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Pandolfo</span><span class="given-names" tagx="given-names" title="given-names">M</span></span></span><span class="mixed-article-title" title="mixed-article-title">A candidate gene study of antiepileptic drug tolerability and efficacy identifies an association of CYP2C9 variants with phenytoin toxicity</span><span class="source" tagx="source" title="source">Eur J Neurol.</span><span class="year" tagx="year" title="year">2011</span><span class="volume" tagx="volume" title="volume">18</span><span class="fpage" tagx="fpage" title="fpage">1159</span><span class="lpage" tagx="lpage" title="lpage">1164</span><span class="pub-id"><a href="https://dx.doi.org/10.1111/j.1468-1331.2011.03361.x">10.1111/j.1468-1331.2011.03361.x</a></span><span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/21338443">21338443</a></span></span></li> <li tag="ref"><a name="CR19" /><span class="label" tagx="label" title="label">19.</span><span class="element-citation'"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Huang</span><span class="given-names" tagx="given-names" title="given-names">Y</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Yang</span><span class="given-names" tagx="given-names" title="given-names">JF</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Qi</span><span class="given-names" tagx="given-names" title="given-names">XL</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Wang</span><span class="given-names" tagx="given-names" title="given-names">YQ</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Wang</span><span class="given-names" tagx="given-names" title="given-names">WZ</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Chen</span><span class="given-names" tagx="given-names" title="given-names">B</span></span></span><span class="mixed-article-title" title="mixed-article-title">Association between genetic polymorphisms of CYP2C19 and CYP2C9 and phenytoin serum concentration</span><span class="source" tagx="source" title="source">Zhongua Yi Xue Za Zhi.</span><span class="year" tagx="year" title="year">2004</span><span class="volume" tagx="volume" title="volume">84</span><span class="fpage" tagx="fpage" title="fpage">1686</span><span class="lpage" tagx="lpage" title="lpage">1689</span></span></li> <li tag="ref"><a name="CR20" /><span class="label" tagx="label" title="label">20.</span><span class="element-citation'"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Hung</span><span class="given-names" tagx="given-names" title="given-names">CC</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Lin</span><span class="given-names" tagx="given-names" title="given-names">CJ</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Chen</span><span class="given-names" tagx="given-names" title="given-names">CC</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Chang</span><span class="given-names" tagx="given-names" title="given-names">CJ</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Liou</span><span class="given-names" tagx="given-names" title="given-names">HH</span></span></span><span class="mixed-article-title" title="mixed-article-title">Dosage recommendation of phenytoin for patients with epilepsy with different CYP2C9/CYP2C19 polymorphisms</span><span class="source" tagx="source" title="source">Ther Drug Monit.</span><span class="year" tagx="year" title="year">2004</span><span class="volume" tagx="volume" title="volume">26</span><span class="fpage" tagx="fpage" title="fpage">534</span><span class="lpage" tagx="lpage" title="lpage">540</span><span class="pub-id"><a href="https://dx.doi.org/10.1097/00007691-200410000-00012">10.1097/00007691-200410000-00012</a></span><span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/15385837">15385837</a></span></span></li> <li tag="ref"><a name="CR21" /><span class="label" tagx="label" title="label">21.</span><span class="element-citation'"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Kousar</span><span class="given-names" tagx="given-names" title="given-names">S</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Wafai</span><span class="given-names" tagx="given-names" title="given-names">ZA</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Wani</span><span class="given-names" tagx="given-names" title="given-names">MA</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Jan</span><span class="given-names" tagx="given-names" title="given-names">TR</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Andrabi</span><span class="given-names" tagx="given-names" title="given-names">KI</span></span></span><span class="mixed-article-title" title="mixed-article-title">Clinical relevance of genetic polymorphism in the CYP2C9 gene to pharmacodynamics and pharmacokinetics of phenytoin in epileptic patients: validatory pharmacogenomic approach to pharmacovigilance</span><span class="source" tagx="source" title="source">Int J Clin Pharmacol Ther.</span><span class="year" tagx="year" title="year">2015</span><span class="volume" tagx="volume" title="volume">53</span><span class="fpage" tagx="fpage" title="fpage">504</span><span class="lpage" tagx="lpage" title="lpage">516</span><span class="pub-id"><a href="https://dx.doi.org/10.5414/CP202112">10.5414/CP202112</a></span><span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/25943175">25943175</a></span></span></li> <li tag="ref"><a name="CR22" /><span class="label" tagx="label" title="label">22.</span><span class="element-citation'"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Kesavan</span><span class="given-names" tagx="given-names" title="given-names">R</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Narayan</span><span class="given-names" tagx="given-names" title="given-names">SK</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Adithan</span><span class="given-names" tagx="given-names" title="given-names">C</span></span></span><span class="mixed-article-title" title="mixed-article-title">Influence of CYP2C9 and CYP2C19 genetic polymorphisms on phenytoin-induced neurological toxicity in Indian epileptic patients</span><span class="source" tagx="source" title="source">Eur J Clin Pharmacol.</span><span class="year" tagx="year" title="year">2010</span><span class="volume" tagx="volume" title="volume">66</span><span class="fpage" tagx="fpage" title="fpage">689</span><span class="lpage" tagx="lpage" title="lpage">696</span><span class="pub-id"><a href="https://dx.doi.org/10.1007/s00228-010-0817-2">10.1007/s00228-010-0817-2</a></span><span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/20390258">20390258</a></span></span></li> <li tag="ref"><a name="CR23" /><span class="label" tagx="label" title="label">23.</span><span class="element-citation'"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Sun</span><span class="given-names" tagx="given-names" title="given-names">F</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Cao</span><span class="given-names" tagx="given-names" title="given-names">BQ</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Wang</span><span class="given-names" tagx="given-names" title="given-names">B</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Wu</span><span class="given-names" tagx="given-names" title="given-names">SQ</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Jiang</span><span class="given-names" tagx="given-names" title="given-names">DH</span></span></span><span class="mixed-article-title" title="mixed-article-title">Association between ABCB1 genetic polymorphism and the effect on epilepsy following phenytoin treatment</span><span class="source" tagx="source" title="source">Exp Ther Med.</span><span class="year" tagx="year" title="year">2016</span><span class="volume" tagx="volume" title="volume">12</span><span class="fpage" tagx="fpage" title="fpage">1780</span><span class="lpage" tagx="lpage" title="lpage">1784</span><span class="pub-id"><a href="https://dx.doi.org/10.3892/etm.2016.3553">10.3892/etm.2016.3553</a></span><span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/27602091">27602091</a></span></span></li> <li tag="ref"><a name="CR24" /><span class="label" tagx="label" title="label">24.</span><span class="element-citation'"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">van der Weide</span><span class="given-names" tagx="given-names" title="given-names">J</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Steijns</span><span class="given-names" tagx="given-names" title="given-names">LS</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">van Weelden</span><span class="given-names" tagx="given-names" title="given-names">MJ</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">de Haan</span><span class="given-names" tagx="given-names" title="given-names">K</span></span></span><span class="mixed-article-title" title="mixed-article-title">The effect of genetic polymorphism of cytochrome P450 CYP2C9 on phenytoin dose requirement</span><span class="source" tagx="source" title="source">Pharmacogenetics.</span><span class="year" tagx="year" title="year">2001</span><span class="volume" tagx="volume" title="volume">11</span><span class="fpage" tagx="fpage" title="fpage">287</span><span class="lpage" tagx="lpage" title="lpage">291</span><span class="pub-id"><a href="https://dx.doi.org/10.1097/00008571-200106000-00002">10.1097/00008571-200106000-00002</a></span><span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/11434505">11434505</a></span></span></li> <li tag="ref"><a name="CR25" /><span class="label" tagx="label" title="label">25.</span><span class="element-citation'"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Ponnala</span><span class="given-names" tagx="given-names" title="given-names">S</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Chaudhari</span><span class="given-names" tagx="given-names" title="given-names">JR</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Jaleel</span><span class="given-names" tagx="given-names" title="given-names">MA</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Bhiladvala</span><span class="given-names" tagx="given-names" title="given-names">D</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Kaipa</span><span class="given-names" tagx="given-names" title="given-names">PR</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Das</span><span class="given-names" tagx="given-names" title="given-names">UN</span></span></span><span class="mixed-article-title" title="mixed-article-title">Role of <i>MDR1</i> C3435T and <i>GABRG2</i> C588T gene polymorphisms in seizure occurrence and <i>MDR1</i> effect on anti-epileptic drug (phenytoin) absorption</span><span class="source" tagx="source" title="source">Genet Test Mol Biomark.</span><span class="year" tagx="year" title="year">2012</span><span class="volume" tagx="volume" title="volume">16</span><span class="fpage" tagx="fpage" title="fpage">550</span><span class="lpage" tagx="lpage" title="lpage">557</span><span class="pub-id"><a href="https://dx.doi.org/10.1089/gtmb.2011.0225">10.1089/gtmb.2011.0225</a></span></span></li> <li tag="ref"><a name="CR26" /><span class="label" tagx="label" title="label">26.</span><span class="element-citation'"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Thaker</span><span class="given-names" tagx="given-names" title="given-names">SJ</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Gandhe</span><span class="given-names" tagx="given-names" title="given-names">PP</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Godbole</span><span class="given-names" tagx="given-names" title="given-names">CJ</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Bendkhale</span><span class="given-names" tagx="given-names" title="given-names">SR</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Mali</span><span class="given-names" tagx="given-names" title="given-names">NB</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Thatte</span><span class="given-names" tagx="given-names" title="given-names">UM</span></span><span class="etal" title="etal"><i>et al.</i></span></span><span class="mixed-article-title" title="mixed-article-title">A prospective study to assess the association between genotype, phenotype and Prakriti in individuals on phenytoin monotherapy</span><span class="source" tagx="source" title="source">J Ayurveda Integr Med.</span><span class="year" tagx="year" title="year">2017</span><span class="volume" tagx="volume" title="volume">8</span><span class="fpage" tagx="fpage" title="fpage">37</span><span class="lpage" tagx="lpage" title="lpage">41</span><span class="pub-id"><a href="https://dx.doi.org/10.1016/j.jaim.2016.12.001">10.1016/j.jaim.2016.12.001</a></span><span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/28302415">28302415</a></span></span></li> <li tag="ref"><a name="CR27" /><span class="label" tagx="label" title="label">27.</span><span class="element-citation'"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Tabari</span><span class="given-names" tagx="given-names" title="given-names">RG</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Naseri</span><span class="given-names" tagx="given-names" title="given-names">F</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Marjani</span><span class="given-names" tagx="given-names" title="given-names">A</span></span></span><span class="mixed-article-title" title="mixed-article-title">Genetic polymorphism of CYPP450 (2C19) enzyme in Iranian Baluch ethnic group</span><span class="source" tagx="source" title="source">Open Biochem J.</span><span class="year" tagx="year" title="year">2015</span><span class="volume" tagx="volume" title="volume">9</span><span class="fpage" tagx="fpage" title="fpage">37</span><span class="lpage" tagx="lpage" title="lpage">41</span><span class="pub-id"><a href="https://dx.doi.org/10.2174/1874091X01509010037">10.2174/1874091X01509010037</a></span><span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/26464589">26464589</a></span></span></li> <li tag="ref"><a name="CR28" /><span class="label" tagx="label" title="label">28.</span><span class="element-citation'"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Seven</span><span class="given-names" tagx="given-names" title="given-names">M</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Batar</span><span class="given-names" tagx="given-names" title="given-names">B</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Unal</span><span class="given-names" tagx="given-names" title="given-names">S</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Yesil</span><span class="given-names" tagx="given-names" title="given-names">G</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Yuksel</span><span class="given-names" tagx="given-names" title="given-names">A</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Guven</span><span class="given-names" tagx="given-names" title="given-names">M</span></span></span><span class="mixed-article-title" title="mixed-article-title">The effect of genetic polymorphisms of cytochrome P450 CYP2C9, CYP2C19, and CYP2D6 on drug-resistant epilepsy in Turkish children</span><span class="source" tagx="source" title="source">Mol Diagn Ther.</span><span class="year" tagx="year" title="year">2014</span><span class="volume" tagx="volume" title="volume">18</span><span class="fpage" tagx="fpage" title="fpage">229</span><span class="lpage" tagx="lpage" title="lpage">236</span><span class="pub-id"><a href="https://dx.doi.org/10.1007/s40291-013-0078-8">10.1007/s40291-013-0078-8</a></span><span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/24338437">24338437</a></span></span></li> <li tag="ref"><a name="CR29" /><span class="label" tagx="label" title="label">29.</span><span class="element-citation'"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Seven</span><span class="given-names" tagx="given-names" title="given-names">M</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Batar</span><span class="given-names" tagx="given-names" title="given-names">B</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Unal</span><span class="given-names" tagx="given-names" title="given-names">S</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Yesil</span><span class="given-names" tagx="given-names" title="given-names">G</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Yuksel</span><span class="given-names" tagx="given-names" title="given-names">A</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Guven</span><span class="given-names" tagx="given-names" title="given-names">M</span></span></span><span class="mixed-article-title" title="mixed-article-title">The drug-transporter gene MDR1 C3435T and G2677T/A polymorphisms and the risk of multidrug-resistant epilepsy in Turkish children</span><span class="source" tagx="source" title="source">Mol Biol Rep.</span><span class="year" tagx="year" title="year">2014</span><span class="volume" tagx="volume" title="volume">41</span><span class="fpage" tagx="fpage" title="fpage">331</span><span class="lpage" tagx="lpage" title="lpage">336</span><span class="pub-id"><a href="https://dx.doi.org/10.1007/s11033-013-2866-y">10.1007/s11033-013-2866-y</a></span><span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/24213830">24213830</a></span></span></li> <li tag="ref"><a name="CR30" /><span class="label" tagx="label" title="label">30.</span><span class="element-citation'"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Britzi</span><span class="given-names" tagx="given-names" title="given-names">M</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Bialer</span><span class="given-names" tagx="given-names" title="given-names">M</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Arcavi</span><span class="given-names" tagx="given-names" title="given-names">L</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Shachbari</span><span class="given-names" tagx="given-names" title="given-names">A</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Kapitulnik</span><span class="given-names" tagx="given-names" title="given-names">T</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Soback</span><span class="given-names" tagx="given-names" title="given-names">S</span></span></span><span class="mixed-article-title" title="mixed-article-title">Genetic polymorphism of CYP2D6 and CYP2C19 metabolism determined by phenotyping Israeli ethnic groups</span><span class="source" tagx="source" title="source">Ther Drug Monit.</span><span class="year" tagx="year" title="year">2000</span><span class="volume" tagx="volume" title="volume">22</span><span class="fpage" tagx="fpage" title="fpage">510</span><span class="lpage" tagx="lpage" title="lpage">516</span><span class="pub-id"><a href="https://dx.doi.org/10.1097/00007691-200010000-00002">10.1097/00007691-200010000-00002</a></span><span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/11034254">11034254</a></span></span></li> <li tag="ref"><a name="CR31" /><span class="label" tagx="label" title="label">31.</span><span class="element-citation'"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Sviri</span><span class="given-names" tagx="given-names" title="given-names">S</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Shpizen</span><span class="given-names" tagx="given-names" title="given-names">S</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Leitersdorf</span><span class="given-names" tagx="given-names" title="given-names">E</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Levy</span><span class="given-names" tagx="given-names" title="given-names">M</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Caraco</span><span class="given-names" tagx="given-names" title="given-names">Y</span></span></span><span class="mixed-article-title" title="mixed-article-title">Phenotypic-genotypic analysis of CYP2C19 in the Jewish Israeli population</span><span class="source" tagx="source" title="source">Clin Pharmacol Ther.</span><span class="year" tagx="year" title="year">1999</span><span class="volume" tagx="volume" title="volume">65</span><span class="fpage" tagx="fpage" title="fpage">275</span><span class="lpage" tagx="lpage" title="lpage">282</span><span class="pub-id"><a href="https://dx.doi.org/10.1016/S0009-9236(99)70106-2">10.1016/S0009-9236(99)70106-2</a></span><span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/10096259">10096259</a></span></span></li> <li tag="ref"><a name="CR32" /><span class="label" tagx="label" title="label">32.</span><span class="element-citation'"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Maleki</span><span class="given-names" tagx="given-names" title="given-names">M</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Sayyah</span><span class="given-names" tagx="given-names" title="given-names">M</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Kamgarpour</span><span class="given-names" tagx="given-names" title="given-names">F</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Karimipoor</span><span class="given-names" tagx="given-names" title="given-names">M</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Arab</span><span class="given-names" tagx="given-names" title="given-names">A</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Rajabi</span><span class="given-names" tagx="given-names" title="given-names">A</span></span><span class="etal" title="etal"><i>et al.</i></span></span><span class="mixed-article-title" title="mixed-article-title">Association between ABCB1-T1236C polymorphism and drug-resistant epilepsy in Iranian female patients</span><span class="source" tagx="source" title="source">Iran Biomed J.</span><span class="year" tagx="year" title="year">2010</span><span class="volume" tagx="volume" title="volume">14</span><span class="fpage" tagx="fpage" title="fpage">89</span><span class="lpage" tagx="lpage" title="lpage">96</span><span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/21079659">21079659</a></span></span></li> <li tag="ref"><a name="CR33" /><span class="label" tagx="label" title="label">33.</span><span class="element-citation'"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Sayyah</span><span class="given-names" tagx="given-names" title="given-names">M</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Kamgarpour</span><span class="given-names" tagx="given-names" title="given-names">F</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Maleki</span><span class="given-names" tagx="given-names" title="given-names">M</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Karimipoor</span><span class="given-names" tagx="given-names" title="given-names">M</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Gharagozli</span><span class="given-names" tagx="given-names" title="given-names">K</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Shamshiri</span><span class="given-names" tagx="given-names" title="given-names">AR</span></span></span><span class="mixed-article-title" title="mixed-article-title">Association analysis of intractable epilepsy with C3435T and G2677T/A ABCB1 gene polymorphisms in Iranian patients</span><span class="source" tagx="source" title="source">Epileptic Disord.</span><span class="year" tagx="year" title="year">2011</span><span class="volume" tagx="volume" title="volume">13</span><span class="fpage" tagx="fpage" title="fpage">155</span><span class="lpage" tagx="lpage" title="lpage">165</span><span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/21636342">21636342</a></span></span></li> <li tag="ref"><a name="CR34" /><span class="label" tagx="label" title="label">34.</span><span class="element-citation'"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Hennessy</span><span class="given-names" tagx="given-names" title="given-names">S</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Leonard</span><span class="given-names" tagx="given-names" title="given-names">CE</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Freeman</span><span class="given-names" tagx="given-names" title="given-names">CP</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Metlay</span><span class="given-names" tagx="given-names" title="given-names">JP</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Chu</span><span class="given-names" tagx="given-names" title="given-names">X</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Strom</span><span class="given-names" tagx="given-names" title="given-names">BL</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Bilker</span><span class="given-names" tagx="given-names" title="given-names">WB</span></span></span><span class="mixed-article-title" title="mixed-article-title">CYP2C9, CYP2C19 and ABCB1 genotype and hospitalization for phenytoin toxicity</span><span class="source" tagx="source" title="source">Clin Lymphoma</span><span class="year" tagx="year" title="year">2010</span><span class="volume" tagx="volume" title="volume">9</span><span class="fpage" tagx="fpage" title="fpage">19</span><span class="lpage" tagx="lpage" title="lpage">22</span></span></li> <li tag="ref"><a name="CR35" /><span class="label" tagx="label" title="label">35.</span><span class="element-citation'"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Lai</span><span class="given-names" tagx="given-names" title="given-names">ML</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Tien</span><span class="given-names" tagx="given-names" title="given-names">YE</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Huang</span><span class="given-names" tagx="given-names" title="given-names">YS</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Huang</span><span class="given-names" tagx="given-names" title="given-names">JD</span></span></span><span class="mixed-article-title" title="mixed-article-title">Studies on pharmacokinetic mechanism of phenytoin resistance in refractory epilepsy</span><span class="source" tagx="source" title="source">J Pharm Sci.</span><span class="year" tagx="year" title="year">2013</span><span class="volume" tagx="volume" title="volume">102</span><span class="fpage" tagx="fpage" title="fpage">3189</span><span class="lpage" tagx="lpage" title="lpage">3195</span><span class="pub-id"><a href="https://dx.doi.org/10.1002/jps.23593">10.1002/jps.23593</a></span><span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/23658067">23658067</a></span></span></li> <li tag="ref"><a name="CR36" /><span class="label" tagx="label" title="label">36.</span><span class="element-citation'"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Shaheen</span><span class="given-names" tagx="given-names" title="given-names">U</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Prasad</span><span class="given-names" tagx="given-names" title="given-names">DKV</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Sharma</span><span class="given-names" tagx="given-names" title="given-names">V</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Suryaprabha</span><span class="given-names" tagx="given-names" title="given-names">T</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Ahuja</span><span class="given-names" tagx="given-names" title="given-names">YR</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Jyothy</span><span class="given-names" tagx="given-names" title="given-names">A</span></span><span class="etal" title="etal"><i>et al.</i></span></span><span class="mixed-article-title" title="mixed-article-title">Significance of MDR1 gene polymorphism C3435T in predicting drug response in epilepsy</span><span class="source" tagx="source" title="source">Epilepsy Res.</span><span class="year" tagx="year" title="year">2014</span><span class="volume" tagx="volume" title="volume">108</span><span class="fpage" tagx="fpage" title="fpage">251</span><span class="lpage" tagx="lpage" title="lpage">256</span><span class="pub-id"><a href="https://dx.doi.org/10.1016/j.eplepsyres.2013.11.009">10.1016/j.eplepsyres.2013.11.009</a></span><span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/24300029">24300029</a></span></span></li> <li tag="ref"><a name="CR37" /><span class="label" tagx="label" title="label">37.</span><span class="element-citation'"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Grover</span><span class="given-names" tagx="given-names" title="given-names">S</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Gourie-Devi</span><span class="given-names" tagx="given-names" title="given-names">M</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Baghel</span><span class="given-names" tagx="given-names" title="given-names">R</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Sharma</span><span class="given-names" tagx="given-names" title="given-names">S</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Bala</span><span class="given-names" tagx="given-names" title="given-names">K</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Gupta</span><span class="given-names" tagx="given-names" title="given-names">M</span></span><span class="etal" title="etal"><i>et al.</i></span></span><span class="mixed-article-title" title="mixed-article-title">Genetic profile of patients with epilepsy on first-line antiepileptic drugs and potential directions for personalized treatment</span><span class="source" tagx="source" title="source">Pharmacogenomics.</span><span class="year" tagx="year" title="year">2010</span><span class="volume" tagx="volume" title="volume">11</span><span class="fpage" tagx="fpage" title="fpage">927</span><span class="lpage" tagx="lpage" title="lpage">941</span><span class="pub-id"><a href="https://dx.doi.org/10.2217/pgs.10.62">10.2217/pgs.10.62</a></span><span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/20602612">20602612</a></span></span></li> <li tag="ref"><a name="CR38" /><span class="label" tagx="label" title="label">38.</span><span class="element-citation'"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Yampayon</span><span class="given-names" tagx="given-names" title="given-names">K</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Sukasem</span><span class="given-names" tagx="given-names" title="given-names">C</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Limwongse</span><span class="given-names" tagx="given-names" title="given-names">C</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Chinvarun</span><span class="given-names" tagx="given-names" title="given-names">Y</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Tempark</span><span class="given-names" tagx="given-names" title="given-names">T</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Rerkpattanapipat</span><span class="given-names" tagx="given-names" title="given-names">T</span></span><span class="etal" title="etal"><i>et al.</i></span></span><span class="mixed-article-title" title="mixed-article-title">Influence of genetic and non-genetic factors on phenytoin-induced severe cutaneous adverse drug reactions</span><span class="source" tagx="source" title="source">Eur J Clin Pharmacol.</span><span class="year" tagx="year" title="year">2017</span><span class="volume" tagx="volume" title="volume">73</span><span class="fpage" tagx="fpage" title="fpage">855</span><span class="lpage" tagx="lpage" title="lpage">865</span><span class="pub-id"><a href="https://dx.doi.org/10.1007/s00228-017-2250-2">10.1007/s00228-017-2250-2</a></span><span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/28391407">28391407</a></span></span></li> <li tag="ref"><a name="CR39" /><span class="label" tagx="label" title="label">39.</span><span class="element-citation'"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Salehifar</span><span class="given-names" tagx="given-names" title="given-names">E</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Zohrabi</span><span class="given-names" tagx="given-names" title="given-names">M</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Eshghi</span><span class="given-names" tagx="given-names" title="given-names">S</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Saeedi</span><span class="given-names" tagx="given-names" title="given-names">M</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Ebrahimi</span><span class="given-names" tagx="given-names" title="given-names">P</span></span></span><span class="mixed-article-title" title="mixed-article-title">Different pharmacokinetic parameters of phenytoin in Iranian outpatients: need to optimize the current dosage regimen</span><span class="source" tagx="source" title="source">IJPR.</span><span class="year" tagx="year" title="year">2009</span><span class="volume" tagx="volume" title="volume">8</span><span class="fpage" tagx="fpage" title="fpage">37</span><span class="lpage" tagx="lpage" title="lpage">45</span></span></li> <li tag="ref"><a name="CR40" /><span class="label" tagx="label" title="label">40.</span><span class="element-citation'"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Alhazzani</span><span class="given-names" tagx="given-names" title="given-names">AA</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Munisamy</span><span class="given-names" tagx="given-names" title="given-names">M</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Karunakaran</span><span class="given-names" tagx="given-names" title="given-names">G</span></span></span><span class="mixed-article-title" title="mixed-article-title">Pharmacogenetics of ATP binding cassette transporter—MDR1 gene polymorphism (MDR1—1236C&amp;gt;T polymorphism) and response to antiepileptic drug phenytoin pharmacokinetics in epilepsy</span><span class="source" tagx="source" title="source">Neurology.</span><span class="year" tagx="year" title="year">2016</span><span class="volume" tagx="volume" title="volume">86</span><span class="issue" tagx="issue" title="issue">Suppl. 16</span><span class="fpage" tagx="fpage" title="fpage">P2.046</span></span></li> <li tag="ref"><a name="CR41" /><span class="label" tagx="label" title="label">41.</span><span class="element-citation'"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Alhazzani</span><span class="given-names" tagx="given-names" title="given-names">A</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Al-Gahtany</span><span class="given-names" tagx="given-names" title="given-names">M</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Munisamy</span><span class="given-names" tagx="given-names" title="given-names">M</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Karunakaran</span><span class="given-names" tagx="given-names" title="given-names">G</span></span></span><span class="mixed-article-title" title="mixed-article-title">Pharmacogenetics of ATP binding cassette transporter-MDR1 gene polymorphism (C3435T) and response to antiepileptic drug phenytoin pharmacokinetics in epilepsy</span><span class="source" tagx="source" title="source">J Neurol Sci.</span><span class="year" tagx="year" title="year">2015</span><span class="volume" tagx="volume" title="volume">357</span><span class="fpage" tagx="fpage" title="fpage">e142</span><span class="lpage" tagx="lpage" title="lpage">e160</span><span class="pub-id"><a href="https://dx.doi.org/10.1016/j.jns.2015.08.486">10.1016/j.jns.2015.08.486</a></span></span></li> <li tag="ref"><a name="CR42" /><span class="label" tagx="label" title="label">42.</span><span class="element-citation'"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Aynacioglu</span><span class="given-names" tagx="given-names" title="given-names">AS</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Brockmöller</span><span class="given-names" tagx="given-names" title="given-names">J</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Bauer</span><span class="given-names" tagx="given-names" title="given-names">S</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Sachse</span><span class="given-names" tagx="given-names" title="given-names">C</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Guzelbey</span><span class="given-names" tagx="given-names" title="given-names">P</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Ongen</span><span class="given-names" tagx="given-names" title="given-names">Z</span></span><span class="etal" title="etal"><i>et al.</i></span></span><span class="mixed-article-title" title="mixed-article-title">Frequency of cytochrome P450 CYP2C9 variants in a Turkish population and functional relevance for phenytoin</span><span class="source" tagx="source" title="source">Br J Clin Pharmacol.</span><span class="year" tagx="year" title="year">1999</span><span class="volume" tagx="volume" title="volume">48</span><span class="fpage" tagx="fpage" title="fpage">409</span><span class="lpage" tagx="lpage" title="lpage">415</span><span class="pub-id"><a href="https://dx.doi.org/10.1046/j.1365-2125.1999.00012.x">10.1046/j.1365-2125.1999.00012.x</a></span><span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/10510154">10510154</a></span></span></li> <li tag="ref"><a name="CR43" /><span class="label" tagx="label" title="label">43.</span><span class="element-citation'"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Kerb</span><span class="given-names" tagx="given-names" title="given-names">R</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Aynacioglu</span><span class="given-names" tagx="given-names" title="given-names">AS</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Brockmöller</span><span class="given-names" tagx="given-names" title="given-names">J</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Schlagenhaufer</span><span class="given-names" tagx="given-names" title="given-names">R</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Bauer</span><span class="given-names" tagx="given-names" title="given-names">S</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Szekeres</span><span class="given-names" tagx="given-names" title="given-names">T</span></span><span class="etal" title="etal"><i>et al.</i></span></span><span class="mixed-article-title" title="mixed-article-title">The predictive value of MDR1, CYP2C9, and CYP2C19 polymorphisms for phenytoin plasma levels</span><span class="source" tagx="source" title="source">Pharmacogenom J.</span><span class="year" tagx="year" title="year">2001</span><span class="volume" tagx="volume" title="volume">1</span><span class="fpage" tagx="fpage" title="fpage">204</span><span class="lpage" tagx="lpage" title="lpage">210</span><span class="pub-id"><a href="https://dx.doi.org/10.1038/sj.tpj.6500025">10.1038/sj.tpj.6500025</a></span></span></li> <li tag="ref"><a name="CR44" /><span class="label" tagx="label" title="label">44.</span><span class="element-citation'"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Ozkaynakci</span><span class="given-names" tagx="given-names" title="given-names">A</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Gulcebi</span><span class="given-names" tagx="given-names" title="given-names">MI</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Ergeç</span><span class="given-names" tagx="given-names" title="given-names">D</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Ulucan</span><span class="given-names" tagx="given-names" title="given-names">K</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Uzan</span><span class="given-names" tagx="given-names" title="given-names">M</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Ozkara</span><span class="given-names" tagx="given-names" title="given-names">C</span></span><span class="etal" title="etal"><i>et al.</i></span></span><span class="mixed-article-title" title="mixed-article-title">The effect of polymorphic metabolism enzymes on serum phenytoin level</span><span class="source" tagx="source" title="source">Neurol Sci.</span><span class="year" tagx="year" title="year">2015</span><span class="volume" tagx="volume" title="volume">36</span><span class="fpage" tagx="fpage" title="fpage">397</span><span class="lpage" tagx="lpage" title="lpage">401</span><span class="pub-id"><a href="https://dx.doi.org/10.1007/s10072-014-1961-8">10.1007/s10072-014-1961-8</a></span><span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/25311916">25311916</a></span></span></li> <li tag="ref"><a name="CR45" /><span class="label" tagx="label" title="label">45.</span><span class="element-citation'"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Alhazzani</span><span class="given-names" tagx="given-names" title="given-names">AA</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Munisamy</span><span class="given-names" tagx="given-names" title="given-names">M</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Karunakaran</span><span class="given-names" tagx="given-names" title="given-names">G</span></span></span><span class="mixed-article-title" title="mixed-article-title">MDR1 gene polymorphism and phenytoin pharmacokinetics in epilepsy</span><span class="source" tagx="source" title="source">Bahrain Med Bull.</span><span class="year" tagx="year" title="year">2017</span><span class="volume" tagx="volume" title="volume">39</span><span class="fpage" tagx="fpage" title="fpage">29</span><span class="lpage" tagx="lpage" title="lpage">32</span></span></li> <li tag="ref"><a name="CR46" /><span class="label" tagx="label" title="label">46.</span><span class="element-citation'"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Ebid</span><span class="given-names" tagx="given-names" title="given-names">AH</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Ahmed</span><span class="given-names" tagx="given-names" title="given-names">MM</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Mohammed</span><span class="given-names" tagx="given-names" title="given-names">SA</span></span></span><span class="mixed-article-title" title="mixed-article-title">Therapeutic drug monitoring and clinical outcomes in epileptic Egyptian patients: a gene polymorphism perspective study</span><span class="source" tagx="source" title="source">Ther Drug Monit.</span><span class="year" tagx="year" title="year">2007</span><span class="volume" tagx="volume" title="volume">29</span><span class="fpage" tagx="fpage" title="fpage">305</span><span class="lpage" tagx="lpage" title="lpage">312</span><span class="pub-id"><a href="https://dx.doi.org/10.1097/FTD.0b013e318067ce90">10.1097/FTD.0b013e318067ce90</a></span><span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/17529887">17529887</a></span></span></li> <li tag="ref"><a name="CR47" /><span class="label" tagx="label" title="label">47.</span><span class="element-citation'"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Hamdy</span><span class="given-names" tagx="given-names" title="given-names">SI</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Hiratsuka</span><span class="given-names" tagx="given-names" title="given-names">M</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Narahara</span><span class="given-names" tagx="given-names" title="given-names">K</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">El-Enany</span><span class="given-names" tagx="given-names" title="given-names">M</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Moursi</span><span class="given-names" tagx="given-names" title="given-names">N</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Ahmed</span><span class="given-names" tagx="given-names" title="given-names">MS</span></span><span class="etal" title="etal"><i>et al.</i></span></span><span class="mixed-article-title" title="mixed-article-title">Allele and genotype frequencies of polymorphic cytochromes P450 (CYP2C9, CYP2C19, and CYP2E1) and dihydropyrimidine dehydrogenase (DPYD) in the Egyptian population</span><span class="source" tagx="source" title="source">Br J Clin Pharmacol.</span><span class="year" tagx="year" title="year">2002</span><span class="volume" tagx="volume" title="volume">52</span><span class="fpage" tagx="fpage" title="fpage">596</span><span class="lpage" tagx="lpage" title="lpage">603</span><span class="pub-id"><a href="https://dx.doi.org/10.1046/j.1365-2125.2002.01604.x">10.1046/j.1365-2125.2002.01604.x</a></span></span></li> <li tag="ref"><a name="CR48" /><span class="label" tagx="label" title="label">48.</span><span class="element-citation'"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">El Din</span><span class="given-names" tagx="given-names" title="given-names">MS</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Amin</span><span class="given-names" tagx="given-names" title="given-names">DG</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Ragab</span><span class="given-names" tagx="given-names" title="given-names">SB</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Ashour</span><span class="given-names" tagx="given-names" title="given-names">EE</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Mohamed</span><span class="given-names" tagx="given-names" title="given-names">MH</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Mohamed</span><span class="given-names" tagx="given-names" title="given-names">AM</span></span></span><span class="mixed-article-title" title="mixed-article-title">Frequency of VKORC1 (C1173T) and CYP2C9 genetic polymorphisms in Egyptians and their influence on warfarin maintenance dose: proposal for a new dosing regimen</span><span class="source" tagx="source" title="source">Int J Lab Hematol.</span><span class="year" tagx="year" title="year">2012</span><span class="volume" tagx="volume" title="volume">34</span><span class="fpage" tagx="fpage" title="fpage">517</span><span class="lpage" tagx="lpage" title="lpage">524</span><span class="pub-id"><a href="https://dx.doi.org/10.1111/j.1751-553X.2012.01426.x">10.1111/j.1751-553X.2012.01426.x</a></span><span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/22533669">22533669</a></span></span></li> <li tag="ref"><a name="CR49" /><span class="label" tagx="label" title="label">49.</span><span class="element-citation'"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Azzam</span><span class="given-names" tagx="given-names" title="given-names">H</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Elwakeel</span><span class="given-names" tagx="given-names" title="given-names">H</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Awad</span><span class="given-names" tagx="given-names" title="given-names">I</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">El-Farahaty</span><span class="given-names" tagx="given-names" title="given-names">R</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">El-Gilany</span><span class="given-names" tagx="given-names" title="given-names">AH</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">El-Sharawy</span><span class="given-names" tagx="given-names" title="given-names">S</span></span></span><span class="mixed-article-title" title="mixed-article-title">VKORC1 and CYP2C9 genotypes in Egyptian patients with warfarin resistance</span><span class="source" tagx="source" title="source">Blood Coagul Fibrinolysis.</span><span class="year" tagx="year" title="year">2016</span><span class="volume" tagx="volume" title="volume">27</span><span class="fpage" tagx="fpage" title="fpage">121</span><span class="lpage" tagx="lpage" title="lpage">126</span><span class="pub-id"><a href="https://dx.doi.org/10.1097/MBC.0000000000000168">10.1097/MBC.0000000000000168</a></span><span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/24978953">24978953</a></span></span></li> <li tag="ref"><a name="CR50" /><span class="label" tagx="label" title="label">50.</span><span class="element-citation'"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Bazan</span><span class="given-names" tagx="given-names" title="given-names">NS</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Sabry</span><span class="given-names" tagx="given-names" title="given-names">NA</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Rizk</span><span class="given-names" tagx="given-names" title="given-names">A</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Mokhtar</span><span class="given-names" tagx="given-names" title="given-names">S</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Badary</span><span class="given-names" tagx="given-names" title="given-names">OA</span></span></span><span class="mixed-article-title" title="mixed-article-title">Factors affecting warfarin dose requirements and quality of anticoagulation in adult Egyptian patients: role of gene polymorphism</span><span class="source" tagx="source" title="source">Ir J Med Sci.</span><span class="year" tagx="year" title="year">2014</span><span class="volume" tagx="volume" title="volume">183</span><span class="fpage" tagx="fpage" title="fpage">161</span><span class="lpage" tagx="lpage" title="lpage">172</span><span class="pub-id"><a href="https://dx.doi.org/10.1007/s11845-013-0978-y">10.1007/s11845-013-0978-y</a></span><span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/23800980">23800980</a></span></span></li> <li tag="ref"><a name="CR51" /><span class="label" tagx="label" title="label">51.</span><span class="element-citation'"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Ekladious</span><span class="given-names" tagx="given-names" title="given-names">SM</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Issac</span><span class="given-names" tagx="given-names" title="given-names">MS</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Sharaf</span><span class="given-names" tagx="given-names" title="given-names">SA</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Abou-Youssef</span><span class="given-names" tagx="given-names" title="given-names">HS</span></span></span><span class="mixed-article-title" title="mixed-article-title">Validation of a proposed warfarin dosing algorithm based on the genetic make-up of Egyptian patients</span><span class="source" tagx="source" title="source">Mol Diagn Ther.</span><span class="year" tagx="year" title="year">2013</span><span class="volume" tagx="volume" title="volume">17</span><span class="fpage" tagx="fpage" title="fpage">381</span><span class="lpage" tagx="lpage" title="lpage">390</span><span class="pub-id"><a href="https://dx.doi.org/10.1007/s40291-013-0046-3">10.1007/s40291-013-0046-3</a></span><span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/23839801">23839801</a></span></span></li> <li tag="ref"><a name="CR52" /><span class="label" tagx="label" title="label">52.</span><span class="element-citation'"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Shahin</span><span class="given-names" tagx="given-names" title="given-names">MH</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Khalifa</span><span class="given-names" tagx="given-names" title="given-names">SI</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Gong</span><span class="given-names" tagx="given-names" title="given-names">Y</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Hammad</span><span class="given-names" tagx="given-names" title="given-names">LN</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Sallam</span><span class="given-names" tagx="given-names" title="given-names">MT</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Shafey</span><span class="given-names" tagx="given-names" title="given-names">ME</span></span><span class="etal" title="etal"><i>et al.</i></span></span><span class="mixed-article-title" title="mixed-article-title">Genetic and nongenetic factors associated with warfarin dose requirements in Egyptian patients</span><span class="source" tagx="source" title="source">Pharmacogenet Genom.</span><span class="year" tagx="year" title="year">2011</span><span class="volume" tagx="volume" title="volume">21</span><span class="fpage" tagx="fpage" title="fpage">130</span><span class="lpage" tagx="lpage" title="lpage">135</span><span class="pub-id"><a href="https://dx.doi.org/10.1097/FPC.0b013e3283436b86">10.1097/FPC.0b013e3283436b86</a></span></span></li> <li tag="ref"><a name="CR53" /><span class="label" tagx="label" title="label">53.</span><span class="element-citation'"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Zand</span><span class="given-names" tagx="given-names" title="given-names">N</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Tajik</span><span class="given-names" tagx="given-names" title="given-names">N</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Moghaddam</span><span class="given-names" tagx="given-names" title="given-names">AS</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Milanian</span><span class="given-names" tagx="given-names" title="given-names">I</span></span></span><span class="mixed-article-title" title="mixed-article-title">Genetic polymorphisms of cytochrome P450 enzymes 2C9 and 2C19 in a healthy Iranian population</span><span class="source" tagx="source" title="source">Clin Exp Pharmacol Physiol.</span><span class="year" tagx="year" title="year">2007</span><span class="volume" tagx="volume" title="volume">34</span><span class="fpage" tagx="fpage" title="fpage">102</span><span class="lpage" tagx="lpage" title="lpage">105</span><span class="pub-id"><a href="https://dx.doi.org/10.1111/j.1440-1681.2007.04538.x">10.1111/j.1440-1681.2007.04538.x</a></span><span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/17201743">17201743</a></span></span></li> <li tag="ref"><a name="CR54" /><span class="label" tagx="label" title="label">54.</span><span class="element-citation'"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Amini-Shirazi</span><span class="given-names" tagx="given-names" title="given-names">N</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Ghahremani</span><span class="given-names" tagx="given-names" title="given-names">MH</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Ahmadkhaniha</span><span class="given-names" tagx="given-names" title="given-names">R</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Mandegary</span><span class="given-names" tagx="given-names" title="given-names">A</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Dadgar</span><span class="given-names" tagx="given-names" title="given-names">A</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Abdollahi</span><span class="given-names" tagx="given-names" title="given-names">M</span></span><span class="etal" title="etal"><i>et al.</i></span></span><span class="mixed-article-title" title="mixed-article-title">Influence of CYP2C9 polymorphism on metabolism of valproate and its hepatotoxin metabolite in Iranian patients</span><span class="source" tagx="source" title="source">Toxicol Mech Methods.</span><span class="year" tagx="year" title="year">2010</span><span class="volume" tagx="volume" title="volume">20</span><span class="issue" tagx="issue" title="issue">8</span><span class="fpage" tagx="fpage" title="fpage">452</span><span class="lpage" tagx="lpage" title="lpage">457</span><span class="pub-id"><a href="https://dx.doi.org/10.3109/15376516.2010.497977">10.3109/15376516.2010.497977</a></span><span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/20602621">20602621</a></span></span></li> <li tag="ref"><a name="CR55" /><span class="label" tagx="label" title="label">55.</span><span class="element-citation'"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Ghadam</span><span class="given-names" tagx="given-names" title="given-names">P</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Sharifian</span><span class="given-names" tagx="given-names" title="given-names">R</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Farsangi</span><span class="given-names" tagx="given-names" title="given-names">ZJ</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Kianmehr</span><span class="given-names" tagx="given-names" title="given-names">Z</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Lak</span><span class="given-names" tagx="given-names" title="given-names">M</span></span></span><span class="mixed-article-title" title="mixed-article-title">CYP2C9 gene analysis of some Iranian hypersensitive patients to warfarin</span><span class="source" tagx="source" title="source">Pak J Biol Sci.</span><span class="year" tagx="year" title="year">2009</span><span class="volume" tagx="volume" title="volume">12</span><span class="issue" tagx="issue" title="issue">16</span><span class="fpage" tagx="fpage" title="fpage">1160</span><span class="lpage" tagx="lpage" title="lpage">1163</span><span class="pub-id"><a href="https://dx.doi.org/10.3923/pjbs.2009.1160.1163">10.3923/pjbs.2009.1160.1163</a></span><span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/19899329">19899329</a></span></span></li> <li tag="ref"><a name="CR56" /><span class="label" tagx="label" title="label">56.</span><span class="element-citation'"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Namazi</span><span class="given-names" tagx="given-names" title="given-names">S</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Azarpira</span><span class="given-names" tagx="given-names" title="given-names">N</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Hendijani</span><span class="given-names" tagx="given-names" title="given-names">F</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Khorshid</span><span class="given-names" tagx="given-names" title="given-names">MB</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Vessal</span><span class="given-names" tagx="given-names" title="given-names">G</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Mehdipour</span><span class="given-names" tagx="given-names" title="given-names">AR</span></span></span><span class="mixed-article-title" title="mixed-article-title">The impact of genetic polymorphisms and patient characteristics on warfarin dose requirements: a cross-sectional study in Iran</span><span class="source" tagx="source" title="source">Clin Ther.</span><span class="year" tagx="year" title="year">2010</span><span class="volume" tagx="volume" title="volume">32</span><span class="issue" tagx="issue" title="issue">6</span><span class="fpage" tagx="fpage" title="fpage">1050</span><span class="lpage" tagx="lpage" title="lpage">1060</span><span class="pub-id"><a href="https://dx.doi.org/10.1016/j.clinthera.2010.06.010">10.1016/j.clinthera.2010.06.010</a></span><span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/20637959">20637959</a></span></span></li> <li tag="ref"><a name="CR57" /><span class="label" tagx="label" title="label">57.</span><span class="element-citation'"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Yousef</span><span class="given-names" tagx="given-names" title="given-names">A-M</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Bulatova</span><span class="given-names" tagx="given-names" title="given-names">NR</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Newman</span><span class="given-names" tagx="given-names" title="given-names">W</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Hakooz</span><span class="given-names" tagx="given-names" title="given-names">N</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Ismail</span><span class="given-names" tagx="given-names" title="given-names">S</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Qusa</span><span class="given-names" tagx="given-names" title="given-names">H</span></span><span class="etal" title="etal"><i>et al.</i></span></span><span class="mixed-article-title" title="mixed-article-title">Allele and genotype frequencies of the polymorphic cytochrome P450 genes (CYP1A1, CYP3A4, CYP3A5, CYP2C9 and CYP2C19) in the Jordanian population</span><span class="source" tagx="source" title="source">Mol Biol Rep.</span><span class="year" tagx="year" title="year">2012</span><span class="volume" tagx="volume" title="volume">39</span><span class="issue" tagx="issue" title="issue">10</span><span class="fpage" tagx="fpage" title="fpage">9423</span><span class="lpage" tagx="lpage" title="lpage">9433</span><span class="pub-id"><a href="https://dx.doi.org/10.1007/s11033-012-1807-5">10.1007/s11033-012-1807-5</a></span><span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/22722998">22722998</a></span></span></li> <li tag="ref"><a name="CR58" /><span class="label" tagx="label" title="label">58.</span><span class="element-citation'"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Alrashid</span><span class="given-names" tagx="given-names" title="given-names">MH</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Al-Serri</span><span class="given-names" tagx="given-names" title="given-names">A</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Alshemmari</span><span class="given-names" tagx="given-names" title="given-names">SH</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Koshi</span><span class="given-names" tagx="given-names" title="given-names">P</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Al-Bustan</span><span class="given-names" tagx="given-names" title="given-names">SA</span></span></span><span class="mixed-article-title" title="mixed-article-title">Association of genetic polymorphisms in the VKORC1 and CYP2C9 genes with warfarin dosage in a group of Kuwaiti individuals</span><span class="source" tagx="source" title="source">Mol Diagn Ther.</span><span class="year" tagx="year" title="year">2016</span><span class="volume" tagx="volume" title="volume">20</span><span class="issue" tagx="issue" title="issue">2</span><span class="fpage" tagx="fpage" title="fpage">183</span><span class="lpage" tagx="lpage" title="lpage">190</span><span class="pub-id"><a href="https://dx.doi.org/10.1007/s40291-016-0190-7">10.1007/s40291-016-0190-7</a></span><span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/26940072">26940072</a></span></span></li> <li tag="ref"><a name="CR59" /><span class="label" tagx="label" title="label">59.</span><span class="element-citation'"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Djaffar-Jureidini</span><span class="given-names" tagx="given-names" title="given-names">I</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Chamseddine</span><span class="given-names" tagx="given-names" title="given-names">N</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Keleshian</span><span class="given-names" tagx="given-names" title="given-names">S</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Naoufal</span><span class="given-names" tagx="given-names" title="given-names">R</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Zahed</span><span class="given-names" tagx="given-names" title="given-names">L</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Hakime</span><span class="given-names" tagx="given-names" title="given-names">N</span></span></span><span class="mixed-article-title" title="mixed-article-title">Pharmacogenomics of coumarin dosing: prevalence of CYP2C9 and VKORC1 polymorphisms in the Lebanese population</span><span class="source" tagx="source" title="source">Genet Test Mol Biomark.</span><span class="year" tagx="year" title="year">2011</span><span class="volume" tagx="volume" title="volume">15</span><span class="issue" tagx="issue" title="issue">11</span><span class="fpage" tagx="fpage" title="fpage">827</span><span class="lpage" tagx="lpage" title="lpage">830</span><span class="pub-id"><a href="https://dx.doi.org/10.1089/gtmb.2010.0248">10.1089/gtmb.2010.0248</a></span></span></li> <li tag="ref"><a name="CR60" /><span class="label" tagx="label" title="label">60.</span><span class="element-citation'"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Esmerian</span><span class="given-names" tagx="given-names" title="given-names">MO</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Mitri</span><span class="given-names" tagx="given-names" title="given-names">Z</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Habbal</span><span class="given-names" tagx="given-names" title="given-names">MZ</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Geryess</span><span class="given-names" tagx="given-names" title="given-names">E</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Zaatari</span><span class="given-names" tagx="given-names" title="given-names">G</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Alam</span><span class="given-names" tagx="given-names" title="given-names">S</span></span><span class="etal" title="etal"><i>et al.</i></span></span><span class="mixed-article-title" title="mixed-article-title">Influence of CYP2C9 and VKORC1 polymorphisms on warfarin and acenocoumarol in a sample of Lebanese people</span><span class="source" tagx="source" title="source">J Clin Pharmacol.</span><span class="year" tagx="year" title="year">2011</span><span class="volume" tagx="volume" title="volume">51</span><span class="issue" tagx="issue" title="issue">10</span><span class="fpage" tagx="fpage" title="fpage">1418</span><span class="lpage" tagx="lpage" title="lpage">1428</span><span class="pub-id"><a href="https://dx.doi.org/10.1177/0091270010382910">10.1177/0091270010382910</a></span><span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/21148049">21148049</a></span></span></li> <li tag="ref"><a name="CR61" /><span class="label" tagx="label" title="label">61.</span><span class="element-citation'"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Smires</span><span class="given-names" tagx="given-names" title="given-names">FZ</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Habbal</span><span class="given-names" tagx="given-names" title="given-names">R</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Moreau</span><span class="given-names" tagx="given-names" title="given-names">C</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Assaidi</span><span class="given-names" tagx="given-names" title="given-names">A</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Loriot</span><span class="given-names" tagx="given-names" title="given-names">MA</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Nadifi</span><span class="given-names" tagx="given-names" title="given-names">S</span></span></span><span class="mixed-article-title" title="mixed-article-title">Effect of different genetics variants: CYP2C9*2, CYP2C9*3 of cytochrome P450 CYP2C9 and 1639G&amp;gt;A of the VKORC1 gene; on acenocoumarol requirement in Moroccan patients</span><span class="source" tagx="source" title="source">Pathol Biol.</span><span class="year" tagx="year" title="year">2013</span><span class="volume" tagx="volume" title="volume">61</span><span class="issue" tagx="issue" title="issue">3</span><span class="fpage" tagx="fpage" title="fpage">88</span><span class="lpage" tagx="lpage" title="lpage">92</span><span class="pub-id"><a href="https://dx.doi.org/10.1016/j.patbio.2012.10.002">10.1016/j.patbio.2012.10.002</a></span><span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/23201087">23201087</a></span></span></li> <li tag="ref"><a name="CR62" /><span class="label" tagx="label" title="label">62.</span><span class="element-citation'"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Pathare</span><span class="given-names" tagx="given-names" title="given-names">A</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Khabori</span><span class="given-names" tagx="given-names" title="given-names">MA</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Alkindi</span><span class="given-names" tagx="given-names" title="given-names">S</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Zadjali</span><span class="given-names" tagx="given-names" title="given-names">SA</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Misquith</span><span class="given-names" tagx="given-names" title="given-names">R</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Khan</span><span class="given-names" tagx="given-names" title="given-names">H</span></span><span class="etal" title="etal"><i>et al.</i></span></span><span class="mixed-article-title" title="mixed-article-title">Warfarin pharmacogenetics: development of a dosing algorithm for Omani patients</span><span class="source" tagx="source" title="source">J Hum Genet.</span><span class="year" tagx="year" title="year">2012</span><span class="volume" tagx="volume" title="volume">57</span><span class="issue" tagx="issue" title="issue">10</span><span class="fpage" tagx="fpage" title="fpage">665</span><span class="lpage" tagx="lpage" title="lpage">669</span><span class="pub-id"><a href="https://dx.doi.org/10.1038/jhg.2012.94">10.1038/jhg.2012.94</a></span><span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/22854539">22854539</a></span></span></li> <li tag="ref"><a name="CR63" /><span class="label" tagx="label" title="label">63.</span><span class="element-citation'"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Tanira</span><span class="given-names" tagx="given-names" title="given-names">MO</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Al-Mukhaini</span><span class="given-names" tagx="given-names" title="given-names">MK</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Al-Hinai</span><span class="given-names" tagx="given-names" title="given-names">AT</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Al Balushi</span><span class="given-names" tagx="given-names" title="given-names">KA</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Ahmed</span><span class="given-names" tagx="given-names" title="given-names">IS</span></span></span><span class="mixed-article-title" title="mixed-article-title">Frequency of CYP2C9 genotypes among Omani patients receiving warfarin and its correlation with warfarin dose</span><span class="source" tagx="source" title="source">Community Genet.</span><span class="year" tagx="year" title="year">2006</span><span class="volume" tagx="volume" title="volume">10</span><span class="issue" tagx="issue" title="issue">1</span><span class="fpage" tagx="fpage" title="fpage">32</span><span class="lpage" tagx="lpage" title="lpage">37</span><span class="pub-id"><a href="https://dx.doi.org/10.1159/000096279">10.1159/000096279</a></span></span></li> <li tag="ref"><a name="CR64" /><span class="label" tagx="label" title="label">64.</span><span class="element-citation'"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Alzahrani</span><span class="given-names" tagx="given-names" title="given-names">AM</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Ragia</span><span class="given-names" tagx="given-names" title="given-names">G</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Hanieh</span><span class="given-names" tagx="given-names" title="given-names">H</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Manolopoulos</span><span class="given-names" tagx="given-names" title="given-names">VG</span></span></span><span class="mixed-article-title" title="mixed-article-title">Genotyping of CYP2C9 and VKORC1 in the Arabic population of Al-Ahsa, Saudi Arabia</span><span class="source" tagx="source" title="source">Biomed Res Int.</span><span class="year" tagx="year" title="year">2013</span><span class="volume" tagx="volume" title="volume">2013</span><span class="fpage" tagx="fpage" title="fpage">3</span><span class="lpage" tagx="lpage" title="lpage">8</span><span class="pub-id"><a href="https://dx.doi.org/10.1155/2013/315980">10.1155/2013/315980</a></span></span></li> <li tag="ref"><a name="CR65" /><span class="label" tagx="label" title="label">65.</span><span class="element-citation'"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Mirghani</span><span class="given-names" tagx="given-names" title="given-names">RA</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Chowdhary</span><span class="given-names" tagx="given-names" title="given-names">G</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Elghazali</span><span class="given-names" tagx="given-names" title="given-names">G</span></span></span><span class="mixed-article-title" title="mixed-article-title">Distribution of the major cytochrome P450 (CYP) 2C9 genetic variants in a Saudi Population</span><span class="source" tagx="source" title="source">Basic Clin Pharmacol Toxicol.</span><span class="year" tagx="year" title="year">2011</span><span class="volume" tagx="volume" title="volume">109</span><span class="issue" tagx="issue" title="issue">2</span><span class="fpage" tagx="fpage" title="fpage">111</span><span class="lpage" tagx="lpage" title="lpage">114</span><span class="pub-id"><a href="https://dx.doi.org/10.1111/j.1742-7843.2011.00692.x">10.1111/j.1742-7843.2011.00692.x</a></span><span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/21371265">21371265</a></span></span></li> <li tag="ref"><a name="CR66" /><span class="label" tagx="label" title="label">66.</span><span class="element-citation'"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Shrif</span><span class="given-names" tagx="given-names" title="given-names">NE</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Won</span><span class="given-names" tagx="given-names" title="given-names">HH</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Lee</span><span class="given-names" tagx="given-names" title="given-names">ST</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Park</span><span class="given-names" tagx="given-names" title="given-names">JH</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Kim</span><span class="given-names" tagx="given-names" title="given-names">KK</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Kim</span><span class="given-names" tagx="given-names" title="given-names">MJ</span></span><span class="etal" title="etal"><i>et al.</i></span></span><span class="mixed-article-title" title="mixed-article-title">Evaluation of the effects of VKORC1 polymorphisms and haplotypes, CYP2C9 genotypes, and clinical factors on warfarin response in Sudanese patients</span><span class="source" tagx="source" title="source">Eur J Clin Pharmacol.</span><span class="year" tagx="year" title="year">2011</span><span class="volume" tagx="volume" title="volume">67</span><span class="issue" tagx="issue" title="issue">11</span><span class="fpage" tagx="fpage" title="fpage">1119</span><span class="lpage" tagx="lpage" title="lpage">1130</span><span class="pub-id"><a href="https://dx.doi.org/10.1007/s00228-011-1060-1">10.1007/s00228-011-1060-1</a></span><span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/21590310">21590310</a></span></span></li> <li tag="ref"><a name="CR67" /><span class="label" tagx="label" title="label">67.</span><span class="element-citation'"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Abdelhedi</span><span class="given-names" tagx="given-names" title="given-names">R</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Bouayed</span><span class="given-names" tagx="given-names" title="given-names">NA</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Alfadhli</span><span class="given-names" tagx="given-names" title="given-names">S</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Abid</span><span class="given-names" tagx="given-names" title="given-names">L</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Rebai</span><span class="given-names" tagx="given-names" title="given-names">A</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Kharrat</span><span class="given-names" tagx="given-names" title="given-names">N</span></span></span><span class="mixed-article-title" title="mixed-article-title">Characterization of drug-metabolizing enzymes CYP2C9, CYP2C19 polymorphisms in Tunisian, Kuwaiti and Bahraini populations</span><span class="source" tagx="source" title="source">J Genet.</span><span class="year" tagx="year" title="year">2015</span><span class="volume" tagx="volume" title="volume">94</span><span class="issue" tagx="issue" title="issue">4</span><span class="fpage" tagx="fpage" title="fpage">765</span><span class="lpage" tagx="lpage" title="lpage">770</span><span class="pub-id"><a href="https://dx.doi.org/10.1007/s12041-015-0581-2">10.1007/s12041-015-0581-2</a></span><span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/26690534">26690534</a></span></span></li> <li tag="ref"><a name="CR68" /><span class="label" tagx="label" title="label">68.</span><span class="element-citation'"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Yilmaz</span><span class="given-names" tagx="given-names" title="given-names">N</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Erbağci</span><span class="given-names" tagx="given-names" title="given-names">AB</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Aynacioğlu</span><span class="given-names" tagx="given-names" title="given-names">AŞ</span></span></span><span class="mixed-article-title" title="mixed-article-title">Cytochrome P4502C9 genotype in Southeast Anatolia and possible relation with some serum tumour markers and cytokines</span><span class="source" tagx="source" title="source">Acta Biochim Pol.</span><span class="year" tagx="year" title="year">2001</span><span class="volume" tagx="volume" title="volume">48</span><span class="issue" tagx="issue" title="issue">3</span><span class="fpage" tagx="fpage" title="fpage">775</span><span class="lpage" tagx="lpage" title="lpage">782</span><span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/11833786">11833786</a></span></span></li> <li tag="ref"><a name="CR69" /><span class="label" tagx="label" title="label">69.</span><span class="element-citation'"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Babaoglu</span><span class="given-names" tagx="given-names" title="given-names">MO</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Yasar</span><span class="given-names" tagx="given-names" title="given-names">U</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Sandberg</span><span class="given-names" tagx="given-names" title="given-names">M</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Eliasson</span><span class="given-names" tagx="given-names" title="given-names">E</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Dahl</span><span class="given-names" tagx="given-names" title="given-names">ML</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Kayaalp</span><span class="given-names" tagx="given-names" title="given-names">SO</span></span><span class="etal" title="etal"><i>et al.</i></span></span><span class="mixed-article-title" title="mixed-article-title">CYP2C9 genetic variants and losartan oxidation in a Turkish population</span><span class="source" tagx="source" title="source">Eur J Clin Pharmacol.</span><span class="year" tagx="year" title="year">2004</span><span class="volume" tagx="volume" title="volume">60</span><span class="issue" tagx="issue" title="issue">5</span><span class="fpage" tagx="fpage" title="fpage">337</span><span class="lpage" tagx="lpage" title="lpage">342</span><span class="pub-id"><a href="https://dx.doi.org/10.1007/s00228-004-0785-5">10.1007/s00228-004-0785-5</a></span><span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/15197523">15197523</a></span></span></li> <li tag="ref"><a name="CR70" /><span class="label" tagx="label" title="label">70.</span><span class="element-citation'"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Ozgon</span><span class="given-names" tagx="given-names" title="given-names">GO</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Langaee</span><span class="given-names" tagx="given-names" title="given-names">TY</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Feng</span><span class="given-names" tagx="given-names" title="given-names">H</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Buyru</span><span class="given-names" tagx="given-names" title="given-names">N</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Ulutin</span><span class="given-names" tagx="given-names" title="given-names">T</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Hatemi</span><span class="given-names" tagx="given-names" title="given-names">AC</span></span><span class="etal" title="etal"><i>et al.</i></span></span><span class="mixed-article-title" title="mixed-article-title">VKORC1 and CYP2C9 polymorphisms are associated with warfarin dose requirements in Turkish patients</span><span class="source" tagx="source" title="source">Eur J Clin Pharmacol.</span><span class="year" tagx="year" title="year">2008</span><span class="volume" tagx="volume" title="volume">64</span><span class="issue" tagx="issue" title="issue">9</span><span class="fpage" tagx="fpage" title="fpage">889</span><span class="lpage" tagx="lpage" title="lpage">894</span><span class="pub-id"><a href="https://dx.doi.org/10.1007/s00228-008-0507-5">10.1007/s00228-008-0507-5</a></span><span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/18542936">18542936</a></span></span></li> <li tag="ref"><a name="CR71" /><span class="label" tagx="label" title="label">71.</span><span class="element-citation'"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Ozer</span><span class="given-names" tagx="given-names" title="given-names">N</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Cam</span><span class="given-names" tagx="given-names" title="given-names">N</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Tangurek</span><span class="given-names" tagx="given-names" title="given-names">B</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Ozer</span><span class="given-names" tagx="given-names" title="given-names">S</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Uyarel</span><span class="given-names" tagx="given-names" title="given-names">H</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Oz</span><span class="given-names" tagx="given-names" title="given-names">D</span></span><span class="etal" title="etal"><i>et al.</i></span></span><span class="mixed-article-title" title="mixed-article-title">The impact of CYP2C9 and VKORC1 genetic polymorphism and patient characteristics upon warfarin dose requirements in an adult Turkish population</span><span class="source" tagx="source" title="source">Heart Vessels.</span><span class="year" tagx="year" title="year">2010</span><span class="volume" tagx="volume" title="volume">25</span><span class="issue" tagx="issue" title="issue">2</span><span class="fpage" tagx="fpage" title="fpage">155</span><span class="lpage" tagx="lpage" title="lpage">162</span><span class="pub-id"><a href="https://dx.doi.org/10.1007/s00380-009-1177-7">10.1007/s00380-009-1177-7</a></span><span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/20339978">20339978</a></span></span></li> <li tag="ref"><a name="CR72" /><span class="label" tagx="label" title="label">72.</span><span class="element-citation'"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Silan</span><span class="given-names" tagx="given-names" title="given-names">C</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Dogan</span><span class="given-names" tagx="given-names" title="given-names">OT</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Silan</span><span class="given-names" tagx="given-names" title="given-names">F</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Kukulguven</span><span class="given-names" tagx="given-names" title="given-names">FM</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Asgun</span><span class="given-names" tagx="given-names" title="given-names">HF</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Ozdemir</span><span class="given-names" tagx="given-names" title="given-names">S</span></span><span class="etal" title="etal"><i>et al.</i></span></span><span class="mixed-article-title" title="mixed-article-title">The prevalence of VKORC1 1639 G&amp;gt;A and CYP2C9*2*3 genotypes in patients that requiring anticoagulant therapy in Turkish population</span><span class="source" tagx="source" title="source">Mol Biol Rep.</span><span class="year" tagx="year" title="year">2012</span><span class="volume" tagx="volume" title="volume">39</span><span class="fpage" tagx="fpage" title="fpage">11017</span><span class="lpage" tagx="lpage" title="lpage">11022</span><span class="pub-id"><a href="https://dx.doi.org/10.1007/s11033-012-2004-2">10.1007/s11033-012-2004-2</a></span><span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/23065265">23065265</a></span></span></li> <li tag="ref"><a name="CR73" /><span class="label" tagx="label" title="label">73.</span><span class="element-citation'"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Ellison</span><span class="given-names" tagx="given-names" title="given-names">CA</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Abou El-Ella</span><span class="given-names" tagx="given-names" title="given-names">SS</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Tawfik</span><span class="given-names" tagx="given-names" title="given-names">M</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Lein</span><span class="given-names" tagx="given-names" title="given-names">PJ</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Olson</span><span class="given-names" tagx="given-names" title="given-names">JR</span></span></span><span class="mixed-article-title" title="mixed-article-title">Allele and genotype frequencies of CYP2B6 and CYP2C19 polymorphisms in Egyptian agricultural workers</span><span class="source" tagx="source" title="source">J Toxicol Environ Health A.</span><span class="year" tagx="year" title="year">2012</span><span class="volume" tagx="volume" title="volume">75</span><span class="issue" tagx="issue" title="issue">4</span><span class="fpage" tagx="fpage" title="fpage">232</span><span class="lpage" tagx="lpage" title="lpage">241</span><span class="pub-id"><a href="https://dx.doi.org/10.1080/15287394.2012.641201">10.1080/15287394.2012.641201</a></span><span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/22352331">22352331</a></span></span></li> <li tag="ref"><a name="CR74" /><span class="label" tagx="label" title="label">74.</span><span class="element-citation'"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Sameer</span><span class="given-names" tagx="given-names" title="given-names">AE</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Amany</span><span class="given-names" tagx="given-names" title="given-names">GM</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Abdela</span><span class="given-names" tagx="given-names" title="given-names">AA</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Fadel</span><span class="given-names" tagx="given-names" title="given-names">SA</span></span></span><span class="mixed-article-title" title="mixed-article-title">CYP2C19 genotypes in a population of healthy volunteers and in children with hematological malignancies in Gaza Strip</span><span class="source" tagx="source" title="source">Can J Clin Pharmacol.</span><span class="year" tagx="year" title="year">2009</span><span class="volume" tagx="volume" title="volume">16</span><span class="issue" tagx="issue" title="issue">1</span><span class="fpage" tagx="fpage" title="fpage">156</span><span class="lpage" tagx="lpage" title="lpage">162</span></span></li> <li tag="ref"><a name="CR75" /><span class="label" tagx="label" title="label">75.</span><span class="element-citation'"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Payan</span><span class="given-names" tagx="given-names" title="given-names">M</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Rouini</span><span class="given-names" tagx="given-names" title="given-names">MR</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Tajik</span><span class="given-names" tagx="given-names" title="given-names">N</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Ghahremani</span><span class="given-names" tagx="given-names" title="given-names">MH</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Tahvilian</span><span class="given-names" tagx="given-names" title="given-names">R</span></span></span><span class="mixed-article-title" title="mixed-article-title">Hydroxylation index of omeprazole in relation to CYP2C19 polymorphism and sex in a healthy Iranian population</span><span class="source" tagx="source" title="source">Daru.</span><span class="year" tagx="year" title="year">2014</span><span class="volume" tagx="volume" title="volume">22</span><span class="fpage" tagx="fpage" title="fpage">81</span><span class="pub-id"><a href="https://dx.doi.org/10.1186/s40199-014-0081-6">10.1186/s40199-014-0081-6</a></span><span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/25498969">25498969</a></span></span></li> <li tag="ref"><a name="CR76" /><span class="label" tagx="label" title="label">76.</span><span class="element-citation'"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Zendehdel</span><span class="given-names" tagx="given-names" title="given-names">N</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Biramijamal</span><span class="given-names" tagx="given-names" title="given-names">F</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Hossein-Nezhad</span><span class="given-names" tagx="given-names" title="given-names">A</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Zendehdel</span><span class="given-names" tagx="given-names" title="given-names">N</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Sarie</span><span class="given-names" tagx="given-names" title="given-names">H</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Doughaiemoghaddam</span><span class="given-names" tagx="given-names" title="given-names">M</span></span><span class="etal" title="etal"><i>et al.</i></span></span><span class="mixed-article-title" title="mixed-article-title">Role of cytochrome P450 2C19 genetic polymorphisms in the therapeutic efficacy of omeprazole in iranian patients with erosive reflux esophagitis</span><span class="source" tagx="source" title="source">Arch Iran Med.</span><span class="year" tagx="year" title="year">2010</span><span class="volume" tagx="volume" title="volume">13</span><span class="issue" tagx="issue" title="issue">5</span><span class="fpage" tagx="fpage" title="fpage">406</span><span class="lpage" tagx="lpage" title="lpage">412</span><span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/20804307">20804307</a></span></span></li> <li tag="ref"><a name="CR77" /><span class="label" tagx="label" title="label">77.</span><span class="element-citation'"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Namazi</span><span class="given-names" tagx="given-names" title="given-names">S</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Kojuri</span><span class="given-names" tagx="given-names" title="given-names">J</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Khalili</span><span class="given-names" tagx="given-names" title="given-names">A</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Azarpira</span><span class="given-names" tagx="given-names" title="given-names">N</span></span></span><span class="mixed-article-title" title="mixed-article-title">The impact of genetic polymorphisms of P2Y12, CYP3A5 and CYP2C19 on clopidogrel response variability in Iranian patients</span><span class="source" tagx="source" title="source">Biochem Pharmacol.</span><span class="year" tagx="year" title="year">2012</span><span class="volume" tagx="volume" title="volume">83</span><span class="fpage" tagx="fpage" title="fpage">903</span><span class="lpage" tagx="lpage" title="lpage">908</span><span class="pub-id"><a href="https://dx.doi.org/10.1016/j.bcp.2012.01.003">10.1016/j.bcp.2012.01.003</a></span><span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/22265638">22265638</a></span></span></li> <li tag="ref"><a name="CR78" /><span class="label" tagx="label" title="label">78.</span><span class="element-citation'"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Akhlaghi</span><span class="given-names" tagx="given-names" title="given-names">A</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Shirani</span><span class="given-names" tagx="given-names" title="given-names">S</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Ziaie</span><span class="given-names" tagx="given-names" title="given-names">N</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Pirhaji</span><span class="given-names" tagx="given-names" title="given-names">O</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Yaran</span><span class="given-names" tagx="given-names" title="given-names">M</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Shahverdi</span><span class="given-names" tagx="given-names" title="given-names">G</span></span><span class="etal" title="etal"><i>et al.</i></span></span><span class="mixed-article-title" title="mixed-article-title">Cytochrome P450 2C19 polymorphism in Iranian patients with coronary artery disease</span><span class="source" tagx="source" title="source">ARYA Atheroscler.</span><span class="year" tagx="year" title="year">2011</span><span class="volume" tagx="volume" title="volume">7</span><span class="issue" tagx="issue" title="issue">3</span><span class="fpage" tagx="fpage" title="fpage">106</span><span class="lpage" tagx="lpage" title="lpage">110</span><span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/22577456">22577456</a></span></span></li> <li tag="ref"><a name="CR79" /><span class="label" tagx="label" title="label">79.</span><span class="element-citation'"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Nozari</span><span class="given-names" tagx="given-names" title="given-names">Y</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Vosooghi</span><span class="given-names" tagx="given-names" title="given-names">S</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Boroumand</span><span class="given-names" tagx="given-names" title="given-names">M</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Poorhosseini</span><span class="given-names" tagx="given-names" title="given-names">H</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Nematipour</span><span class="given-names" tagx="given-names" title="given-names">E</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Salarifar</span><span class="given-names" tagx="given-names" title="given-names">M</span></span><span class="etal" title="etal"><i>et al.</i></span></span><span class="mixed-article-title" title="mixed-article-title">The impact of cytochrome P450 2C19 polymorphism on the occurrence of one-year in-stent restenosis in patients who underwent percutaneous coronary intervention: a case-match study</span><span class="source" tagx="source" title="source">Anatol J Cardiol.</span><span class="year" tagx="year" title="year">2015</span><span class="volume" tagx="volume" title="volume">15</span><span class="fpage" tagx="fpage" title="fpage">348</span><span class="lpage" tagx="lpage" title="lpage">353</span><span class="pub-id"><a href="https://dx.doi.org/10.5152/akd.2014.5418">10.5152/akd.2014.5418</a></span><span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/25993709">25993709</a></span></span></li> <li tag="ref"><a name="CR80" /><span class="label" tagx="label" title="label">80.</span><span class="element-citation'"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Sviri</span><span class="given-names" tagx="given-names" title="given-names">S</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Shpizen</span><span class="given-names" tagx="given-names" title="given-names">S</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Leitersdorf</span><span class="given-names" tagx="given-names" title="given-names">E</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Levy</span><span class="given-names" tagx="given-names" title="given-names">M</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Caraco</span><span class="given-names" tagx="given-names" title="given-names">Y</span></span></span><span class="mixed-article-title" title="mixed-article-title">Phenotypic-genotypic analysis of CYP2C19 in the Jewish Israeli population</span><span class="source" tagx="source" title="source">Clin Pharmacol Ther.</span><span class="year" tagx="year" title="year">1999</span><span class="volume" tagx="volume" title="volume">65</span><span class="issue" tagx="issue" title="issue">3</span><span class="fpage" tagx="fpage" title="fpage">275</span><span class="lpage" tagx="lpage" title="lpage">282</span><span class="pub-id"><a href="https://dx.doi.org/10.1016/S0009-9236(99)70106-2">10.1016/S0009-9236(99)70106-2</a></span><span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/10096259">10096259</a></span></span></li> <li tag="ref"><a name="CR81" /><span class="label" tagx="label" title="label">81.</span><span class="element-citation'"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Luo</span><span class="given-names" tagx="given-names" title="given-names">HR</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Aloumanis</span><span class="given-names" tagx="given-names" title="given-names">V</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Lin</span><span class="given-names" tagx="given-names" title="given-names">KM</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Gurwitz</span><span class="given-names" tagx="given-names" title="given-names">D</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Wan</span><span class="given-names" tagx="given-names" title="given-names">YJ</span></span></span><span class="mixed-article-title" title="mixed-article-title">Polymorphisms of CYP2C19 and CYP2D6 in Israeli ethnic groups</span><span class="source" tagx="source" title="source">Am J Pharmacogenom.</span><span class="year" tagx="year" title="year">2004</span><span class="volume" tagx="volume" title="volume">4</span><span class="issue" tagx="issue" title="issue">6</span><span class="fpage" tagx="fpage" title="fpage">395</span><span class="lpage" tagx="lpage" title="lpage">401</span><span class="pub-id"><a href="https://dx.doi.org/10.2165/00129785-200404060-00006">10.2165/00129785-200404060-00006</a></span></span></li> <li tag="ref"><a name="CR82" /><span class="label" tagx="label" title="label">82.</span><span class="element-citation'"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Zalloum</span><span class="given-names" tagx="given-names" title="given-names">I</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Hakooz</span><span class="given-names" tagx="given-names" title="given-names">N</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Arafat</span><span class="given-names" tagx="given-names" title="given-names">T</span></span></span><span class="mixed-article-title" title="mixed-article-title">Genetic polymorphism of CYP2C19 in a Jordanian population: influence of allele frequencies of CYP2C19*1 and CYP2C19*2 on the pharmacokinetic profile of lansoprazole</span><span class="source" tagx="source" title="source">Mol Biol Rep.</span><span class="year" tagx="year" title="year">2012</span><span class="volume" tagx="volume" title="volume">39</span><span class="issue" tagx="issue" title="issue">4</span><span class="fpage" tagx="fpage" title="fpage">4195</span><span class="lpage" tagx="lpage" title="lpage">4200</span><span class="pub-id"><a href="https://dx.doi.org/10.1007/s11033-011-1204-5">10.1007/s11033-011-1204-5</a></span><span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/21769476">21769476</a></span></span></li> <li tag="ref"><a name="CR83" /><span class="label" tagx="label" title="label">83.</span><span class="element-citation'"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Jureidini</span><span class="given-names" tagx="given-names" title="given-names">ID</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Chamseddine</span><span class="given-names" tagx="given-names" title="given-names">N</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Keleshian</span><span class="given-names" tagx="given-names" title="given-names">S</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Naoufal</span><span class="given-names" tagx="given-names" title="given-names">R</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Zahed</span><span class="given-names" tagx="given-names" title="given-names">L</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Hakime</span><span class="given-names" tagx="given-names" title="given-names">N</span></span></span><span class="mixed-article-title" title="mixed-article-title">Prevalence of CYP2C19 polymorphisms in the Lebanese population</span><span class="source" tagx="source" title="source">Mol Biol Rep.</span><span class="year" tagx="year" title="year">2011</span><span class="volume" tagx="volume" title="volume">38</span><span class="issue" tagx="issue" title="issue">8</span><span class="fpage" tagx="fpage" title="fpage">5449</span><span class="lpage" tagx="lpage" title="lpage">5452</span><span class="pub-id"><a href="https://dx.doi.org/10.1007/s11033-011-0700-y">10.1007/s11033-011-0700-y</a></span><span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/21380557">21380557</a></span></span></li> <li tag="ref"><a name="CR84" /><span class="label" tagx="label" title="label">84.</span><span class="element-citation'"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Saeed</span><span class="given-names" tagx="given-names" title="given-names">LH</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Mayet</span><span class="given-names" tagx="given-names" title="given-names">AY</span></span></span><span class="mixed-article-title" title="mixed-article-title">Genotype-phenotype analysis of CYP2C19 in healthy Saudi individuals and its potential clinical implication in drug therapy</span><span class="source" tagx="source" title="source">Int J Med Sci.</span><span class="year" tagx="year" title="year">2013</span><span class="volume" tagx="volume" title="volume">10</span><span class="issue" tagx="issue" title="issue">11</span><span class="fpage" tagx="fpage" title="fpage">1497</span><span class="lpage" tagx="lpage" title="lpage">1502</span><span class="pub-id"><a href="https://dx.doi.org/10.7150/ijms.6795">10.7150/ijms.6795</a></span><span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/24046523">24046523</a></span></span></li> <li tag="ref"><a name="CR85" /><span class="label" tagx="label" title="label">85.</span><span class="element-citation'"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Goldstein</span><span class="given-names" tagx="given-names" title="given-names">JA</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Ishizaki</span><span class="given-names" tagx="given-names" title="given-names">T</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Chiba</span><span class="given-names" tagx="given-names" title="given-names">K</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">de Morais</span><span class="given-names" tagx="given-names" title="given-names">SM</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Bell</span><span class="given-names" tagx="given-names" title="given-names">D</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Krahn</span><span class="given-names" tagx="given-names" title="given-names">PM</span></span><span class="etal" title="etal"><i>et al.</i></span></span><span class="mixed-article-title" title="mixed-article-title">Frequencies of defective CYP2C19 alleles responsible for the mephenytoin poor metabolizer phenotype in various Oriental, Caucasian, Saudi Arabian and American black populations</span><span class="source" tagx="source" title="source">Pharmacogenetics.</span><span class="year" tagx="year" title="year">1997</span><span class="volume" tagx="volume" title="volume">7</span><span class="fpage" tagx="fpage" title="fpage">59</span><span class="lpage" tagx="lpage" title="lpage">64</span><span class="pub-id"><a href="https://dx.doi.org/10.1097/00008571-199702000-00008">10.1097/00008571-199702000-00008</a></span><span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/9110363">9110363</a></span></span></li> <li tag="ref"><a name="CR86" /><span class="label" tagx="label" title="label">86.</span><span class="element-citation'"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Khalaf</span><span class="given-names" tagx="given-names" title="given-names">H</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Al Meman</span><span class="given-names" tagx="given-names" title="given-names">AR</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Rasool</span><span class="given-names" tagx="given-names" title="given-names">S</span></span></span><span class="mixed-article-title" title="mixed-article-title">Impact of cytochrome P450 2C19*2 and *3 on clopidogrel loading dose in Saudi patients with acute coronary syndrome</span><span class="source" tagx="source" title="source">Drug Metab Lett.</span><span class="year" tagx="year" title="year">2016</span><span class="volume" tagx="volume" title="volume">10</span><span class="fpage" tagx="fpage" title="fpage">65</span><span class="lpage" tagx="lpage" title="lpage">70</span><span class="pub-id"><a href="https://dx.doi.org/10.2174/1872312810666151117122841">10.2174/1872312810666151117122841</a></span><span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/26573281">26573281</a></span></span></li> <li tag="ref"><a name="CR87" /><span class="label" tagx="label" title="label">87.</span><span class="element-citation'"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Aynacioglu</span><span class="given-names" tagx="given-names" title="given-names">AS</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Sachse</span><span class="given-names" tagx="given-names" title="given-names">C</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Bozkurt</span><span class="given-names" tagx="given-names" title="given-names">A</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Kortunay</span><span class="given-names" tagx="given-names" title="given-names">S</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Nacak</span><span class="given-names" tagx="given-names" title="given-names">M</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Schroder</span><span class="given-names" tagx="given-names" title="given-names">T</span></span><span class="etal" title="etal"><i>et al.</i></span></span><span class="mixed-article-title" title="mixed-article-title">Low frequency of defective alleles of cytochrome P450 enzymes 2C19 and 2D6 in the Turkish population</span><span class="source" tagx="source" title="source">Clin Pharmacol Ther.</span><span class="year" tagx="year" title="year">1999</span><span class="volume" tagx="volume" title="volume">66</span><span class="issue" tagx="issue" title="issue">2</span><span class="fpage" tagx="fpage" title="fpage">185</span><span class="lpage" tagx="lpage" title="lpage">192</span><span class="pub-id"><a href="https://dx.doi.org/10.1053/cp.1999.v66.100072001">10.1053/cp.1999.v66.100072001</a></span><span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/10460072">10460072</a></span></span></li> <li tag="ref"><a name="CR88" /><span class="label" tagx="label" title="label">88.</span><span class="element-citation'"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Gumus</span><span class="given-names" tagx="given-names" title="given-names">E</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Karaca</span><span class="given-names" tagx="given-names" title="given-names">O</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Babaoglu</span><span class="given-names" tagx="given-names" title="given-names">MO</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Baysoy</span><span class="given-names" tagx="given-names" title="given-names">G</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Balamtekin</span><span class="given-names" tagx="given-names" title="given-names">N</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Demir</span><span class="given-names" tagx="given-names" title="given-names">H</span></span><span class="etal" title="etal"><i>et al.</i></span></span><span class="mixed-article-title" title="mixed-article-title">Evaluation of lansoprazole as a probe for assessing cytochrome P450 2C19 activity and genotype-phenotype correlation in childhood</span><span class="source" tagx="source" title="source">Eur J Clin Pharmacol.</span><span class="year" tagx="year" title="year">2012</span><span class="volume" tagx="volume" title="volume">68</span><span class="issue" tagx="issue" title="issue">5</span><span class="fpage" tagx="fpage" title="fpage">629</span><span class="lpage" tagx="lpage" title="lpage">636</span><span class="pub-id"><a href="https://dx.doi.org/10.1007/s00228-011-1151-z">10.1007/s00228-011-1151-z</a></span><span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/22076562">22076562</a></span></span></li> <li tag="ref"><a name="CR89" /><span class="label" tagx="label" title="label">89.</span><span class="element-citation'"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Sen</span><span class="given-names" tagx="given-names" title="given-names">HM</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Silan</span><span class="given-names" tagx="given-names" title="given-names">F</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Silan</span><span class="given-names" tagx="given-names" title="given-names">C</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Degirmenci</span><span class="given-names" tagx="given-names" title="given-names">Y</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Ozisik Kamaran</span><span class="given-names" tagx="given-names" title="given-names">HI</span></span></span><span class="mixed-article-title" title="mixed-article-title">Effects of CYP2C19 and P2Y12 gene polymorphisms on clinical results of patients using clopidogrel after acute ischemic cerebrovascular disease</span><span class="source" tagx="source" title="source">Balkan J Med Genet.</span><span class="year" tagx="year" title="year">2014</span><span class="volume" tagx="volume" title="volume">17</span><span class="issue" tagx="issue" title="issue">2</span><span class="fpage" tagx="fpage" title="fpage">37</span><span class="lpage" tagx="lpage" title="lpage">41</span><span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/25937796">25937796</a></span></span></li> <li tag="ref"><a name="CR90" /><span class="label" tagx="label" title="label">90.</span><span class="element-citation'"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Khalil</span><span class="given-names" tagx="given-names" title="given-names">BM</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Shahin</span><span class="given-names" tagx="given-names" title="given-names">MH</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Solayman</span><span class="given-names" tagx="given-names" title="given-names">MHF</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Gong</span><span class="given-names" tagx="given-names" title="given-names">Y</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Hammad</span><span class="given-names" tagx="given-names" title="given-names">LN</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Al-Mesallamy</span><span class="given-names" tagx="given-names" title="given-names">HO</span></span><span class="etal" title="etal"><i>et al.</i></span></span><span class="mixed-article-title" title="mixed-article-title">Genetic and nongenetic factors affecting clopidogrel response in the Egyptian population</span><span class="source" tagx="source" title="source">Clin Transl Sci.</span><span class="year" tagx="year" title="year">2016</span><span class="volume" tagx="volume" title="volume">9</span><span class="issue" tagx="issue" title="issue">1</span><span class="fpage" tagx="fpage" title="fpage">23</span><span class="lpage" tagx="lpage" title="lpage">28</span><span class="pub-id"><a href="https://dx.doi.org/10.1111/cts.12383">10.1111/cts.12383</a></span><span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/26757134">26757134</a></span></span></li> <li tag="ref"><a name="CR91" /><span class="label" tagx="label" title="label">91.</span><span class="element-citation'"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Issac</span><span class="given-names" tagx="given-names" title="given-names">MS</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">El-Nahid</span><span class="given-names" tagx="given-names" title="given-names">MS</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Wissa</span><span class="given-names" tagx="given-names" title="given-names">MY</span></span></span><span class="mixed-article-title" title="mixed-article-title">Is there a role for MDR1, EPHX1 and Protein Z gene variants in modulation of warfarin dosage? A study on a cohort of the Egyptian population</span><span class="source" tagx="source" title="source">Mol Diagn Ther.</span><span class="year" tagx="year" title="year">2014</span><span class="volume" tagx="volume" title="volume">18</span><span class="issue" tagx="issue" title="issue">1</span><span class="fpage" tagx="fpage" title="fpage">73</span><span class="lpage" tagx="lpage" title="lpage">83</span><span class="pub-id"><a href="https://dx.doi.org/10.1007/s40291-013-0055-2">10.1007/s40291-013-0055-2</a></span><span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/24092646">24092646</a></span></span></li> <li tag="ref"><a name="CR92" /><span class="label" tagx="label" title="label">92.</span><span class="element-citation'"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Shabana</span><span class="given-names" tagx="given-names" title="given-names">MF</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Mishriki</span><span class="given-names" tagx="given-names" title="given-names">AA</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Issac</span><span class="given-names" tagx="given-names" title="given-names">MS</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Bakhoum</span><span class="given-names" tagx="given-names" title="given-names">SW</span></span></span><span class="mixed-article-title" title="mixed-article-title">Do MDR1 and SLCO1B1 polymorphisms influence the therapeutic response to atorvastatin? A study on a cohort of Egyptian patients with hypercholesterolemia</span><span class="source" tagx="source" title="source">Mol Diagn Ther.</span><span class="year" tagx="year" title="year">2013</span><span class="volume" tagx="volume" title="volume">17</span><span class="issue" tagx="issue" title="issue">5</span><span class="fpage" tagx="fpage" title="fpage">299</span><span class="lpage" tagx="lpage" title="lpage">309</span><span class="pub-id"><a href="https://dx.doi.org/10.1007/s40291-013-0038-3">10.1007/s40291-013-0038-3</a></span><span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/23677857">23677857</a></span></span></li> <li tag="ref"><a name="CR93" /><span class="label" tagx="label" title="label">93.</span><span class="element-citation'"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Ali</span><span class="given-names" tagx="given-names" title="given-names">MA</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Elsalakawy</span><span class="given-names" tagx="given-names" title="given-names">WA</span></span></span><span class="mixed-article-title" title="mixed-article-title">ABCB1 haplotypes but not individual SNPs predict for optimal response/failure in Egyptian patients with chronic-phase chronic myeloid leukemia receiving imatinib mesylate</span><span class="source" tagx="source" title="source">Med Oncol.</span><span class="year" tagx="year" title="year">2014</span><span class="volume" tagx="volume" title="volume">31</span><span class="issue" tagx="issue" title="issue">11</span><span class="fpage" tagx="fpage" title="fpage">279</span><span class="pub-id"><a href="https://dx.doi.org/10.1007/s12032-014-0279-y">10.1007/s12032-014-0279-y</a></span><span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/25301112">25301112</a></span></span></li> <li tag="ref"><a name="CR94" /><span class="label" tagx="label" title="label">94.</span><span class="element-citation'"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">El-Beblawy</span><span class="given-names" tagx="given-names" title="given-names">NM</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Elbarbary</span><span class="given-names" tagx="given-names" title="given-names">NS</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Kamal</span><span class="given-names" tagx="given-names" title="given-names">TM</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Mahmoud</span><span class="given-names" tagx="given-names" title="given-names">PM</span></span></span><span class="mixed-article-title" title="mixed-article-title">A study of human killer cell immunoglobulin-like receptor and multidrug resistance gene polymorphisms in children with immune thrombocytopenia</span><span class="source" tagx="source" title="source">Clin Appl Thromb Hemost.</span><span class="year" tagx="year" title="year">2016</span><span class="volume" tagx="volume" title="volume">22</span><span class="issue" tagx="issue" title="issue">5</span><span class="fpage" tagx="fpage" title="fpage">429</span><span class="lpage" tagx="lpage" title="lpage">440</span><span class="pub-id"><a href="https://dx.doi.org/10.1177/1076029615576738">10.1177/1076029615576738</a></span><span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/25792670">25792670</a></span></span></li> <li tag="ref"><a name="CR95" /><span class="label" tagx="label" title="label">95.</span><span class="element-citation'"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Saidijam</span><span class="given-names" tagx="given-names" title="given-names">M</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Mahjub</span><span class="given-names" tagx="given-names" title="given-names">H</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Shabab</span><span class="given-names" tagx="given-names" title="given-names">N</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Yadegarazari</span><span class="given-names" tagx="given-names" title="given-names">R</span></span></span><span class="mixed-article-title" title="mixed-article-title">Simultaneous analysis of multidrug resistance 1 (MDR1) C3435T, G2677T/A, and C1236T genotypes in Hamadan city population, West of Iran</span><span class="source" tagx="source" title="source">Iran Biomed J.</span><span class="year" tagx="year" title="year">2015</span><span class="volume" tagx="volume" title="volume">19</span><span class="issue" tagx="issue" title="issue">1</span><span class="fpage" tagx="fpage" title="fpage">57</span><span class="lpage" tagx="lpage" title="lpage">62</span><span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/25605491">25605491</a></span></span></li> <li tag="ref"><a name="CR96" /><span class="label" tagx="label" title="label">96.</span><span class="element-citation'"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Sayyah</span><span class="given-names" tagx="given-names" title="given-names">M</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Kamgarpour</span><span class="given-names" tagx="given-names" title="given-names">F</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Maleki</span><span class="given-names" tagx="given-names" title="given-names">M</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Karimipoor</span><span class="given-names" tagx="given-names" title="given-names">M</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Gharagozli</span><span class="given-names" tagx="given-names" title="given-names">K</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Shamshiri</span><span class="given-names" tagx="given-names" title="given-names">AR</span></span></span><span class="mixed-article-title" title="mixed-article-title">Association analysis of intractable epilepsy with C3435T and G2677T/A ABCB1 gene polymorphisms in Iranian patients</span><span class="source" tagx="source" title="source">Epileptic Disord.</span><span class="year" tagx="year" title="year">2011</span><span class="volume" tagx="volume" title="volume">13</span><span class="issue" tagx="issue" title="issue">2</span><span class="fpage" tagx="fpage" title="fpage">155</span><span class="lpage" tagx="lpage" title="lpage">165</span><span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/21636342">21636342</a></span></span></li> <li tag="ref"><a name="CR97" /><span class="label" tagx="label" title="label">97.</span><span class="element-citation'"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Bonyadi</span><span class="given-names" tagx="given-names" title="given-names">M</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Gholizadeh</span><span class="given-names" tagx="given-names" title="given-names">M</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Soltan-Ali</span><span class="given-names" tagx="given-names" title="given-names">M</span></span></span><span class="mixed-article-title" title="mixed-article-title">MDR1 C3435T polymorphism associated with the development of clinical features in Behçet’s disease in Iranian Azeri Turkish patients</span><span class="source" tagx="source" title="source">Int J Dermatol.</span><span class="year" tagx="year" title="year">2014</span><span class="volume" tagx="volume" title="volume">53</span><span class="fpage" tagx="fpage" title="fpage">1235</span><span class="lpage" tagx="lpage" title="lpage">1240</span><span class="pub-id"><a href="https://dx.doi.org/10.1111/ijd.12540">10.1111/ijd.12540</a></span><span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/24898446">24898446</a></span></span></li> <li tag="ref"><a name="CR98" /><span class="label" tagx="label" title="label">98.</span><span class="element-citation'"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Ghafouri</span><span class="given-names" tagx="given-names" title="given-names">H</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Ghaderi</span><span class="given-names" tagx="given-names" title="given-names">B</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Amini</span><span class="given-names" tagx="given-names" title="given-names">S</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Nikkhoo</span><span class="given-names" tagx="given-names" title="given-names">B</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Abdi</span><span class="given-names" tagx="given-names" title="given-names">M</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Hoseini</span><span class="given-names" tagx="given-names" title="given-names">A</span></span></span><span class="mixed-article-title" title="mixed-article-title">Association of ABCB1 and ABCG2 single nucleotide polymorphisms with clinical findings and response to chemotherapy treatments in Kurdish patients with breast cancer</span><span class="source" tagx="source" title="source">Tumor Biol</span><span class="year" tagx="year" title="year">2016</span><span class="volume" tagx="volume" title="volume">37</span><span class="issue" tagx="issue" title="issue">6</span><span class="fpage" tagx="fpage" title="fpage">7901</span><span class="lpage" tagx="lpage" title="lpage">7906</span><span class="pub-id"><a href="https://dx.doi.org/10.1007/s13277-015-4679-1">10.1007/s13277-015-4679-1</a></span></span></li> <li tag="ref"><a name="CR99" /><span class="label" tagx="label" title="label">99.</span><span class="element-citation'"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Taheri</span><span class="given-names" tagx="given-names" title="given-names">M</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Mahjoubi</span><span class="given-names" tagx="given-names" title="given-names">F</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Omranipour</span><span class="given-names" tagx="given-names" title="given-names">R</span></span></span><span class="mixed-article-title" title="mixed-article-title">Effect of MDR1 polymorphism on multidrug resistance expression in breast cancer patients</span><span class="source" tagx="source" title="source">Genet Mol Res.</span><span class="year" tagx="year" title="year">2010</span><span class="volume" tagx="volume" title="volume">9</span><span class="issue" tagx="issue" title="issue">1</span><span class="fpage" tagx="fpage" title="fpage">34</span><span class="lpage" tagx="lpage" title="lpage">40</span><span class="pub-id"><a href="https://dx.doi.org/10.4238/vol9-1gmr669">10.4238/vol9-1gmr669</a></span><span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/20082268">20082268</a></span></span></li> <li tag="ref"><a name="CR100" /><span class="label" tagx="label" title="label">100.</span><span class="element-citation'"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Tatari</span><span class="given-names" tagx="given-names" title="given-names">F</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Salek</span><span class="given-names" tagx="given-names" title="given-names">R</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Mosaffa</span><span class="given-names" tagx="given-names" title="given-names">F</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Khedri</span><span class="given-names" tagx="given-names" title="given-names">A</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Behravan</span><span class="given-names" tagx="given-names" title="given-names">J</span></span></span><span class="mixed-article-title" title="mixed-article-title">Association of C3435T single-nucleotide polymorphism of MDR1 gene with breast cancer in an Iranian population</span><span class="source" tagx="source" title="source">DNA Cell Biol.</span><span class="year" tagx="year" title="year">2009</span><span class="volume" tagx="volume" title="volume">28</span><span class="issue" tagx="issue" title="issue">5</span><span class="fpage" tagx="fpage" title="fpage">259</span><span class="lpage" tagx="lpage" title="lpage">263</span><span class="pub-id"><a href="https://dx.doi.org/10.1089/dna.2008.0826">10.1089/dna.2008.0826</a></span><span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/19388849">19388849</a></span></span></li> <li tag="ref"><a name="CR101" /><span class="label" tagx="label" title="label">101.</span><span class="element-citation'"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Khabour</span><span class="given-names" tagx="given-names" title="given-names">OF</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Alzoubi</span><span class="given-names" tagx="given-names" title="given-names">KH</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Al-Azzam</span><span class="given-names" tagx="given-names" title="given-names">SI</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Mhaidat</span><span class="given-names" tagx="given-names" title="given-names">NM</span></span></span><span class="mixed-article-title" title="mixed-article-title">Frequency of MDR1 single nucleotide polymorphisms in a Jordanian population, including a novel variant</span><span class="source" tagx="source" title="source">Genet Mol Res.</span><span class="year" tagx="year" title="year">2013</span><span class="volume" tagx="volume" title="volume">12</span><span class="issue" tagx="issue" title="issue">1</span><span class="fpage" tagx="fpage" title="fpage">801</span><span class="lpage" tagx="lpage" title="lpage">808</span><span class="pub-id"><a href="https://dx.doi.org/10.4238/2013.March.13.9">10.4238/2013.March.13.9</a></span><span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/23546964">23546964</a></span></span></li> <li tag="ref"><a name="CR102" /><span class="label" tagx="label" title="label">102.</span><span class="element-citation'"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Alzoubi</span><span class="given-names" tagx="given-names" title="given-names">KH</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Khabour</span><span class="given-names" tagx="given-names" title="given-names">OF</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Al-Azzam</span><span class="given-names" tagx="given-names" title="given-names">SI</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Mayyas</span><span class="given-names" tagx="given-names" title="given-names">F</span></span></span><span class="mixed-article-title" title="mixed-article-title">The role of multidrug resistance-1 (MDR1) variants in response to fexofenadine among Jordanians</span><span class="source" tagx="source" title="source">Int J Clin Pharmacol Ther.</span><span class="year" tagx="year" title="year">2013</span><span class="volume" tagx="volume" title="volume">51</span><span class="issue" tagx="issue" title="issue">11</span><span class="fpage" tagx="fpage" title="fpage">880</span><span class="lpage" tagx="lpage" title="lpage">887</span><span class="pub-id"><a href="https://dx.doi.org/10.5414/CP201968">10.5414/CP201968</a></span><span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/24040855">24040855</a></span></span></li> <li tag="ref"><a name="CR103" /><span class="label" tagx="label" title="label">103.</span><span class="element-citation'"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Samara</span><span class="given-names" tagx="given-names" title="given-names">SA</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Irshaid</span><span class="given-names" tagx="given-names" title="given-names">YM</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Mustafa</span><span class="given-names" tagx="given-names" title="given-names">KN</span></span></span><span class="mixed-article-title" title="mixed-article-title">Association of MDR1 C3435T and RFC1 G80A polymorphisms with methotrexate toxicity and response in Jordanian rheumatoid arthritis patients</span><span class="source" tagx="source" title="source">Int J Clin Pharmacol Ther.</span><span class="year" tagx="year" title="year">2014</span><span class="volume" tagx="volume" title="volume">52</span><span class="issue" tagx="issue" title="issue">9</span><span class="fpage" tagx="fpage" title="fpage">746</span><span class="lpage" tagx="lpage" title="lpage">755</span><span class="pub-id"><a href="https://dx.doi.org/10.5414/CP202098">10.5414/CP202098</a></span><span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/25074866">25074866</a></span></span></li> <li tag="ref"><a name="CR104" /><span class="label" tagx="label" title="label">104.</span><span class="element-citation'"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Abuhaliema</span><span class="given-names" tagx="given-names" title="given-names">AM</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Yousef</span><span class="given-names" tagx="given-names" title="given-names">AM</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">El-Madany</span><span class="given-names" tagx="given-names" title="given-names">NN</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Bulatova</span><span class="given-names" tagx="given-names" title="given-names">NR</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Awwad</span><span class="given-names" tagx="given-names" title="given-names">NM</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Yousef</span><span class="given-names" tagx="given-names" title="given-names">MA</span></span><span class="etal" title="etal"><i>et al.</i></span></span><span class="mixed-article-title" title="mixed-article-title">Influence of genotype and haplotype of MDR1 (C3435T, G2677A/T, C1236T) on the incidence of breast cancer: a case-control study in Jordan</span><span class="source" tagx="source" title="source">Asian Pacific J Cancer Prev.</span><span class="year" tagx="year" title="year">2016</span><span class="volume" tagx="volume" title="volume">17</span><span class="issue" tagx="issue" title="issue">1</span><span class="fpage" tagx="fpage" title="fpage">261</span><span class="lpage" tagx="lpage" title="lpage">266</span><span class="pub-id"><a href="https://dx.doi.org/10.7314/APJCP.2016.17.1.261">10.7314/APJCP.2016.17.1.261</a></span></span></li> <li tag="ref"><a name="CR105" /><span class="label" tagx="label" title="label">105.</span><span class="element-citation'"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Zgheib</span><span class="given-names" tagx="given-names" title="given-names">NK</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Akra-Ismail</span><span class="given-names" tagx="given-names" title="given-names">M</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Aridi</span><span class="given-names" tagx="given-names" title="given-names">C</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Mahfouz</span><span class="given-names" tagx="given-names" title="given-names">R</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Abboud</span><span class="given-names" tagx="given-names" title="given-names">MR</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Solh</span><span class="given-names" tagx="given-names" title="given-names">H</span></span><span class="etal" title="etal"><i>et al.</i></span></span><span class="mixed-article-title" title="mixed-article-title">Genetic polymorphisms in candidate genes predict increased toxicity with methotrexate therapy in Lebanese children with acute lymphoblastic leukemia</span><span class="source" tagx="source" title="source">Pharmacogenet Genomics.</span><span class="year" tagx="year" title="year">2014</span><span class="volume" tagx="volume" title="volume">24</span><span class="issue" tagx="issue" title="issue">8</span><span class="fpage" tagx="fpage" title="fpage">387</span><span class="lpage" tagx="lpage" title="lpage">396</span><span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/25007187">25007187</a></span></span></li> <li tag="ref"><a name="CR106" /><span class="label" tagx="label" title="label">106.</span><span class="element-citation'"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Kassogue</span><span class="given-names" tagx="given-names" title="given-names">Y</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Dehbi</span><span class="given-names" tagx="given-names" title="given-names">H</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Nassereddine</span><span class="given-names" tagx="given-names" title="given-names">S</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Quachouh</span><span class="given-names" tagx="given-names" title="given-names">M</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Nadifi</span><span class="given-names" tagx="given-names" title="given-names">S</span></span></span><span class="mixed-article-title" title="mixed-article-title">Genotype variability and haplotype frequency of MDR1 (ABCB1) gene polymorphism in Morocco</span><span class="source" tagx="source" title="source">DNA Cell Biol.</span><span class="year" tagx="year" title="year">2013</span><span class="volume" tagx="volume" title="volume">32</span><span class="issue" tagx="issue" title="issue">10</span><span class="fpage" tagx="fpage" title="fpage">582</span><span class="lpage" tagx="lpage" title="lpage">588</span><span class="pub-id"><a href="https://dx.doi.org/10.1089/dna.2013.2108">10.1089/dna.2013.2108</a></span><span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/23930592">23930592</a></span></span></li> <li tag="ref"><a name="CR107" /><span class="label" tagx="label" title="label">107.</span><span class="element-citation'"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Al-Mohizea</span><span class="given-names" tagx="given-names" title="given-names">AM</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Alkharfy</span><span class="given-names" tagx="given-names" title="given-names">KM</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Bagulb</span><span class="given-names" tagx="given-names" title="given-names">KM</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Alghamdi</span><span class="given-names" tagx="given-names" title="given-names">AM</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Al-Jenoobi</span><span class="given-names" tagx="given-names" title="given-names">FI</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Al-Muhsen</span><span class="given-names" tagx="given-names" title="given-names">S</span></span><span class="etal" title="etal"><i>et al.</i></span></span><span class="mixed-article-title" title="mixed-article-title">Genetic variability and haplotype profile of MDR1 in Saudi Arabian males</span><span class="source" tagx="source" title="source">Mol Biol Rep.</span><span class="year" tagx="year" title="year">2012</span><span class="volume" tagx="volume" title="volume">39</span><span class="fpage" tagx="fpage" title="fpage">10294</span><span class="lpage" tagx="lpage" title="lpage">10301</span><span class="pub-id"><a href="https://dx.doi.org/10.1007/s11033-012-1906-3">10.1007/s11033-012-1906-3</a></span></span></li> <li tag="ref"><a name="CR108" /><span class="label" tagx="label" title="label">108.</span><span class="element-citation'"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Alsaif</span><span class="given-names" tagx="given-names" title="given-names">AA</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Hasan</span><span class="given-names" tagx="given-names" title="given-names">TN</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Shafi</span><span class="given-names" tagx="given-names" title="given-names">G</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Syed</span><span class="given-names" tagx="given-names" title="given-names">NA</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Alsaif</span><span class="given-names" tagx="given-names" title="given-names">MA</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Al-Assaf</span><span class="given-names" tagx="given-names" title="given-names">A</span></span><span class="etal" title="etal"><i>et al.</i></span></span><span class="mixed-article-title" title="mixed-article-title">Association of multiple drug resistance-1 gene polymorphism with multiple drug resistance in breast cancer patients from an ethnic Saudi Arabian population</span><span class="source" tagx="source" title="source">Cancer Epidemiol.</span><span class="year" tagx="year" title="year">2013</span><span class="volume" tagx="volume" title="volume">37</span><span class="issue" tagx="issue" title="issue">5</span><span class="fpage" tagx="fpage" title="fpage">762</span><span class="lpage" tagx="lpage" title="lpage">766</span><span class="pub-id"><a href="https://dx.doi.org/10.1016/j.canep.2013.04.011">10.1016/j.canep.2013.04.011</a></span><span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/23725642">23725642</a></span></span></li> <li tag="ref"><a name="CR109" /><span class="label" tagx="label" title="label">109.</span><span class="element-citation'"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Gümüş-Akay</span><span class="given-names" tagx="given-names" title="given-names">G</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Rüstemoğlu</span><span class="given-names" tagx="given-names" title="given-names">A</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Karadağ</span><span class="given-names" tagx="given-names" title="given-names">A</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Sunguroğlu</span><span class="given-names" tagx="given-names" title="given-names">A</span></span></span><span class="mixed-article-title" title="mixed-article-title">Haplotype-based analysis of MDR1/ABCB1 gene polymorphisms in a Turkish population</span><span class="source" tagx="source" title="source">DNA Cell Biol.</span><span class="year" tagx="year" title="year">2010</span><span class="volume" tagx="volume" title="volume">29</span><span class="issue" tagx="issue" title="issue">2</span><span class="fpage" tagx="fpage" title="fpage">83</span><span class="lpage" tagx="lpage" title="lpage">90</span><span class="pub-id"><a href="https://dx.doi.org/10.1089/dna.2009.0953">10.1089/dna.2009.0953</a></span><span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/20025534">20025534</a></span></span></li> <li tag="ref"><a name="CR110" /><span class="label" tagx="label" title="label">110.</span><span class="element-citation'"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Ozgon</span><span class="given-names" tagx="given-names" title="given-names">GO</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Bebek</span><span class="given-names" tagx="given-names" title="given-names">N</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Gul</span><span class="given-names" tagx="given-names" title="given-names">G</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Cine</span><span class="given-names" tagx="given-names" title="given-names">N</span></span></span><span class="mixed-article-title" title="mixed-article-title">Association of MDR1 (C3435T) polymorphism and resistance to carbamazepine in epileptic patients from Turkey</span><span class="source" tagx="source" title="source">Eur Neurol.</span><span class="year" tagx="year" title="year">2008</span><span class="volume" tagx="volume" title="volume">59</span><span class="issue" tagx="issue" title="issue">1–2</span><span class="fpage" tagx="fpage" title="fpage">67</span><span class="lpage" tagx="lpage" title="lpage">70</span><span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/17917461">17917461</a></span></span></li> <li tag="ref"><a name="CR111" /><span class="label" tagx="label" title="label">111.</span><span class="element-citation'"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Kesimci</span><span class="given-names" tagx="given-names" title="given-names">E</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Engin</span><span class="given-names" tagx="given-names" title="given-names">AB</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Kanbak</span><span class="given-names" tagx="given-names" title="given-names">O</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Karahalil</span><span class="given-names" tagx="given-names" title="given-names">B</span></span></span><span class="mixed-article-title" title="mixed-article-title">Association between ABCB1 gene polymorphisms and fentanyl’s adverse effects in Turkish patients undergoing spinal anesthesia</span><span class="source" tagx="source" title="source">Gene.</span><span class="year" tagx="year" title="year">2012</span><span class="volume" tagx="volume" title="volume">493</span><span class="issue" tagx="issue" title="issue">2</span><span class="fpage" tagx="fpage" title="fpage">273</span><span class="lpage" tagx="lpage" title="lpage">277</span><span class="pub-id"><a href="https://dx.doi.org/10.1016/j.gene.2011.11.040">10.1016/j.gene.2011.11.040</a></span><span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/22197686">22197686</a></span></span></li> <li tag="ref"><a name="CR112" /><span class="label" tagx="label" title="label">112.</span><span class="element-citation'"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Ayaz</span><span class="given-names" tagx="given-names" title="given-names">G</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Batar</span><span class="given-names" tagx="given-names" title="given-names">B</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Kanigur</span><span class="given-names" tagx="given-names" title="given-names">G</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Guven</span><span class="given-names" tagx="given-names" title="given-names">M</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Onaran</span><span class="given-names" tagx="given-names" title="given-names">I</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Karadag</span><span class="given-names" tagx="given-names" title="given-names">B</span></span><span class="etal" title="etal"><i>et al.</i></span></span><span class="mixed-article-title" title="mixed-article-title">The association of MDR1 C3435T and G2677T/A polymorphisms with plasma platelet-activating factor levels and coronary artery disease risk in Turkish population</span><span class="source" tagx="source" title="source">Gene.</span><span class="year" tagx="year" title="year">2013</span><span class="volume" tagx="volume" title="volume">527</span><span class="issue" tagx="issue" title="issue">1</span><span class="fpage" tagx="fpage" title="fpage">301</span><span class="lpage" tagx="lpage" title="lpage">305</span><span class="pub-id"><a href="https://dx.doi.org/10.1016/j.gene.2013.06.046">10.1016/j.gene.2013.06.046</a></span><span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/23816407">23816407</a></span></span></li> <li tag="ref"><a name="CR113" /><span class="label" tagx="label" title="label">113.</span><span class="element-citation'"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Aydos</span><span class="given-names" tagx="given-names" title="given-names">SE</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Karadağ</span><span class="given-names" tagx="given-names" title="given-names">A</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Özkan</span><span class="given-names" tagx="given-names" title="given-names">T</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Altınok</span><span class="given-names" tagx="given-names" title="given-names">B</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Bunsuz</span><span class="given-names" tagx="given-names" title="given-names">M</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Heidargholizadeh</span><span class="given-names" tagx="given-names" title="given-names">S</span></span><span class="etal" title="etal"><i>et al.</i></span></span><span class="mixed-article-title" title="mixed-article-title">Association of MDR1 C3435T and C1236T single nucleotide polymorphisms with male factor infertility</span><span class="source" tagx="source" title="source">Genet Mol Res.</span><span class="year" tagx="year" title="year">2015</span><span class="volume" tagx="volume" title="volume">14</span><span class="issue" tagx="issue" title="issue">2</span><span class="fpage" tagx="fpage" title="fpage">6330</span><span class="lpage" tagx="lpage" title="lpage">6339</span><span class="pub-id"><a href="https://dx.doi.org/10.4238/2015.June.11.8">10.4238/2015.June.11.8</a></span><span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/26125837">26125837</a></span></span></li> <li tag="ref"><a name="CR114" /><span class="label" tagx="label" title="label">114.</span><span class="element-citation'"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Rustemoglu</span><span class="given-names" tagx="given-names" title="given-names">A</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Gumus-Akay</span><span class="given-names" tagx="given-names" title="given-names">G</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Yigit</span><span class="given-names" tagx="given-names" title="given-names">S</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Tasliyurt</span><span class="given-names" tagx="given-names" title="given-names">T</span></span></span><span class="mixed-article-title" title="mixed-article-title">Analysis of common MDR1 (ABCB1) gene C1236T and C3435T polymorphisms in Turkish patients with familial mediterranean fever</span><span class="source" tagx="source" title="source">Genet Mol Res.</span><span class="year" tagx="year" title="year">2011</span><span class="volume" tagx="volume" title="volume">10</span><span class="issue" tagx="issue" title="issue">4</span><span class="fpage" tagx="fpage" title="fpage">3411</span><span class="lpage" tagx="lpage" title="lpage">3420</span><span class="pub-id"><a href="https://dx.doi.org/10.4238/2011.December.14.7">10.4238/2011.December.14.7</a></span><span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/22194207">22194207</a></span></span></li> <li tag="ref"><a name="CR115" /><span class="label" tagx="label" title="label">115.</span><span class="element-citation'"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Rustemoglu</span><span class="given-names" tagx="given-names" title="given-names">A</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Gumus-Akay</span><span class="given-names" tagx="given-names" title="given-names">G</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Karakus</span><span class="given-names" tagx="given-names" title="given-names">N</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Yigit</span><span class="given-names" tagx="given-names" title="given-names">S</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Sahin</span><span class="given-names" tagx="given-names" title="given-names">S</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Tasliyurt</span><span class="given-names" tagx="given-names" title="given-names">T</span></span></span><span class="mixed-article-title" title="mixed-article-title">Association analysis of three ABCB1 (MDR1) gene variants (C1236T, G2677A/T and C3435T) and their genotype/haplotype combinations with the familial Mediterranean fever</span><span class="source" tagx="source" title="source">Xenobiotica.</span><span class="year" tagx="year" title="year">2014</span><span class="volume" tagx="volume" title="volume">44</span><span class="issue" tagx="issue" title="issue">10</span><span class="fpage" tagx="fpage" title="fpage">933</span><span class="lpage" tagx="lpage" title="lpage">940</span><span class="pub-id"><a href="https://dx.doi.org/10.3109/00498254.2014.915071">10.3109/00498254.2014.915071</a></span><span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/24773260">24773260</a></span></span></li> <li tag="ref"><a name="CR116" /><span class="label" tagx="label" title="label">116.</span><span class="element-citation'"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Dogruer</span><span class="given-names" tagx="given-names" title="given-names">D</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Tug</span><span class="given-names" tagx="given-names" title="given-names">E</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Bes</span><span class="given-names" tagx="given-names" title="given-names">C</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Soy</span><span class="given-names" tagx="given-names" title="given-names">M</span></span></span><span class="mixed-article-title" title="mixed-article-title">Lack of an effect of CYP3A4 and MDR1 gene polymorphisms on colchicine pharmacogenetics in the treatment of familial Mediterranean fever</span><span class="source" tagx="source" title="source">Genet Mol Res.</span><span class="year" tagx="year" title="year">2013</span><span class="volume" tagx="volume" title="volume">12</span><span class="issue" tagx="issue" title="issue">3</span><span class="fpage" tagx="fpage" title="fpage">3521</span><span class="lpage" tagx="lpage" title="lpage">3528</span><span class="pub-id"><a href="https://dx.doi.org/10.4238/2013.January.24.2">10.4238/2013.January.24.2</a></span><span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/23408444">23408444</a></span></span></li> <li tag="ref"><a name="CR117" /><span class="label" tagx="label" title="label">117.</span><span class="element-citation'"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Akbas</span><span class="given-names" tagx="given-names" title="given-names">SH</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Bilgen</span><span class="given-names" tagx="given-names" title="given-names">T</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Keser</span><span class="given-names" tagx="given-names" title="given-names">I</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Tuncer</span><span class="given-names" tagx="given-names" title="given-names">M</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Yucetin</span><span class="given-names" tagx="given-names" title="given-names">L</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Tosun</span><span class="given-names" tagx="given-names" title="given-names">O</span></span><span class="etal" title="etal"><i>et al.</i></span></span><span class="mixed-article-title" title="mixed-article-title">The effect of MDR1 (ABCB1) polymorphism on the pharmacokinetic of tacrolimus in Turkish renal transplant recipients</span><span class="source" tagx="source" title="source">Transplant Proc.</span><span class="year" tagx="year" title="year">2006</span><span class="volume" tagx="volume" title="volume">38</span><span class="issue" tagx="issue" title="issue">5</span><span class="fpage" tagx="fpage" title="fpage">1290</span><span class="lpage" tagx="lpage" title="lpage">1292</span><span class="pub-id"><a href="https://dx.doi.org/10.1016/j.transproceed.2006.02.079">10.1016/j.transproceed.2006.02.079</a></span><span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/16797284">16797284</a></span></span></li> <li tag="ref"><a name="CR118" /><span class="label" tagx="label" title="label">118.</span><span class="element-citation'"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Kazancioglu</span><span class="given-names" tagx="given-names" title="given-names">HO</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Ak</span><span class="given-names" tagx="given-names" title="given-names">G</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Turkmen</span><span class="given-names" tagx="given-names" title="given-names">A</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Ozbek</span><span class="given-names" tagx="given-names" title="given-names">U</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Tuncer</span><span class="given-names" tagx="given-names" title="given-names">FN</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Karabulut</span><span class="given-names" tagx="given-names" title="given-names">A</span></span></span><span class="mixed-article-title" title="mixed-article-title">The role of MDR1 C3435T gene polymorphism on gingival hyperplasia in Turkish renal transplant patients treated with cyclosporine in the absence of calcium channel blockers</span><span class="source" tagx="source" title="source">Transplant Proc.</span><span class="year" tagx="year" title="year">2013</span><span class="volume" tagx="volume" title="volume">45</span><span class="issue" tagx="issue" title="issue">6</span><span class="fpage" tagx="fpage" title="fpage">2233</span><span class="lpage" tagx="lpage" title="lpage">2237</span><span class="pub-id"><a href="https://dx.doi.org/10.1016/j.transproceed.2012.12.007">10.1016/j.transproceed.2012.12.007</a></span><span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/23756537">23756537</a></span></span></li> <li tag="ref"><a name="CR119" /><span class="label" tagx="label" title="label">119.</span><span class="element-citation'"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Yağcioğlu</span><span class="given-names" tagx="given-names" title="given-names">AE</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Yoca</span><span class="given-names" tagx="given-names" title="given-names">G</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Ayhan</span><span class="given-names" tagx="given-names" title="given-names">Y</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Karaca</span><span class="given-names" tagx="given-names" title="given-names">RÖ</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Çevik</span><span class="given-names" tagx="given-names" title="given-names">L</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Müderrisoğlu</span><span class="given-names" tagx="given-names" title="given-names">A</span></span><span class="etal" title="etal"><i>et al.</i></span></span><span class="mixed-article-title" title="mixed-article-title">Relation of the allelic variants of multidrug resistance gene to agranulocytosis associated with clozapine</span><span class="source" tagx="source" title="source">J Clin Psychopharmacol.</span><span class="year" tagx="year" title="year">2016</span><span class="volume" tagx="volume" title="volume">36</span><span class="issue" tagx="issue" title="issue">3</span><span class="fpage" tagx="fpage" title="fpage">257</span><span class="lpage" tagx="lpage" title="lpage">261</span><span class="pub-id"><a href="https://dx.doi.org/10.1097/JCP.0000000000000495">10.1097/JCP.0000000000000495</a></span><span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/27043126">27043126</a></span></span></li> <li tag="ref"><a name="CR120" /><span class="label" tagx="label" title="label">120.</span><span class="element-citation'"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Dogu</span><span class="given-names" tagx="given-names" title="given-names">GG</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Kargi</span><span class="given-names" tagx="given-names" title="given-names">A</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Turgut</span><span class="given-names" tagx="given-names" title="given-names">S</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Ayada</span><span class="given-names" tagx="given-names" title="given-names">C</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Taskoylu</span><span class="given-names" tagx="given-names" title="given-names">BY</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Demiray</span><span class="given-names" tagx="given-names" title="given-names">G</span></span><span class="etal" title="etal"><i>et al.</i></span></span><span class="mixed-article-title" title="mixed-article-title">MDR1 single nucleotide polymorphism C3435T in Turkish patients with non-small-cell lung cancer</span><span class="source" tagx="source" title="source">Gene.</span><span class="year" tagx="year" title="year">2012</span><span class="volume" tagx="volume" title="volume">506</span><span class="issue" tagx="issue" title="issue">2</span><span class="fpage" tagx="fpage" title="fpage">404</span><span class="lpage" tagx="lpage" title="lpage">407</span><span class="pub-id"><a href="https://dx.doi.org/10.1016/j.gene.2012.06.057">10.1016/j.gene.2012.06.057</a></span><span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/22766400">22766400</a></span></span></li> <li tag="ref"><a name="CR121" /><span class="label" tagx="label" title="label">121.</span><span class="element-citation'"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Özhan</span><span class="given-names" tagx="given-names" title="given-names">G</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Kara</span><span class="given-names" tagx="given-names" title="given-names">M</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Sari</span><span class="given-names" tagx="given-names" title="given-names">FM</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Yanar</span><span class="given-names" tagx="given-names" title="given-names">HT</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Ercan</span><span class="given-names" tagx="given-names" title="given-names">G</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Alpertunga</span><span class="given-names" tagx="given-names" title="given-names">B</span></span></span><span class="mixed-article-title" title="mixed-article-title">Associations between the functional polymorphisms in the ABCB1 transporter gene and colorectal cancer risk: a case-control study in Turkish population</span><span class="source" tagx="source" title="source">Toxicol Mech Methods.</span><span class="year" tagx="year" title="year">2013</span><span class="volume" tagx="volume" title="volume">23</span><span class="issue" tagx="issue" title="issue">4</span><span class="fpage" tagx="fpage" title="fpage">235</span><span class="lpage" tagx="lpage" title="lpage">239</span><span class="pub-id"><a href="https://dx.doi.org/10.3109/15376516.2012.743639">10.3109/15376516.2012.743639</a></span><span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/23193993">23193993</a></span></span></li> <li tag="ref"><a name="CR122" /><span class="label" tagx="label" title="label">122.</span><span class="element-citation'"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Saruwatari</span><span class="given-names" tagx="given-names" title="given-names">J</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Ishitsu</span><span class="given-names" tagx="given-names" title="given-names">T</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Nakagawa</span><span class="given-names" tagx="given-names" title="given-names">K</span></span></span><span class="mixed-article-title" title="mixed-article-title">Update on the genetic polymorphisms of drug-metabolizing enzymes in antiepileptic drug therapy</span><span class="source" tagx="source" title="source">Pharmaceuticals.</span><span class="year" tagx="year" title="year">2010</span><span class="volume" tagx="volume" title="volume">3</span><span class="fpage" tagx="fpage" title="fpage">2709</span><span class="lpage" tagx="lpage" title="lpage">2732</span><span class="pub-id"><a href="https://dx.doi.org/10.3390/ph3082709">10.3390/ph3082709</a></span><span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/27713373">27713373</a></span></span></li> <li tag="ref"><a name="CR123" /><span class="label" tagx="label" title="label">123.</span><span class="mixed-citation" tagx="mixed-citation" title="mixed-citation">PharmGKB. CYP2C9. 2017. <a href="https://www.pharmgkb.org/">https://www.pharmgkb.org/</a>. Accessed 25 Feb 2017.</span></li> <li tag="ref"><a name="CR124" /><span class="label" tagx="label" title="label">124.</span><span class="element-citation'"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Ma</span><span class="given-names" tagx="given-names" title="given-names">Q</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Lu</span><span class="given-names" tagx="given-names" title="given-names">AY</span></span></span><span class="mixed-article-title" title="mixed-article-title">Pharmacogenetics, pharmacogenomics, and individualized medicine</span><span class="source" tagx="source" title="source">Pharmacol Rev.</span><span class="year" tagx="year" title="year">2011</span><span class="volume" tagx="volume" title="volume">63</span><span class="fpage" tagx="fpage" title="fpage">437</span><span class="lpage" tagx="lpage" title="lpage">459</span><span class="pub-id"><a href="https://dx.doi.org/10.1124/pr.110.003533">10.1124/pr.110.003533</a></span><span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/21436344">21436344</a></span></span></li> <li tag="ref"><a name="CR125" /><span class="label" tagx="label" title="label">125.</span><span class="element-citation'"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Zanger</span><span class="given-names" tagx="given-names" title="given-names">UM</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Turpeinen</span><span class="given-names" tagx="given-names" title="given-names">M</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Klein</span><span class="given-names" tagx="given-names" title="given-names">K</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Schwab</span><span class="given-names" tagx="given-names" title="given-names">M</span></span></span><span class="mixed-article-title" title="mixed-article-title">Functional pharmacogenetics/genomics of human cytochromes P450 involved in drug biotransformation</span><span class="source" tagx="source" title="source">Anal Bioanal Chem.</span><span class="year" tagx="year" title="year">2008</span><span class="volume" tagx="volume" title="volume">392</span><span class="fpage" tagx="fpage" title="fpage">1093</span><span class="lpage" tagx="lpage" title="lpage">1108</span><span class="pub-id"><a href="https://dx.doi.org/10.1007/s00216-008-2291-6">10.1007/s00216-008-2291-6</a></span><span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/18695978">18695978</a></span></span></li> <li tag="ref"><a name="CR126" /><span class="label" tagx="label" title="label">126.</span><span class="element-citation'"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Rettie</span><span class="given-names" tagx="given-names" title="given-names">AE</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Haining</span><span class="given-names" tagx="given-names" title="given-names">RL</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Bajpai</span><span class="given-names" tagx="given-names" title="given-names">M</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Levy</span><span class="given-names" tagx="given-names" title="given-names">RH</span></span></span><span class="mixed-article-title" title="mixed-article-title">A common genetic basis for idiosyncratic toxicity of warfarin and phenytoin</span><span class="source" tagx="source" title="source">Epilepsy Res.</span><span class="year" tagx="year" title="year">1999</span><span class="volume" tagx="volume" title="volume">35</span><span class="fpage" tagx="fpage" title="fpage">253</span><span class="lpage" tagx="lpage" title="lpage">255</span><span class="pub-id"><a href="https://dx.doi.org/10.1016/S0920-1211(99)00017-0">10.1016/S0920-1211(99)00017-0</a></span><span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/10413320">10413320</a></span></span></li> <li tag="ref"><a name="CR127" /><span class="label" tagx="label" title="label">127.</span><span class="element-citation'"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Bajpai</span><span class="given-names" tagx="given-names" title="given-names">M</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Roskos</span><span class="given-names" tagx="given-names" title="given-names">L</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Shen</span><span class="given-names" tagx="given-names" title="given-names">D</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Levy</span><span class="given-names" tagx="given-names" title="given-names">R</span></span></span><span class="mixed-article-title" title="mixed-article-title">Roles of cytochrome P4502C9 and cytochrome P4502C19 in the stereoselective metabolism of phenytoin to its major metabolite</span><span class="source" tagx="source" title="source">Drug Metab Dispos.</span><span class="year" tagx="year" title="year">1996</span><span class="volume" tagx="volume" title="volume">24</span><span class="issue" tagx="issue" title="issue">12</span><span class="fpage" tagx="fpage" title="fpage">1401</span><span class="lpage" tagx="lpage" title="lpage">1403</span><span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/8971149">8971149</a></span></span></li> <li tag="ref"><a name="CR128" /><span class="label" tagx="label" title="label">128.</span><span class="element-citation'"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Luna-Tortós</span><span class="given-names" tagx="given-names" title="given-names">C</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Fedrowitz</span><span class="given-names" tagx="given-names" title="given-names">M</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Löscher</span><span class="given-names" tagx="given-names" title="given-names">W</span></span></span><span class="mixed-article-title" title="mixed-article-title">Several major antiepileptic drugs are substrates for human P-glycoprotein</span><span class="source" tagx="source" title="source">Neuropharmacology.</span><span class="year" tagx="year" title="year">2008</span><span class="volume" tagx="volume" title="volume">55</span><span class="fpage" tagx="fpage" title="fpage">1364</span><span class="lpage" tagx="lpage" title="lpage">1375</span><span class="pub-id"><a href="https://dx.doi.org/10.1016/j.neuropharm.2008.08.032">10.1016/j.neuropharm.2008.08.032</a></span><span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/18824002">18824002</a></span></span></li> <li tag="ref"><a name="CR129" /><span class="label" tagx="label" title="label">129.</span><span class="element-citation'"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Zhang</span><span class="given-names" tagx="given-names" title="given-names">C</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Kwan</span><span class="given-names" tagx="given-names" title="given-names">P</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Zuo</span><span class="given-names" tagx="given-names" title="given-names">Z</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Baum</span><span class="given-names" tagx="given-names" title="given-names">L</span></span></span><span class="mixed-article-title" title="mixed-article-title">In vitro concentration dependent transport of phenytoin and phenobarbital, but not ethosuximide, by human P-glycoprotein</span><span class="source" tagx="source" title="source">Life Sci.</span><span class="year" tagx="year" title="year">2010</span><span class="volume" tagx="volume" title="volume">86</span><span class="fpage" tagx="fpage" title="fpage">899</span><span class="lpage" tagx="lpage" title="lpage">905</span><span class="pub-id"><a href="https://dx.doi.org/10.1016/j.lfs.2010.04.008">10.1016/j.lfs.2010.04.008</a></span><span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/20417647">20417647</a></span></span></li> <li tag="ref"><a name="CR130" /><span class="label" tagx="label" title="label">130.</span><span class="element-citation'"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Hoffmeyer</span><span class="given-names" tagx="given-names" title="given-names">S</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Burk</span><span class="given-names" tagx="given-names" title="given-names">O</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">von Richter</span><span class="given-names" tagx="given-names" title="given-names">O</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Arnold</span><span class="given-names" tagx="given-names" title="given-names">HP</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Brockmöller</span><span class="given-names" tagx="given-names" title="given-names">J</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Johne</span><span class="given-names" tagx="given-names" title="given-names">A</span></span><span class="etal" title="etal"><i>et al.</i></span></span><span class="mixed-article-title" title="mixed-article-title">Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo</span><span class="source" tagx="source" title="source">Proc Natl Acad Sci USA</span><span class="year" tagx="year" title="year">2000</span><span class="volume" tagx="volume" title="volume">97</span><span class="fpage" tagx="fpage" title="fpage">3473</span><span class="lpage" tagx="lpage" title="lpage">3478</span><span class="pub-id"><a href="https://dx.doi.org/10.1073/pnas.97.7.3473">10.1073/pnas.97.7.3473</a></span><span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/10716719">10716719</a></span></span></li> <li tag="ref"><a name="CR131" /><span class="label" tagx="label" title="label">131.</span><span class="element-citation'"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Kimchi-Sarfaty</span><span class="given-names" tagx="given-names" title="given-names">C</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Oh</span><span class="given-names" tagx="given-names" title="given-names">JM</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Kim</span><span class="given-names" tagx="given-names" title="given-names">IW</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Sauna</span><span class="given-names" tagx="given-names" title="given-names">ZE</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Calcagno</span><span class="given-names" tagx="given-names" title="given-names">AM</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Ambudkar</span><span class="given-names" tagx="given-names" title="given-names">SV</span></span><span class="etal" title="etal"><i>et al.</i></span></span><span class="mixed-article-title" title="mixed-article-title">A "silent" polymorphism in the <i>MDR1</i> gene changes substrate specificity</span><span class="source" tagx="source" title="source">Science.</span><span class="year" tagx="year" title="year">2007</span><span class="volume" tagx="volume" title="volume">315</span><span class="fpage" tagx="fpage" title="fpage">525</span><span class="lpage" tagx="lpage" title="lpage">527</span><span class="pub-id"><a href="https://dx.doi.org/10.1126/science.1135308">10.1126/science.1135308</a></span><span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/17185560">17185560</a></span></span></li> <li tag="ref"><a name="CR132" /><span class="label" tagx="label" title="label">132.</span><span class="element-citation'"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Li</span><span class="given-names" tagx="given-names" title="given-names">H</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Wang</span><span class="given-names" tagx="given-names" title="given-names">B</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Chang</span><span class="given-names" tagx="given-names" title="given-names">C</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Wu</span><span class="given-names" tagx="given-names" title="given-names">M</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Xu</span><span class="given-names" tagx="given-names" title="given-names">Y</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Jiang</span><span class="given-names" tagx="given-names" title="given-names">Y</span></span></span><span class="mixed-article-title" title="mixed-article-title">The roles of variants in human multidrug resistance (MDR1) gene and their haplotypes on antiepileptic drugs response: a meta-analysis of 57 studies</span><span class="source" tagx="source" title="source">PLoS One.</span><span class="year" tagx="year" title="year">2015</span><span class="volume" tagx="volume" title="volume">10</span><span class="fpage" tagx="fpage" title="fpage">1</span><span class="lpage" tagx="lpage" title="lpage">16</span></span></li> <li tag="ref"><a name="CR133" /><span class="label" tagx="label" title="label">133.</span><span class="element-citation'"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Thakkar</span><span class="given-names" tagx="given-names" title="given-names">AN</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Bendkhale</span><span class="given-names" tagx="given-names" title="given-names">SR</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Taur</span><span class="given-names" tagx="given-names" title="given-names">SR</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Gogtay</span><span class="given-names" tagx="given-names" title="given-names">NJ</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Thatte</span><span class="given-names" tagx="given-names" title="given-names">UM</span></span></span><span class="mixed-article-title" title="mixed-article-title">Association of CYP2C9 polymorphisms with phenytoin toxicity in Indian patients</span><span class="source" tagx="source" title="source">Neurol India.</span><span class="year" tagx="year" title="year">2012</span><span class="volume" tagx="volume" title="volume">60</span><span class="fpage" tagx="fpage" title="fpage">577</span><span class="lpage" tagx="lpage" title="lpage">580</span><span class="pub-id"><a href="https://dx.doi.org/10.4103/0028-3886.105189">10.4103/0028-3886.105189</a></span><span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/23287317">23287317</a></span></span></li> <li tag="ref"><a name="CR134" /><span class="label" tagx="label" title="label">134.</span><span class="element-citation'"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Suvichapanic</span><span class="given-names" tagx="given-names" title="given-names">S</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Jittikoon</span><span class="given-names" tagx="given-names" title="given-names">J</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Wichukchinda</span><span class="given-names" tagx="given-names" title="given-names">N</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Kamchaisatian</span><span class="given-names" tagx="given-names" title="given-names">W</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Visudtbhan</span><span class="given-names" tagx="given-names" title="given-names">A</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Benjapopitak</span><span class="given-names" tagx="given-names" title="given-names">S</span></span><span class="etal" title="etal"><i>et al.</i></span></span><span class="mixed-article-title" title="mixed-article-title">Association analysis of <i>CYP2C9*3</i> and phenytoin-induced severe cutaneous adverse reactions (SCARs) in Thai epilepsy children</span><span class="source" tagx="source" title="source">J Hum Genet.</span><span class="year" tagx="year" title="year">2015</span><span class="volume" tagx="volume" title="volume">60</span><span class="fpage" tagx="fpage" title="fpage">413</span><span class="lpage" tagx="lpage" title="lpage">417</span><span class="pub-id"><a href="https://dx.doi.org/10.1038/jhg.2015.47">10.1038/jhg.2015.47</a></span><span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/25994870">25994870</a></span></span></li> <li tag="ref"><a name="CR135" /><span class="label" tagx="label" title="label">135.</span><span class="element-citation'"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Loscher</span><span class="given-names" tagx="given-names" title="given-names">W</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Potschka</span><span class="given-names" tagx="given-names" title="given-names">H</span></span></span><span class="mixed-article-title" title="mixed-article-title">Role of multidrug transporters in pharmacoresistance to antiepileptic drugs</span><span class="source" tagx="source" title="source">J Pharmacol Exp Ther.</span><span class="year" tagx="year" title="year">2002</span><span class="volume" tagx="volume" title="volume">301</span><span class="fpage" tagx="fpage" title="fpage">7</span><span class="lpage" tagx="lpage" title="lpage">14</span><span class="pub-id"><a href="https://dx.doi.org/10.1124/jpet.301.1.7">10.1124/jpet.301.1.7</a></span><span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/11907151">11907151</a></span></span></li> <li tag="ref"><a name="CR136" /><span class="label" tagx="label" title="label">136.</span><span class="element-citation'"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Sisodiya</span><span class="given-names" tagx="given-names" title="given-names">SM</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Lin</span><span class="given-names" tagx="given-names" title="given-names">WR</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Harding</span><span class="given-names" tagx="given-names" title="given-names">BN</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Squier</span><span class="given-names" tagx="given-names" title="given-names">MV</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Thom</span><span class="given-names" tagx="given-names" title="given-names">M</span></span></span><span class="mixed-article-title" title="mixed-article-title">Drug resistance in epilepsy: expression of drug resistance proteins in common causes of refractory epilepsy</span><span class="source" tagx="source" title="source">Brain.</span><span class="year" tagx="year" title="year">2002</span><span class="volume" tagx="volume" title="volume">125</span><span class="fpage" tagx="fpage" title="fpage">22</span><span class="lpage" tagx="lpage" title="lpage">31</span><span class="pub-id"><a href="https://dx.doi.org/10.1093/brain/awf002">10.1093/brain/awf002</a></span><span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/11834590">11834590</a></span></span></li> <li tag="ref"><a name="CR137" /><span class="label" tagx="label" title="label">137.</span><span class="element-citation'"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Tishler</span><span class="given-names" tagx="given-names" title="given-names">DM</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Weinberg</span><span class="given-names" tagx="given-names" title="given-names">KI</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Hinton</span><span class="given-names" tagx="given-names" title="given-names">DR</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Barbaro</span><span class="given-names" tagx="given-names" title="given-names">N</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Annett</span><span class="given-names" tagx="given-names" title="given-names">GM</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Raffel</span><span class="given-names" tagx="given-names" title="given-names">C</span></span></span><span class="mixed-article-title" title="mixed-article-title">MDR1 gene expression in brain of patients with medically intractable epilepsy</span><span class="source" tagx="source" title="source">Epilepsia.</span><span class="year" tagx="year" title="year">1995</span><span class="volume" tagx="volume" title="volume">36</span><span class="fpage" tagx="fpage" title="fpage">1</span><span class="lpage" tagx="lpage" title="lpage">6</span><span class="pub-id"><a href="https://dx.doi.org/10.1111/j.1528-1157.1995.tb01657.x">10.1111/j.1528-1157.1995.tb01657.x</a></span><span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/8001500">8001500</a></span></span></li> <li tag="ref"><a name="CR138" /><span class="label" tagx="label" title="label">138.</span><span class="element-citation'"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Siddiqui</span><span class="given-names" tagx="given-names" title="given-names">A</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Kerb</span><span class="given-names" tagx="given-names" title="given-names">R</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Weale</span><span class="given-names" tagx="given-names" title="given-names">ME</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Brinkmann</span><span class="given-names" tagx="given-names" title="given-names">U</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Smith</span><span class="given-names" tagx="given-names" title="given-names">A</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Goldstein</span><span class="given-names" tagx="given-names" title="given-names">DB</span></span><span class="etal" title="etal"><i>et al.</i></span></span><span class="mixed-article-title" title="mixed-article-title">Association of multidrug resistance in epilepsy with a polymorphism in the drug-transporter gene ABCB1</span><span class="source" tagx="source" title="source">N Engl J Med.</span><span class="year" tagx="year" title="year">2003</span><span class="volume" tagx="volume" title="volume">348</span><span class="fpage" tagx="fpage" title="fpage">1442</span><span class="lpage" tagx="lpage" title="lpage">1448</span><span class="pub-id"><a href="https://dx.doi.org/10.1056/NEJMoa021986">10.1056/NEJMoa021986</a></span><span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/12686700">12686700</a></span></span></li> <li tag="ref"><a name="CR139" /><span class="label" tagx="label" title="label">139.</span><span class="mixed-citation" tagx="mixed-citation" title="mixed-citation">PharmGKB. Gene-specific information tables for CYP2C9. 2017. <a href="https://www.pharmgkb.org/">https://www.pharmgkb.org/</a>. Accessed 10 Mar 2017.</span></li> <li tag="ref"><a name="CR140" /><span class="label" tagx="label" title="label">140.</span><span class="mixed-citation" tagx="mixed-citation" title="mixed-citation">PharmGKB. Gene-specific information tables for CYP2C19. 2017. <a href="https://www.pharmgkb.org/">https://www.pharmgkb.org/</a>. Accessed 10 Mar 2017.</span></li> <li tag="ref"><a name="CR141" /><span class="label" tagx="label" title="label">141.</span><span class="element-citation'"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Kassogue</span><span class="given-names" tagx="given-names" title="given-names">Y</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Dehbi</span><span class="given-names" tagx="given-names" title="given-names">H</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Nassereddine</span><span class="given-names" tagx="given-names" title="given-names">S</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Quachouh</span><span class="given-names" tagx="given-names" title="given-names">M</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Nadifi</span><span class="given-names" tagx="given-names" title="given-names">S</span></span></span><span class="mixed-article-title" title="mixed-article-title">Genotype variability and haplotype frequency of MDR1 (ABCB1) gene polymorphism in Morocco</span><span class="source" tagx="source" title="source">DNA Cell Biol.</span><span class="year" tagx="year" title="year">2013</span><span class="volume" tagx="volume" title="volume">32</span><span class="fpage" tagx="fpage" title="fpage">582</span><span class="lpage" tagx="lpage" title="lpage">588</span><span class="pub-id"><a href="https://dx.doi.org/10.1089/dna.2013.2108">10.1089/dna.2013.2108</a></span><span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/23930592">23930592</a></span></span></li> <li tag="ref"><a name="CR142" /><span class="label" tagx="label" title="label">142.</span><span class="element-citation'"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Bournissen</span><span class="given-names" tagx="given-names" title="given-names">FG</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Moretti</span><span class="given-names" tagx="given-names" title="given-names">ME</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Juurlink</span><span class="given-names" tagx="given-names" title="given-names">DN</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Koren</span><span class="given-names" tagx="given-names" title="given-names">G</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Walker</span><span class="given-names" tagx="given-names" title="given-names">M</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Finkelstein</span><span class="given-names" tagx="given-names" title="given-names">Y</span></span></span><span class="mixed-article-title" title="mixed-article-title">Polymorphism of the MDR1/ABCB1 C3435T drug-transporter and resistance to anticonvulsant drugs: a meta-analysis</span><span class="source" tagx="source" title="source">Epilepsia.</span><span class="year" tagx="year" title="year">2009</span><span class="volume" tagx="volume" title="volume">50</span><span class="fpage" tagx="fpage" title="fpage">898</span><span class="lpage" tagx="lpage" title="lpage">903</span><span class="pub-id"><a href="https://dx.doi.org/10.1111/j.1528-1167.2008.01858.x">10.1111/j.1528-1167.2008.01858.x</a></span><span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/19178561">19178561</a></span></span></li> <li tag="ref"><a name="CR143" /><span class="label" tagx="label" title="label">143.</span><span class="element-citation'"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Chang</span><span class="given-names" tagx="given-names" title="given-names">CC</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Ng</span><span class="given-names" tagx="given-names" title="given-names">CC</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Too</span><span class="given-names" tagx="given-names" title="given-names">CL</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Choon</span><span class="given-names" tagx="given-names" title="given-names">SE</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Lee</span><span class="given-names" tagx="given-names" title="given-names">CK</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Chung</span><span class="given-names" tagx="given-names" title="given-names">WH</span></span><span class="etal" title="etal"><i>et al.</i></span></span><span class="mixed-article-title" title="mixed-article-title">Association of HLA-B*15:13 and HLA-B*15:02 with phenytoin-induced severe cutaneous adverse reactions in a Malay population</span><span class="source" tagx="source" title="source">Pharmacogenom J.</span><span class="year" tagx="year" title="year">2017</span><span class="volume" tagx="volume" title="volume">17</span><span class="fpage" tagx="fpage" title="fpage">170</span><span class="lpage" tagx="lpage" title="lpage">173</span><span class="pub-id"><a href="https://dx.doi.org/10.1038/tpj.2016.10">10.1038/tpj.2016.10</a></span></span></li> <li tag="ref"><a name="CR144" /><span class="label" tagx="label" title="label">144.</span><span class="element-citation'"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Cheung</span><span class="given-names" tagx="given-names" title="given-names">YK</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Cheng</span><span class="given-names" tagx="given-names" title="given-names">SH</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Chan</span><span class="given-names" tagx="given-names" title="given-names">EJ</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Lo</span><span class="given-names" tagx="given-names" title="given-names">SV</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Ng</span><span class="given-names" tagx="given-names" title="given-names">MH</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Kwan</span><span class="given-names" tagx="given-names" title="given-names">P</span></span></span><span class="mixed-article-title" title="mixed-article-title">HLA-B alleles associated with severe cutaneous reactions to antiepileptic drugs in Han Chinese</span><span class="source" tagx="source" title="source">Epilepsia.</span><span class="year" tagx="year" title="year">2013</span><span class="volume" tagx="volume" title="volume">54</span><span class="fpage" tagx="fpage" title="fpage">1307</span><span class="lpage" tagx="lpage" title="lpage">1314</span><span class="pub-id"><a href="https://dx.doi.org/10.1111/epi.12217">10.1111/epi.12217</a></span><span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/23692434">23692434</a></span></span></li> <li tag="ref"><a name="CR145" /><span class="label" tagx="label" title="label">145.</span><span class="element-citation'"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Celeste</span><span class="given-names" tagx="given-names" title="given-names">BL</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Kwan</span><span class="given-names" tagx="given-names" title="given-names">P</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Baum</span><span class="given-names" tagx="given-names" title="given-names">L</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Yu</span><span class="given-names" tagx="given-names" title="given-names">E</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Lau</span><span class="given-names" tagx="given-names" title="given-names">KM</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Cheng</span><span class="given-names" tagx="given-names" title="given-names">AS</span></span><span class="etal" title="etal"><i>et al.</i></span></span><span class="mixed-article-title" title="mixed-article-title">Association between HLA-B*1502 allele and antiepileptic drug-induced cutaneous reactions in Han Chinese</span><span class="source" tagx="source" title="source">Epilepsia.</span><span class="year" tagx="year" title="year">2007</span><span class="volume" tagx="volume" title="volume">48</span><span class="fpage" tagx="fpage" title="fpage">1015</span><span class="lpage" tagx="lpage" title="lpage">1018</span><span class="pub-id"><a href="https://dx.doi.org/10.1111/j.1528-1167.2007.01022.x">10.1111/j.1528-1167.2007.01022.x</a></span><span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/17509004">17509004</a></span></span></li> <li tag="ref"><a name="CR146" /><span class="label" tagx="label" title="label">146.</span><span class="element-citation'"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Moher</span><span class="given-names" tagx="given-names" title="given-names">D</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Liberati</span><span class="given-names" tagx="given-names" title="given-names">A</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Tetzlaff</span><span class="given-names" tagx="given-names" title="given-names">J</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Altman</span><span class="given-names" tagx="given-names" title="given-names">DG</span></span><span class="collab'">collab: The PRISMA Group</span></span><span class="mixed-article-title" title="mixed-article-title">Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement</span><span class="source" tagx="source" title="source">PLoS Med</span><span class="year" tagx="year" title="year">2009</span><span class="volume" tagx="volume" title="volume">6</span><span class="issue" tagx="issue" title="issue">7</span><span class="fpage" tagx="fpage" title="fpage">e1000097</span><span class="pub-id"><a href="https://dx.doi.org/10.1371/journal.pmed.1000097">10.1371/journal.pmed.1000097</a></span><span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/19621072">19621072</a></span></span></li> </ul> </div> </div>  </body></html>